

### 1. 국외 DB

1. Abe Y, Miyake M, Miyazaki T, Horiuchi A, Kimura S. The endogenous induction of tumor necrosis factor serum (TNS) for the adjuvant postoperative immunotherapy of cancer--changes in immunological markers of the blood. Japanese Journal of Surgery. 1990;20(1):19-26.  
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
2. Abusalah MAH, Gan SH, Al-hatamleh MAI, Irekeola AA, Shueb RH, Yean CY. Recent advances in diagnostic approaches for epstein-barr virus. Pathogens. 2020;9 (3) (226).  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
3. Adachi T, Hinoda Y, Nishimori I, Adachi M, Imai K. Increased sensitivity of gastric cancer cells to natural killer and lymphokine-activated killer cells by antisense suppression of N-acetylgalactosaminyltransferase. Journal of Immunology. 1997;159(6):2645-51.  
배제사유 : 동물실험 및 전임상시험연구
4. Adcock DM, Fink LM, Marlar RA, Cavallo F, Zangari M. The hemostatic system and malignancy. Clinical Lymphoma and Myeloma. 2008;8(4):230-6.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
5. Adithan A, John Peter JS, Mohammad AH, Kim B, Kang CW, Kim NS, et al. A gastric cancer cell derived extracellular compounds suppresses CD161+CD3- lymphocytes and aggravates tumor formation in a syngeneic mouse model. Molecular Immunology. 2020;120:136-45.  
배제사유 : 동물실험 및 전임상시험연구
6. Aftimos PG, Barthelemy P, Rolfo CD, Hanssens V, De Jonge N, Silence K, et al. A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors. Journal of Clinical Oncology. Conference. 2015;33(15 SUPPL. 1).  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
7. Agnihotri N, Bhasin DK, Vohra H, Ray P, Singh K, Ganguly NK. Characterization of lymphocytic subsets and cytokine production in gastric biopsy samples from Helicobacter pylori patients. Scandinavian journal of gastroenterology. 1998;33(7):704-9.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

8. Ai L, Wang H. Effects of propofol and sevoflurane on tumor killing activity of peripheral blood natural killer cells in patients with gastric cancer. *Journal of International Medical Research*. 2020;48(3):300060520904861.  
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
9. Akagi J, Baba H. Prognostic value of CD57(+) T lymphocytes in the peripheral blood of patients with advanced gastric cancer. *International Journal of Clinical Oncology*. 2008;13(6):528-35.  
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
10. Akagi J, Baba H. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients. *International Journal of Clinical Oncology*. 2010;15(2):145-52.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
11. Akiyoshi T, Arinaga S, Nanbara S, Karimine N, Inoue H, Takamuku K, et al. The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer. *Japanese Journal of Surgery*. 1990;20(3):365-8.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
12. Akiyoshi T, Koba F, Arinaga S, Tsuji H. Activated killer cell activity of spleen cells from patients with gastric carcinoma. *Journal of Clinical & Laboratory Immunology*. 1987;23(4):197-201.  
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
13. Akiyoshi T, Koba F, Arinaga S, Ueo H. Preoperative cell-mediated immune function and the prognosis of patients with gastric carcinoma. *Journal of Surgical Oncology*. 1990;45(3):137-42.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
14. Akiyoshi T, Koba F, Arinaga S, Wada T, Tsuji H. Cell-mediated cytotoxic activity of spleen cells from patients with gastric carcinoma. *Japanese Journal of Surgery*. 1988;18(2):164-71.  
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
15. Akiyoshi T, Koba F, Miyazaki S, Arinaga S, Tsuji H. [NK activity, TCGF production and generation of cell-mediated cytotoxicity in spleen cells from gastric cancer patients]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1983;84(9):957-60.  
배제사유 : 동물실험 및 전임상시험연구
16. Akiyoshi T, Koba F, Tsuji H. Activated killer cell activity in lymph nodes. *Journal of Clinical & Laboratory Immunology*. 1987;22(2):91-5.  
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
17. Akura Y, Tanaka N, Gotoh K, Kamitani S, Gangi J, Ono M, et al. [Augmentation of cytotoxicity of regional lymph node lymphocytes of the stomach by in vitro culture in IL2 contained medium]. *Nippon Gan Chiryō Gakkai Shi - Journal of Japan Society for Cancer Therapy*. 1986;21(10):2411-20.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

18. Akura Y. [Augmentation of killer activity in regional lymph nodes in gastric cancer by intratumoral injection of immunopotentiators]. *Nippon Gan Chiryō Gakkai Shi - Journal of Japan Society for Cancer Therapy*. 1987;22(9):2265-72.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

19. Al Hadra B, Deliverska EG, Stoianov H, Nedialkova A, Lukanov T, Shivarov V, et al. Investigation of HLA genes, HLA molecules and other factors in patients with oral squamous cell carcinoma. *Journal of IMAB - Annual Proceeding (Scientific Papers)*. 2018;24(3):2133-41.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

20. Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. *PLoS ONE*. 2017;12 (11) (e0176181).

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

21. Al-Batran SE, Zvirbulė Z, Lordick F, Thuss-Patience P, Just M, Bitzer M, et al. Phase 1 study of IMAB362 with immunomodulation in patients with advanced gastric cancer. *Annals of Oncology*. 2017;28 (Supplement 5):v226.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

22. Albuquerque-Gonzalez B, Lopez-Calderon FF, Lopez-Abellan MD, Esteban-Gil A, Garcia-Solano J, Conesa-Zamora P. Biology and therapeutic targets of colorectal serrated adenocarcinoma; clues for a histologically based treatment against an aggressive tumor. *International Journal of Molecular Sciences*. 2020;21 (6) (1991).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

23. Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Kennedy RC. Vaccines and immunotherapeutics for the treatment of malignant disease. *Clinical and Developmental Immunology*. 2010;2010 (697158).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

24. Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. *Cancer Research*. 2014;74(1):104-18.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

25. Allen Chan KC, Dennis Lo YM. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. *Seminars in Cancer Biology*. 2002;12(6):489-96.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

26. Altevogt P, Bretz NP, Ridinger J, Utikal J, Umansky V. Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. *Seminars in Cancer Biology*. 2014;28:51-7.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

27. Amedei A, Benaglio M, della Bella C, Niccolai E, D'Elia MM. Novel immunotherapeutic strategies of gastric cancer treatment. *Journal of Biomedicine & Biotechnology*.

2011:2011:437348.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

28. Amemiya K. [Suppression of immunological response by ascitic fluid from gastrointestinal cancer patients]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society.* 1983;84(12):1229-36.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

29. Amoueian S, Attaranzadeh A, Montazer M. Intratumoral CD68-, CD117-, CD56-, and CD1a-positive immune cells and the survival of Iranian patients with non-metastatic intestinal-type gastric carcinoma. *Pathology, Research & Practice.* 2015;211(4):326-31.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

30. Amoueian S, Attaranzadeh A, Montazer M. The relationship between tumor infiltrating immunologic cells and the survival of gastric carcinoma patients. *Virchows Archiv.* 2012;1):S105-S6.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

31. Anari F, Ramamurthy C, Zibelman M. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. *Future Oncology.* 2018;14(14):1409-21.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

32. Anonymous. 22nd International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer. *Helicobacter. Conference: 22nd International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer. Porto Portugal. Conference Publication:.* 2009;14(4).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

33. Anonymous. Abstract Book of ESMO Asia Congress 2016. *Annals of Oncology. Conference: ESMO Asia Congress.* 2016;27(Supplement 9).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

34. Anonymous. *Eleutherococcus senticosus.* *Alternative Medicine Review.* 2006;11(2):151-5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

35. Aoike A. [The correlation of natural killer activity and interferon in the serum of gastric cancer patients]. *Nippon Shokakibyō Gakkai Zasshi - Japanese Journal of Gastroenterology.* 1985;82(11):2723-32.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

36. Aparicio-Pages MN, den Hartog G, Verspaget HW, Pena AS, van der Meer JW, van Furth R, et al. Decreased natural killer cell activity in late-onset hypogammaglobulinaemia. *Clinical Science.* 1990;78(2):133-7.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

37. Aparicio-Pages MN, Verspaget HW, Pena AS, Lamers CB. Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract. *Journal of Clinical & Laboratory Immunology.* 1991;35(1):27-32.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

38. Aptsiauri N, Cabrera T, Pawelec G, Gouttefangeas C, Derhovannessian E, Garrido F, et al. International conference: Progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain. *Cancer Immunology, Immunotherapy*. 2007;56(8):1311-22.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
39. Arafar A. Cytokine induced killer cell immunotherapy in cancer treatment: from bench to bedside. *Biomedical Research and Therapy*. 2014;1 (2) (12).  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
40. Arinaga S, Karimine N, Nanbara S, Inoue H, Nakashima H, Ueo H, et al. Lymphokine-activated killer cell function of lymphocytes from regional lymph nodes in patients with gastric carcinoma. *Journal of Surgical Oncology*. 1995;58(1):44-9.  
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
41. Arinaga S, Karimine N, Takamuku K, Nanbara S, Inoue H, Nagamatsu M, et al. Enhanced induction of lymphokine-activated killer activity after lentinan administration in patients with gastric carcinoma. *International Journal of Immunopharmacology*. 1992;14(4):535-9.  
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
42. Asao T, Ishibashi R, Inoue M, Fuse M, Miura Y, Ishizaki H, et al. Chimeric antigen receptor T cell therapy targeting NKG2D ligand. *Journal of Clinical Oncology*. Conference. 2016;34(Supplement 15).  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
43. Ascui G, Galvez-Jiron F, Kramm K, Schafer C, Sina J, Pola V, et al. Decreased invariant natural killer T-cell-mediated antitumor immune response in patients with gastric cancer. *Immunology and Cell Biology*. 2020.  
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
44. Ates E, Yilmaz S, Erkasap S, Ihtiyar E, Kaya Y, Pehlivan T, et al. Perioperative immunonutrition ameliorates the postoperative immune depression in patients with gastrointestinal system cancer (prospective clinical study in 42 patients). *Acta Gastro-Enterologica Belgica*. 2004;67(3):250-4.  
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
45. Au WY, Gascoyne RD, Klasa RB, Connors JM, Gallagher RP, Le ND, et al. Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. *British Journal of Haematology*. 2005;128(6):792-6.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
46. Baba M, Hideshima T, Yamashita Y, Shirakusa T. Potentiation of cytotoxicity against a CEA positive cell line by the bispecific antibody OH1 using LAK cells from cancer-bearing patients. *Oncology Reports*. 1998;5(5):1141-6.  
배제사유 : 동물실험 및 전임상시험연구
47. Bai X, Yi M, Jiao Y, Chu Q, Wu K. Blocking tgf-beta signaling to enhance the efficacy of immune checkpoint inhibitor. *OncoTargets and Therapy*. 2019;12:9527-38.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

48. Bai YF, Zhang XY, Mu ZX. [Experimental study of the anti-tumor activity of CD3AK against human gastric cancer cell line in vitro and in vivo]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 1994;16(2):111-4.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
49. Banerjee D, Walton JC, Jory TA, Crukley C, Meek M. Primary gastric T-cell lymphoma of suppressor-cytotoxic (CD8+) phenotype: discordant expression of T-cell receptor subunit beta F1, CD7, and CD3 antigens. *Human Pathology*. 1990;21(8):872-4.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
50. Baxter D. Active and passive immunization for cancer. *Human Vaccines and Immunotherapeutics*. 2014;10(7):2123-9.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
51. Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. *Cancer and Metastasis Reviews*. 2013;32(3-4):643-71.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
52. Begenik H, Turkdogan MK, Dulger AC, Aldemir MN, Esen R, Mete R. Peripheral blood levels of cellular and humoral immunity parameters in esophageal and gastric cancer patients. *Central-European Journal of Immunology*. 2013;38(3):355-7.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
53. Beika T, Tanaka N, Yamada J, Hizuta A, Onishi K, Akura Y, et al. [Effect of human recombinant beta-interferon on natural killer activity of peripheral lymphocytes in cancer patients]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1985;12(2):362-5.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
54. Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. *Molecular Cancer Therapeutics*. 2009;8(11):2983-91.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
55. Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions. *Annual Review of Immunology*. 2009;27:551-89.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
56. Ben-Batalla I, Vargas-Delgado ME, Meier L, Loges S. Sexual dimorphism in solid and hematological malignancies. *Seminars in Immunopathology*. 2019;41(2):251-63.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
57. Ben-Efraim S. One hundred years of cancer immunotherapy: A critical appraisal. *Tumor Biology*. 1999;20(1):1-24.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구

58. Bentsdal OH, Froland SS, Bosnes V, Bergan A, Soreide O, Flatmark A. Alterations in lymphocyte subsets in blood may predict resectability in carcinoma of cardia or oesophagus. *Cancer Letters*. 1996;100(1-2):133-8.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
59. Betten A, Bylund J, Christophe T, Boulay F, Romero A, Hellstrand K, et al. A proinflammatory peptide from *Helicobacter pylori* activates monocytes to induce lymphocyte dysfunction and apoptosis. *Journal of Clinical Investigation*. 2001;108(8):1221-8.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
60. Betzler M, Flad HD, Schlag P. Natural killer cell activity during a treatment with fibroblast interferon in gastric cancer. [German]. *Langenbecks Archiv fur Chirurgie*. 1982;356(Suppl. 1982):111-6.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
61. Beuth J, Ko HL, Peters KM, Bornhofen B, Pulverer G. Behaviour of lymphocyte subsets in response to immunotherapy with *Propionibacterium avidum* KP-40 in cancer patients. *Zentralblatt fur Bakteriologie*. 1990;273(3):386-90.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
62. Bhutani D, Vaishampayan UN. Monoclonal antibodies in oncology therapeutics: Present and future indications. *Expert Opinion on Biological Therapy*. 2013;13(2):269-82.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
63. Bian K, Ghassemi F, Sotolongo A, Siu A, Shauger L, Kots A, et al. NOS-2 signaling and cancer therapy. *IUBMB Life*. 2012;64(8):676-83.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
64. Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. *Cytokine and Growth Factor Reviews*. 2010;21(1):49-59.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
65. Biglari A, Southgate TD, Fairbairn LJ, Gilham DE. Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo. *Gene Therapy*. 2006;13(7):602-10.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
66. Bilgi O, Karagoz B, Turken O, Kandemir EG, Ozturk A, Gumus M, et al. Peripheral blood gamma-delta T cells in advanced-stage cancer patients. *Advances in Therapy*. 2008;25(3):218-24.  
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
67. Bingya L, Yanzhen L, Haoran Y. Inhibition effect of Swainsonine on the growth and metastasis of gastric cancer in vivo. [Chinese]. *Chinese Journal of Oncology*. 1998;20(3):168-70.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구

68. Blagodatski A, Yatsunskaya M, Mikhailova V, Tiasto V, Kagansky A, Katanaev VL. Medicinal mushrooms as an attractive new source of natural compounds for future cancer therapy. *Oncotarget*. 2018;9(49):29259-74.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
69. Bolhassani A, Khavari A, Bathaie SZ. Saffron and natural carotenoids: Biochemical activities and anti-tumor effects. *Biochimica et Biophysica Acta*. 2014;1845(1):20-30.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
70. Brower V. Researchers attempting to define role of cytokines in cancer risk. *Journal of the National Cancer Institute*. 2005;97(16):1175-7.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
71. Bruns CJ, Schafer H, Wolfgarten B, Engert A. [Effect of intraoperative blood loss on the function of natural killer cells in tumors of the upper gastrointestinal tract]. *Langenbecks Archiv fur Chirurgie - Supplement - Kongressband*. 1996;113:146-9.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
72. Bu X, Liu Y, Jia L, Liang B, Zhang J, Yan Y. A recombinant adenovirus vector expressing human IFN-lambda1 inhibits the growth of orthotopic gastric cancer and its possible mechanism. [Chinese]. *Chinese Journal of Microbiology and Immunology (China)*. 2014;34(9):662-7.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
73. Bu X, Xu F, Ma J, Wei L. Evaluation of cellular immune function and gastric tumour for biomarkers after early enteral nutrition. *Farmacia*. 2018;66(4):615-20.  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
74. Bu XF, Zhang J, Jia LJ, Liang B, Zhang J, Liu Y, et al. Effect of human interferon-lambda1 recombinant adenovirus on a gastric cancer orthotopic transplantation model. *Experimental & Therapeutic Medicine*. 2014;8(4):1115-22.  
배제사유 : 동물실험 및 전임상시험연구
75. Budczies J, Bockmayr M, Klauschen F, Stenzinger A, Denkert C. Deciphering the impact of tumor genetics on immune cell infiltration in major solid cancer types. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2017;77(13 Supplement 1).  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
76. Cai GR, Li PW, Jiao LP. [Clinical observation of music therapy combined with anti-tumor drugs in treating 116 cases of tumor patients]. *Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban*. 2001;21(12):891-4.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
77. Canoz O, Belenli O, Patiroglu TE. General features of gastric carcinomas and comparison of HSP70 and NK cell immunoreactivity with prognostic factors. *Pathology Oncology Research*. 2002;8(4):262-9.



배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

78. Cao W, Lin Y, Yin H. [Use of parenteral nutritional support in patients with gastric cancer: the relationship of protein turn over, immunocompetence and tumor cell kinetics]. *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]*. 1995;33(5):265-8.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
79. Cao W, Xi X, Hao Z, Li W, Kong Y, Cui L, et al. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. *Journal of Biological Chemistry*. 2007;282(26):18922-8.  
배제사유 : 동물실험 및 전임상시험연구
80. Cao X, Jiang J, Jin MS, Ma HX, Kong F, Suo J. Galectin-9 as a prognostic factor with antimetastatic potential in gastric cancer. *Journal of Gastroenterology and Hepatology*. 2012;5:413.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
81. Carlsten M, Malmberg KJ, Ljunggren HG. Natural killer cell-mediated lysis of freshly isolated human tumor cells. *International Journal of Cancer*. 2009;124(4):757-62.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
82. Cecere FL, Aguilar A, Rosell R. Lung cavitation in lung metastases of gastric and non-small-cell lung cancer patients treated with apatinib. *Translational Lung Cancer Research*. 2019;8(4):317-8.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
83. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. *Cancer Research*. 2010;70(11):4297-309.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
84. Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, et al. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis. *Annals of Surgical Oncology*. 2007;14(4):1295-304.  
배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
85. Chaaben AB, Abaza H, Douik H, Ayari F, Baroudi O, Kablouti G, et al. The functionally relevant mica-129 dimorphism is associated with gastro-intestinal tract carcinomas in tunisian patients. *Tissue Antigens*. 2014;84 (1):151-2.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
86. Chan JKC, Tsang WYW, Lau WH, Cheung MMC, Ng WF, Yuen WC, et al. Aggressive T/natural killer cell lymphoma presenting as testicular tumor. *Cancer*. 1996;77(6):1198-205.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
87. Chan WY, Chan AB, Liu AY, Chow JH, Ng EK, Chung SS. Chromosome 11 copy number gains and Epstein-Barr virus-associated malignancies. *Diagnostic Molecular Pathology*.

2001;10(4):223-7.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

88. Chang WA, Tsai MJ, Kuo PL, Hung JY. Role of galectins in lung cancer (Review). *Oncology Letters*. 2017;14(5):5077-84.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

89. Chao TY, Hwang WS, Yeh MY. Generation of lymphokine-activated killer (LAK) cell activity from malignant peritoneal effusions. *Proceedings of the National Science Council, Republic of China - Part B, Life Sciences*. 1995;19(2):92-8.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

90. Chao TY, Jiang SY, Shyu RY, Yeh MY, Chu TM. All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity. *British Journal of Cancer*. 1997;75(9):1284-90.

배제사유 : 동물실험 및 전임상시험연구

91. Chen B, Cai XJ, Zhou SJ. [Antitumor activity of monoclonal antibody MI2 against immunosuppressive acidic protein in vitro]. *Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine*. 1994;33(8):531-3.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

92. Chen B, Wang Q, Sun L, Zhao Y, Shen B, Zhu W. Gastric cancer mesenchymal stem cells facilitate the disease progression of gastric cancer and resistance to AntiPD-1Therapy. *European Journal of Immunology*. 2019;49 (Supplement 3):1747-8.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

93. Chen J, Yang J, Jiang J, Zhuang Y, He W. Function and subsets of dendritic cells and natural killer cells were decreased in gastric cancer. *International Journal of Clinical & Experimental Pathology*. 2014;7(11):8304-11.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

94. Chen J, Zhang W, Feng X, Wang G, Jin C, Zhou D. The effect of early enteral nutrition (EEN) on immune function of gastric cardia adenocarcinoma postoperative patients. *Journal of clinical oncology*. 2014;32(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

95. Chen JL, Chen WX, Zhu JS, Chen NW, Zhou T, Yao M, et al. Effect of P-selectin monoclonal antibody on metastasis of gastric cancer and immune function. *World Journal of Gastroenterology*. 2003;9(7):1607-10.

배제사유 : 동물실험 및 전임상시험연구

96. Chen L, Zhang J, Sun H. Immunological adjuvant effect of the peptide fraction from the larvae of *Musca domestica*. *BMC Complementary and Alternative Medicine*. 2015;15 (1) (427).

배제사유 : 동물실험 및 전임상시험연구

97. Chen Q, Qian K, Yan C. Cloning of cDNAs with PDCD2(C) domain and their expressions during apoptosis of HEK293T cells. *Molecular & Cellular Biochemistry*.

2005;280(1-2):185-91.

배제사유 : 동물실험 및 전임상시험연구

98. Chen R, Zhang J, Hu Y, Wang S, Chen M, Wang Y. Potential antineoplastic effects of aloe-emodin: A comprehensive review. *American Journal of Chinese Medicine*. 2014;42(2):275-88.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

99. Chen X, Du Y, Lin X, Qian Y, Zhou T, Huang Z. CD4 + CD25 + regulatory T cells in tumor immunity. *International Immunopharmacology*. 2016;34:244-9.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

100. Chen XJ, Shen J, Zhang GB, Chen WC. B7-H6 protein expression has no prognostic significance in human gastric carcinoma. *Pathology Oncology Research*. 2014;20(1):203-7.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

101. Chen XZ, Hu JK, Liu J, Yang K, Zhou ZG, Wang LL, et al. Comparison of short-term outcomes and perioperative systemic immunity of laparoscopy-assisted and open radical gastrectomy for gastric cancer. *Journal of Evidence-based Medicine*. 2011;4(4):225-31.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

102. Chen Y, Chen B, Yang T, Xiao W, Qian L, Ding Y, et al. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells. *Cellular & Molecular Immunology*. 2017;14(3):293-307.

배제사유 : 동물실험 및 전임상시험연구

103. Chen Y, Chen X, Li Y, Zhang H, Xie Y, Zhang X, et al. Early effects of low dose C ion or X-Ray irradiation on peripheral blood lymphocytes of patients with alimentary tract cancer. *Dose-Response*. 2011;9(3):356-68.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

104. Chen Y, Lin WS, Zhu WF, Lin J, Zhou ZF, Huang CZ, et al. Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer. *Immunologic Research*. 2016;64(1):251-9.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

105. Chen Y, Mo J, Jia X, He Y. The B7 Family Member B7-H6: a New Bane of Tumor. *Pathology and Oncology Research*. 2018;24(4):717-21.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

106. Chen Z, Wang L, Xu T, Wang Q, Kang L, Zhao Q. Generation of bispecific antibodies by Fc heterodimerization and their application. *Current Pharmaceutical Biotechnology*. 2016;17(15):1324-32.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

107. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. *Cellular and Molecular Immunology*. 2013;10(3):230-52.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

108. Cherfils-Vicini J, Iltis C, Cervera L, Pisano S, Croce O, Sadouni N, et al. Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2. *EMBO Journal*. 2019;38 (11) (e100012).  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
109. Chi CO. A controlled trail of Autologous and umbilical cord blood cytokine-induced killer cells (U-CIKs) infusion on influence of the immune function in Advanced Cancer after Radiotherapy.  
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-ONRC-13002992>. 2013.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
110. Chi CO. Multi-center clinical study of umbilical cord blood cytokine-induced killer cells (U-CIKs) infusion on influence of the immune function in Advanced Cancer after Chemotherapy .  
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-ONRC-13002983>. 2013.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
111. Chi CT. A multicenter randomized controlled trial of "Yiqi Yangying" formulation for post-operation patients with gastric carcinoma and colonic cancer receiving combination chemotherapy.  
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TRC-09000389>. 2009.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
112. Chi CT. Effect of Amino Acids on the Quality of Life of Patients with Non-Small Cell Lung Cancer. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TRC-08000274>. 2008.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
113. Chochi K, Ichikura T, Kinoshita M, Majima T, Shinomiya N, HironoriTsujiimoto, et al. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas Its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. *Clinical Cancer Research*. 2008;14(10):2909-17.  
배제사유 : 동물실험 및 전임상시험연구
114. Chochi K, Ichikura T, Majima T, Kawabata T, Matsumoto A, Sugasawa H, et al. The increase of CD57+ T cells in the peripheral blood and their impaired immune functions in patients with advanced gastric cancer. *Oncology Reports*. 2003;10(5):1443-8.  
배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
115. Choi HS, Ha SY, Kim HM, Ahn SM, Kang MS, Kim KM, et al. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. *Oncotarget*. 2016;7(7):7940-51.  
배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
116. Choi JY, Kang HS. [Effects of a home-based exercise program for patients with stomach cancer receiving oral chemotherapy after surgery]. *Journal of Korean Academy of Nursing*. 2012;42(1):95-104.  
배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않

은 연구

117. Choi JY, Paik DJ, Kwon DY, Park Y. Dietary supplementation with rice bran fermented with *Lentinus edodes* increases interferon- activity without causing adverse effects: a randomized, double-blind, placebo-controlled, parallel-group study. *Nutrition journal*. 2014;13(1).  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
118. Chono S. [Immunohistochemical study using a double fluorescent staining on the regional lymph nodes of gastric cancers]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1990;91(1):36-46.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
119. Chun BM, Page DB, McArthur HL. Combination Immunotherapy Strategies in Breast Cancer. *Current Breast Cancer Reports*. 2019;11(4):228-40.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
120. Conlon K, Leidner R, McNeel D, Gupta S, Wang-Gillam A, Waldmann TA, et al. Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
121. Cui J, Li L, Wang C, Jin H, Yao C, Wang Y, et al. Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma. *Cytotherapy*. 2015;17(7):979-88.  
배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
122. Cui J, Li LY, Wang C, Jin HF, Yao C, Wang YZ, et al. Influence of combined cellular immunotherapy and chemotherapy on clinical outcome in patients with gastric carcinoma. *Journal of clinical oncology*. 2015;33(15 SUPPL. 1).  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
123. Cui M, Gong C, Jiang B, Yao Z, Chen L, Di J, et al. Evaluation of immune responses of gastric cancer patients treated by laparoscopic and open gastrectomy. *Medical Oncology*. 2015;32 (11) (253).  
배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
124. Cui R, Yue W, Lattime EC, Stein MN, Xu Q, Tan XL. Targeting tumor-associated macrophages to combat pancreatic cancer. *Oncotarget*. 2016;7(31):50735-54.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
125. Dai C, Lin F, Geng R, Ge X, Tang W, Chang J, et al. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. *Oncotarget*. 2016;7(9):10332-44.  
배제사유 : 동물실험 및 전임상시험연구
126. Daikeler T, Maas K, Weiss B, Hartmann J, Knobloch A, Arning M, et al. The influence of gemcitabine on the CD4/CD8 ratio in patients with solid tumours. *Oncology Reports*. 1997;4(3):561-4.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

127. D'Amata G, Izzo L, Pugliese F, Izzo S, Izzo P, Costi U, et al. New prognostic factors in gastric cancer: the role of lympho-plasmacytic infiltrate. *Annali Italiani di Chirurgia*. 2018;89:398-405.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

128. Dargent JL, Roufosse C, Vanderschueren B, Nouwynck C, Salhadin A, Jamsin S, et al. Natural killer-like T-cell lymphoma of the stomach. *Scandinavian Journal of Gastroenterology*. 1999;34(4):445-8.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

129. Davydova IG, Kassil VL, Filippova NA, Barinov MV. [Characteristics of the effects of artificial alkalosis on electrical activity of the brain and ultrastructure of blood cells in oncologic patients]. *Vestnik Rossiiskoi Akademii Meditsinskikh Nauk*. 1995(4):24-5.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

130. Daza J, Gul Z, Sfakianos JP. Role of heat shock proteins in bladder cancer: Potential biomarkers for treatment response and oncological prognosis. *Translational Andrology and Urology*. 2019;8(Supplement3):S240-S1.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

131. De Moraes-Vasconcelos D, Dorna MB, Grumach AS, Domingues-Ferreira M, Chuffi-Barros N, Silva-Duarte AJ. Malignancies in primary immunodeficiency patients. *Clinical Immunology*. 2010;135 (2):306.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

132. De Re V, Caggiari L, De Zorzi M, Canzonieri V, Maiero S, Cannizzaro R. KIR and HLA combinations in autoimmune gastritis and gastric cancer susceptibility. *Digestive and Liver Disease*. 2011;3):S170.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

133. De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, et al. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting. *Cytokine and Growth Factor Reviews*. 2018;44:1-10.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

134. Dedeepiya V, Ramanan G, Munirathnam D, Sumana P, Terunuma H, Senthilkumar R, et al. Hurdles overcome in technology transfer for AIET and positive outcome in Indian patients. *Journal of Stem Cells and Regenerative Medicine*. 2012;8(3):207-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

135. Delecluse HJ, Feederle R, O'Sullivan B, Taniere P. Epstein Barr virus-associated tumours: an update for the attention of the working pathologist. *Journal of Clinical Pathology*. 2007;60(12):1358-64.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

136. Dell'Agnola C, Biragyn A. Clinical utilization of chemokines to combat cancer: The double-edged sword. *Expert Review of Vaccines*. 2007;6(2):267-83.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

137. Dhalla F, da Silva SP, Lucas M, Travis S, Chapel H. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. *Clinical and Experimental Immunology*. 2011;165(1):1-7.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
138. Dhupkar P, Gordon N. Interleukin-2: Old and new approaches to enhance immune-therapeutic efficacy. *Advances in Experimental Medicine and Biology*. 2017;995:33-51.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
139. Dias Rodrigues V, Barroso De Pinho N, Abdelhay E, Viola JPB, Correia MI, Brum Martucci R. Nutrition and Immune-Modulatory Intervention in Surgical Patients with Gastric Cancer. *Nutrition in Clinical Practice*. 2017;32(1):122-9.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
140. Dietrich EM. Warfarin inhibits tumor metastasis through an immune-modulatory, coagulation-independent manner that involves NK cells: Possible anti-tumor effects in patients with OSCC? *Research Journal of Medical Sciences*. 2015;9(3):64-6.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
141. Ding W, Zhao S, Wang J, Yang Q, Sun H, Yan J, et al. Gastrointestinal Lymphoma in Southwest China: Subtype Distribution of 1,010 Cases Using the WHO (2008) Classification in a Single Institution. *Acta Haematologica*. 2016;135(1):21-8.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
142. Djeu J, Gilvary D, Trinh TL, Tu N, Coppola D. Expression of MICA/b, a ligand for natural killer (NK) cell recognition, on human pancreatic adenocarcinoma and potential for NK intervention. *Journal of Clinical Oncology*. 2017;35 (7 Supplement 1):129.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
143. do Nascimento JCF, de Oliveira Vasconcelos A, Seabra M, Beltrao EIC, Rocha CRC. The challenge of determining the impact of FUT3 tumor-associated polymorphism rs2306969 (-6951 C> T) in invasive breast cancer cells. *Molecular Biology Reports*. 2019;46(3):3531-6.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
144. Dolcetti R, De Re V, Canzonieri V. Immunotherapy for gastric cancer: Time for a personalized approach? *International Journal of Molecular Sciences*. 2018;19 (6) (1602).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
145. Donaldson DS, Williams NA. Bacterial toxins as immunomodulators. *Pathogen-Derived Immunomodulatory Molecules*. 2009;Advances in Experimental Medicine and Biology. 666:1-18.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
146. Dong JR, Wan H, Zhou AG. Effect of "Ru'aishuhou herbs"on the clinical symptom immunity function in patients with breast cancer postoperation. *International forum on chinese and western oncology papers album [guo ji zhong xi yi zhong liu yan jiu lun tan lun wen zhuan ji]*. 2008;12(1):281?8.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

147. Downs-Kelly E, Schade AE, Hansel DE. The role of HLA-G in gastrointestinal inflammatory disease and malignancy. *Seminars in Cancer Biology*. 2007;17(6):451-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

148. Du Y, Wei Y. Therapeutic Potential of Natural Killer Cells in Gastric Cancer. *Frontiers in Immunology*. 2018;9:3095.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

149. Dutta N, Gupta A, Mazumder DNG, Banerjee S. Down-regulation of locus-specific human lymphocyte antigen class I expression in Epstein-Barr Virus-associated gastric cancer: Implication for viral-induced immune evasion. *Cancer*. 2006;106(8):1685-93.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

150. Dutta N, Majumder D, Gupta A, Mazumder DN, Banerjee S. Analysis of human lymphocyte antigen class I expression in gastric cancer by reverse transcriptase-polymerase chain reaction. *Human Immunology*. 2005;66(2):164-9.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

151. Ebihara T, Fukao K, Koyama S. Functional and phenotypic characteristics of recombinant interleukin-2 or T-cell growth factor-activated splenic lymphoid cells from patients with gastric or hepatocellular carcinoma. *Cancer*. 1990;66(5):923-9.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

152. Ebihara T, Koyama S, Fukao K, Osuga T. Lymphokine-activated suppressor (LAS) cells in patients with gastric carcinoma. *Cancer Immunology, Immunotherapy*. 1989;28(3):218-24.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

153. El-Zaatari M, Bass AJ, Bowlby R, Zhang M, Syu LJ, Yang Y, et al. Indoleamine 2,3-Dioxygenase 1, Increased in Human Gastric Pre-Neoplasia, Promotes Inflammation and Metaplasia in Mice and Is Associated With Type II Hypersensitivity/Autoimmunity. *Gastroenterology*. 2018;154(1):140-53.e17.

배제사유 : 동물실험 및 전임상시험연구

154. Eminger LA, Hall LD, Hesterman KS, Heymann WR. Epstein-Barr virus: dermatologic associations and implications: part II. Associated lymphoproliferative disorders and solid tumors. *Journal of the American Academy of Dermatology*. 2015;72(1):21-34; quiz 5-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

155. Endo K, Baba H, Ohno S, Yamamoto M, Maehara Y, Sugimachi K. Early recurrence of gastric cancer in a patient with chronic renal failure. *Anticancer Research*. 1995;15(2):623-5.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

156. Enesel MB, Acalovschi I, Grosu V, Sbarcea A, Rusu C, Dobre A, et al. Perioperative application of the *Viscum album* extract Isorel in digestive tract cancer patients. *Anticancer Research*. 2005;25(6 C):4583-90.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구



157. Everly D, Sharma-Walia N, Sadagopan S, Chandran B. Herpesviruses and cancer. *Cancer Associated Viruses*. 2012;Current Cancer Research. 8:133-67.  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
158. Ezaki K, Ogawa M, Okabe K. Clinical and immunological studies of human fibroblast interferon. *Cancer Chemotherapy and Pharmacology*. 1982;8(1):47-55.  
배제사유 : 동물실험 및 전임상시험연구
159. Ezaki K. [Clinical and immunological studies of human fibroblast interferon and human lymphoblastoid interferon in malignant diseases]. *Gan No Rinsho - Japanese Journal of Cancer Clinics*. 1983;29(6):598-602.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
160. Fabbri L, Ridolfi R, Riccobon A, Maltoni R, Flamini E, Fedriga R, et al. Liver metastases from gastric carcinoma: report of a patient treated with adoptive immunotherapy (tumor-infiltrating lymphocytes plus interleukin-2 and subsequently local-regional lymphokine-activated killer cells plus interleukin-2). *Tumori*. 1995;81(6):445-9.  
배제사유 : 동물실험 및 전임상시험연구
161. Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. *Journal for ImmunoTherapy of Cancer*. 2020;8 (1) (e000450).  
배제사유 : 동물실험 및 전임상시험연구
162. Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. *Journal of Hematology and Oncology*. 2015;8 (1) (130).  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
163. Fang JM, Bi AH. Observation of activity of IL-2 produced by mononuclear cells in tumor draining lymph-node. *Journal of Tongji Medical University*. 1989;9(2):91-4.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
164. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the end of cancer? *BMC Medicine*. 2016;14 (1) (73).  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
165. Farrell PJ. Epstein-Barr Virus and Cancer. *Annual Review of Pathology: Mechanisms of Disease*. 2019;14:29-53.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
166. Feng D, Shi W, Leong M, Li T, He X, Zhang Z. Differential gene expression pattern of the response to neoadjuvant chemotherapy in locally advanced gastric cancer. *International Journal of Clinical and Experimental Medicine*. 2016;9(11):21911-21.  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
167. Feng PF, Liu LM, Shen YY. [Effect of shenmai injection on sIL-2R NK and LAK cells in patients with advanced carcinoma]. *Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western*

Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 1995;15(2):87-9.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

168. Fiedler W, Sessa C, Gianni L, Cresta S, Schulze-Bergkamen H, Weidmann J, et al. First-in-human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity. *Journal of Clinical Oncology. Conference*. 2013;31(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

169. Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): Implications of cancer immunotherapy. *Anticancer Research*. 2002;22(3):1737-54.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

170. Foulds S, Wakefield CH, Giles M, Gillespie J, Dye JF, Guillou PJ. Expression of a suppressive p15E-related epitope in colorectal and gastric cancer. *British Journal of Cancer*. 1993;68(3):610-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

171. Franzolin G, Tamagnone L. Semaphorin signaling in cancer-associated inflammation. *International Journal of Molecular Sciences*. 2019;20 (2) (377).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

172. Fujimoto T, Omote K, Mai M, Natsuume-Sakai S. Evaluation of basic procedures for adoptive immunotherapy for gastric cancer. *Biotherapy*. 1992;5(2):153-63.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

173. Fukayama M. Epstein-Barr virus and gastric carcinoma. *Pathology International*. 2010;60(5):337-50.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

174. Funaki J, Kokura S, Tsuchiya R, Matsuyama T, Okajima M, Sakai H, et al. Promising efficacy of immunotherapy combined with cetuximab-mediated ADCC. [Japanesel]. *Biotherapy*. 2011;25(5):803-10.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

175. Fung KY, Nguyen PM, Putoczki TL. Emerging Roles for Interleukin-18 in the Gastrointestinal Tumor Microenvironment. *Advances in Experimental Medicine and Biology*. 2020;1240:59-72.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

176. Furue H, Kako M, Mugitani H, Fuse K, Kaise R, Hirota F, et al. [Host factors in cancer chemotherapy]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1986;13(4 Pt 2):1126-34.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

177. Furukawa T, Kubota T, Watanabe M, Kuo TH, Kitajima M, Hoffman RM. Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice. *International Journal of Cancer*. 1993;54(3):397-401.

배제사유 : 동물실험 및 전임상시험연구

178. Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L. Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. *Anti-Cancer Drugs*. 2003;14(10):833-43.

배제사유 : 동물실험 및 전임상시험연구

179. Ganesan S, Bhanot G, Mehnert JM, Silk AW, Ross JS, Pavlick D, et al. Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers. *Journal of Clinical Oncology*. 2017;35 (7 Supplement 1):35.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

180. Gao JL, Gao W, Dou ZX. Effect of early postoperative enteral nutrition on nutrition status and immune function in gastric cancer patients. [Chinese]. *World Chinese Journal of Digestology*. 2015;23(21):3451-5.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

181. Gao JQ, Okada N, Mayumi T, Nakagawa S. Immune cell recruitment and cell-based system for cancer therapy. *Pharmaceutical Research*. 2008;25(4):752-68.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

182. Gao YF, Yuan W, Ding XY, Huo XW, Jing GX, Lu Y. Effects of postoperative multimodal analgesia with dezocine and flurbiprofen on cellular immune function in patients after radical gastric cancer surgery. [Chinese]. *Journal of Xi'an Jiaotong University (Medical Sciences)*. 2014;35(5):669-73 and 713.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

183. Garrido F. MHC/HLA class I loss in cancer cells. *Advances in Experimental Medicine and Biology*. 2019;1151:15-78.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

184. Garrido-Tapia M, Hernandez CJ, Ascui G, Kramm K, Morales M, Ga Rate V, et al. STAT3 inhibition by STA21 increases cell surface expression of MICB and the release of soluble MICB by gastric adenocarcinoma cells. *Immunobiology*. 2017;222(11):1043-51.

배제사유 : 동물실험 및 전임상시험연구

185. Gertler A, Elinav E. Novel superactive leptin antagonists and their potential therapeutic applications. *Current Pharmaceutical Design*. 2014;20(4):659-65.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

186. Ghasemi F, Gameiro SF, Tessier TM, Maciver AH, Mymryk JS. High levels of Class I major histocompatibility complex mRNA are present in epstein-barr virus-associated gastric adenocarcinomas. *Cells*. 2020;9 (2) (499).

배제사유 : 동물실험 및 전임상시험연구

187. Ghiringhelli F, Rebe C, Hichami A, Delmas D. Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. *Anti-Cancer Agents in Medicinal Chemistry*. 2012;12(8):852-73.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

188. Ghoddusi M, Pierce K, Powers J, Masteller E, Clark L, Krishnan K, et al. FGFR2b represents a novel target for treatment of urothelial cancer. *European Journal of Cancer*. 2016;69 (Supplement 1):S143.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
189. Gil M, Kim KE. Interleukin-18 is a prognostic biomarker correlated with CD8+ T cell and natural killer cell infiltration in skin cutaneous melanoma. *Journal of Clinical Medicine*. 2019;8 (11) (1993).  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
190. Giraud L, Gammaitoni L, Cangemi M, Rotolo R, Aglietta M, Sangiolo D. Cytokine-induced killer cells as immunotherapy for solid tumors: Current evidence and perspectives. *Immunotherapy*. 2015;7(9):999-1010.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
191. Goh M, Lim ZM, Koh V, Lum J, Zhang X, McGovern N, et al. Single-cell analysis of immunomicroenvironment and immunetumor interaction in human gastric cancers. *Journal of Clinical Oncology. Conference*. 2019;37(Supplement 4).  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
192. Goldstein MR, Mascitelli L. Surgery and cancer promotion: Are we trading beauty for cancer? *Qim*. 2011;104(9):811-5.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
193. Gong LP, Chen JN, Xiao L, He Q, Feng ZY, Zhang ZG, et al. The implication of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric carcinoma. *Human Pathology*. 2019;85:82-91.  
 배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
194. Goto S, Sato M, Kaneko R, Itoh M, Sato S, Takeuchi S. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. *Cancer Immunology Immunotherapy*. 1999;48(8):435-42.  
 배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
195. Gotoh K. [Augmentation of cytotoxicity of tumor infiltrating lymphocytes by interleukin-2 in gastric cancer patients]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1985;86(12):1600-7.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
196. Goynes HE, Cannon MJ. The case for HER2/neu as a therapeutic target for gynecologic malignancies. *Immunotherapy*. 2012;4(8):781-4.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
197. Grierson P, Lim KH, Amin M. Immunotherapy in gastrointestinal cancers. *Journal of Gastrointestinal Oncology*. 2017;8(3):474-84.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
198. Griffith C, Rees RC, Platts AD. Enhanced natural killer cell activity in patients with

malignant disease of stomach and large bowel during intravenous anaesthesia and surgery. Preliminary report. Journal of Experimental and Clinical Cancer Research. 1983;2(4):399-402.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

199. Gu Q, Zhu Z, Yin H. [The effects of IFN-gamma on the antitumor abilities of immunocytes and chemotherapeutic agents]. Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]. 1997;35(2):89-91.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

200. Gu RM, Wen X, Wei D, Ming XZ, Li G, Chen HQ. [Effect of intraoperative intraperitoneal chemotherapy and postoperative nutritional support on intestinal permeability and cellular immune function in patients with advanced gastric cancer]. Zhonghua Weichang Waike Zazhi. 2012;15(5):468-72.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

201. Gulubova M, Manolova I, Kyurkchiev D, Julianov A, Altunkova I. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. APMIS. 2009;117(12):870-9.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

202. Guo M, Zhang CH, Xu Y, Zhai YF. Integrated traditional Chinese medicine assisted hepatic artery infusion in treatment of 43 cases of primary liver cancer at middle and advanced stages. Chinese journal of experimental traditional medical formulae [zhong guo shi yan fang ji xue za zhi]. 2014;20(15):195-9.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

203. Gur C, Maalouf N, Gerhard M, Singer BB, Emgard J, Temper V, et al. The Helicobacter pylori HopQ outer membrane protein inhibits immune cell activities. OncolImmunology. 2019;8 (4) (e1553487).

배제사유 : 위암 환자를 대상으로 하지 않은 연구

204. Gurwitz D. Cancer therapeutics: Reflections on natural killer cells. Drug Development Research. 2008;69(6):285-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

205. Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K, et al. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. Journal of Immunology. 1981;127(1):34-8.

배제사유 : 동물실험 및 전임상시험연구

206. Hahm KB, Kim WH, Lee SI, Kang JK, Park IS. Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scandinavian Journal of Gastroenterology. 1995;30(3):265-71.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

207. Hahm KB, Lee SI, Chung JP, Kim WH, Kim JH, Park IS. Comparison of immunomodulative effects of histamine-2 receptor antagonists in gastric cancer patients:

focus on the lymphoblastogenesis and cytotoxicity of peripheral blood mononuclear cells. *International Journal of Immunopharmacology*. 1994;16(12):985-93.

배제사유 : 동물실험 및 전임상시험연구

208. Han B, Mao FY, Zhao YL, Lv YP, Teng YS, Duan M, et al. Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer. *Journal of Immunological Research*. 2018;2018:6248590.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

209. Han FG. [Treatment of advanced liver cancer by autologous and/or homologous LAK cells combined with human natural LL-2]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 1991;13(2):145-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

210. Hanaue H, Kim DY, Kubota M, Kurosawa T, Shikata J, Kondoh Y, et al. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation. *Tokai Journal of Experimental & Clinical Medicine*. 1987;12(2):97-102.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

211. Hao YB, Yi SY, Ruan J, Zhao L, Nan KJ. New insights into metronomic chemotherapy-induced immunoregulation. *Cancer Letters*. 2014;354(2):220-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

212. Hara M, Nakanishi H, Tsujimura K, Matsui M, Yatabe Y, Manabe T, et al. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity. *Cancer Science*. 2008;99(7):1471-8.

배제사유 : 동물실험 및 전임상시험연구

213. Harada S, Yanagisawa M, Kaneko S, Yorozu K, Yamamoto K, Moriya Y, et al. Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. *Molecular & Clinical Oncology*. 2015;3(5):987-94.

배제사유 : 동물실험 및 전임상시험연구

214. Harrer DC, Dorrie J, Schaft N. Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race. *Human Gene Therapy*. 2018;29(5):547-58.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

215. Hartley S, Beech A, Griffiths C, Richardson F, Knight H, McMillan AK, et al. Kinetics of T-cell subset reconstitution following bendamustine-containing therapy for low-grade lymphoproliferative disease: A population based analysis. *Blood*. Conference: 59th Annual Meeting of the American Society of Hematology, ASH. 2017;130(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

216. Harvey JB, Phan LH, Villarreal OE, Bowser JL. CD73's Potential as an Immunotherapy

Target in Gastrointestinal Cancers. *Frontiers in Immunology*. 2020;11 (508).

배제사유 : 원자가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

217. Hasegawa J, Sue M, Yamato M, Ichikawa J, Ishida S, Shibutani T, et al. Novel anti-EPHA2 antibody, DS-8895a for cancer treatment. *Cancer Biology & Therapy*. 2016;17(11):1158-67.

배제사유 : 동물실험 및 전임상시험연구

218. Hattori T, Niimoto M, Toge T, Hamamoto S, Seto Y, Kameda A, et al. [Local immunotherapy for cancer]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1984;85(9):1157-61.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

219. Hayakawa S, Okada S, Tsumura M, Sakata S, Ueno Y, Imai K, et al. A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer. *Journal of Clinical Immunology*. 2016;36(1):28-32.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

220. Hayashi H, Nio Y, Kawabata K, Araya S, Imamura M. Cis-diamminedichloroplatinum(II) augments expression of tumor-associated antigens on human gastric cancer cell line KATO-3 and increases susceptibility and binding of tumor cells to various cytotoxic effector cells. *Journal of Surgical Oncology*. 1996;62(3):162-70.

배제사유 : 동물실험 및 전임상시험연구

221. Hayashi R, Kitazawa K, Sanada D, Kato N, Ohkoshi T, Katsumata Y, et al. Diffuse leukoencephalopathy associated with dialysis disequilibrium syndrome. *Internal Medicine*. 2015;54(21):2753-8.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

222. Hazama S, Oka M, Yoshino S, Iizuka N, Wadamori K, Yamamoto K, et al. [Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1995;22(11):1595-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

223. Healy LP, Rossi GR, Rautela J, Slade CA, Huntington ND, Winship IM, et al. Loss-of-function in SMad4 might not be critical for human natural killer cell responsiveness to TGF-beta. *Frontiers in Immunology*. 2019;10 (MAY) (904).

배제사유 : 위암 환자를 대상으로 하지 않은 연구

224. Heiss MM, Strohle MA, Jager M, Kimmig R, Burges A, Schoberth A, et al. Immunotherapy of malignant ascites with trifunctional antibodies. *International Journal of Cancer*. 2005;117(3):435-43.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

225. Helmin-Basa A, Michalkiewicz J, Gackowska L, Kubiszewska I, Eljaszewicz A, Mierzwa G, et al. Pediatric *Helicobacter pylori* Infection and Circulating T-Lymphocyte Activation and Differentiation. *Helicobacter*. 2011;16(1):27-35.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

226. Hernandez CJ, Garrido-Tapia M, Kramm K, Ribeiro CH, Molina MC. Heat killed *Helicobacter pylori* increases NK cell cytotoxicity through induction of NKG2DL surface expression on gastric adenocarcinoma cells. *European Journal of Immunology*. 2016;46 (Supplement 1):175.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
227. Hernandez EG, Partida-Rodriguez O, Camorlinga-Ponce M, Nieves-Ramirez M, Ramos-Vega I, Torres J, et al. Genotype B of Killer Cell Immunoglobulin-Like Receptor is Related with Gastric Cancer Lesions. *Scientific Reports*. 2018;8(1):6104.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
228. Hess T, Gyvyte U, Becker J, Heinrichs S, Lindenberg S, Leja M, et al. Stomach specific eQTLs represent risk factors for the development of gastric carcinoma. *Medizinische Genetik*. 2016;28 (1):175.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
229. Hida T, Koike K, Sekido Y, Nishida K, Sugiura T, Ariyoshi Y, et al. Epitope analysis of cluster 1 and NK cell-related monoclonal antibodies. *British Journal of Cancer - Supplement*. 1991;14:24-8.  
 배제사유 : 동물실험 및 전임상시험연구
230. Hideshima T, Kumashiro R, Kamachi H, Doki T, Oku K, Ugaeri H, et al. [Effect of splenectomy in gastric carcinoma surgery on cell-mediated immunity; evaluation with alteration of peripheral blood lymphocyte subsets]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1987;14(5 Pt 1):1268-73.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
231. Hinner MJ, Aiba RSB, Wiedenmann A, Schlosser C, Allersdorfer A, Matschiner G, et al. Costimulatory T-cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein based on Anticalin technology. *Cancer Immunology Research*. Conference: CRI CIMT EATI AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival. United States. 2016;4(1 Supplement).  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
232. Hiraki A, Fujii N, Masuda K, Ikeda K, Tanimoto M. Genetics of Epstein-Barr virus infection. *Biomedicine and Pharmacotherapy*. 2001;55(7):369-72.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
233. Hirashima M, Higuchi S, Sakamoto K, Nishiyama T, Okada H. The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with early gastric cancer. *Journal of Cancer Research and Clinical Oncology*. 1998;124(6):329-34.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
234. Honda J, Oizumi K. Epstein-Barr virus and human cancer. [Japanese]. *Biotherapy*. 1999;13(10):1067-73.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
235. Hone S, Kirschfink M, Mamidi S. Improved complement-dependent cellular cytotoxicity by PBLs and PMNs on HER2 positive tumors upon knockdown of membrane complement



regulators. *Molecular Immunology*. 2014;61 (2):238-9.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

236. Hong CW, Zeng Q. Tapping the treasure of intracellular oncotargets with immunotherapy. *FEBS Letters*. 2014;588(2):350-5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

237. Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin 32, inflammation and cancer. *Pharmacology & Therapeutics*. 2017;174:127-37.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

238. Hong L, Fan D. Cancer mucosa antigens: Novel immunotherapeutic targets. *Expert Opinion on Therapeutic Targets*. 2008;12(6):749-56.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

239. Hong WS, Hong SI, Kim CM, Kang YK, Song JK, Lee MS, et al. Differential depression of lymphocyte subsets according to stage in stomach cancer. *Japanese Journal of Clinical Oncology*. 1991;21(2):87-93.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

240. Hong WS, Kim CM, Lee JO, Kang TW, Yun TK, Kim CY. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy. *Japanese Journal of Clinical Oncology*. 1990;20(1):87-93.

배제사유 : 동물실험 및 전임상시험연구

241. Hong WS, Min YI, Son YS, Hong SI. Peripheral blood lymphocyte subsets in patients with stomach cancer. *Journal of Korean Medical Science*. 1995;10(3):164-8.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

242. Hong XJ, Wang QQ. [A novel cancer-associated antigen RCAS1]. *Zhejiang da Xue Xue Bao. Yi Xue Ban/Journal of Zhejiang University. Medical Sciences*. 2005;34(6):578-81, 84.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

243. Horie Y, Kato K, Kameoka S, Hamano K. Bu ji (hozai) for treatment of postoperative gastric cancer patients. *American Journal of Chinese Medicine*. 1994;22(3-4):309-19.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

244. Horie Y. Alteration of natural killer (NK) activity with gabexate mesilate (FOY) and its metabolite, epsilon-guanidinocaproic acid (GCA). [Japanese]. *Journal of Tokyo Women's Medical College*. 1993;63(2):143-50.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

245. Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. *Nature Reviews Clinical Oncology*. 2015;12(4):213-26.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

246. Hoseini SS, Cheung NKV. Immunotherapy of hepatocellular carcinoma using chimeric

antigen receptors and bispecific antibodies. *Cancer Letters*. 2017;399:44-52.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

247. Houldcroft CJ, Kellam P. Host genetics of Epstein-Barr virus infection, latency and disease. *Reviews in Medical Virology*. 2015;25(2):71-84.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

248. Hsu JT, Hsu CS, Le PH, Chen TC, Chou WC, Lin CY, et al. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1. *Journal of Surgical Research*. 2017;211:30-8.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

249. Hu B, Tian X, Li Y, Liu Y, Yang T, Han Z, et al. Epithelial-mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1. *Cancer Medicine*. 2020;9(8):2686-97.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

250. Hu QP, Kuang JY, Yang QK, Bian XW, Yu SC. Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer. *International Journal of Cancer*. 2016;138(12):2804-12.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

251. Hu W, Liang J, Sun DS, Liu HR, Liu XL, Li Y. Anti-CD3 monoclonal antibody activated autologous killer cells in treatment of advanced malignant tumor: An observation of short-term effectiveness. [Chinese]. *Chinese Journal of Cancer Biotherapy*. 2008;15(2):155-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

252. Huang B, Zhao J, Shen S, Li H, He KL, Shen GX, et al. *Listeria monocytogenes* promotes tumor growth via tumor cell toll-like receptor 2 signaling. *Cancer Research*. 2007;67(9):4346-52.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

253. Huang D, Sun Z, Huang J, Shen Z. Early enteral nutrition in combination with parenteral nutrition in elderly patients after surgery due to gastrointestinal cancer. *International journal of clinical and experimental medicine*. 2015;8(8):13937-45.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

254. Huang S, Fan W, Liu P, Tian J. [Meta analysis of compound matrine injection combined with cisplatin chemotherapy for advanced gastric cancer]. *Zhongguo Zhong Yao Za Zhi/Zhongguo Zhongyao Zazhi/China Journal of Chinese Materia Medica*. 2011;36(22):3198-202.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

255. Huo SH, Kim HS, Park GG. The effect of interferon on NK cell activity in patients with stomach cancer in vitro. [Korean]. *Journal of Korean Cancer Research Association*. 1984;16(1):12-9.

배제사유 : 동물실험 및 전임상시험연구

256. Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A, et al.

Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. *Annals of Surgical Oncology*. 2008;15(6):1775-82.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

257. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. *Cancer and Metastasis Reviews*. 2005;24(4):487-99.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

258. Ieni A, Barresi V, Rigoli L, Fedele F, Tuccari G, Caruso RA. Morphological and cellular features of innate immune reaction in helicobacter pylori gastritis: A brief review. *International Journal of Molecular Sciences*. 2016;17 (1) (109).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

259. Ietomi K. [A study on the role of granulocytes in carcinoma-bearing hosts--G/L ratio as a new host indicator]. *Nippon Gan Chiryō Gakkai Shi - Journal of Japan Society for Cancer Therapy*. 1990;25(3):662-71.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

260. Iguchi-Manaka A, Okumura G, Kojima H, Cho Y, Hirochika R, Bando H, et al. Increased Soluble CD155 in the Serum of Cancer Patients. *PLoS ONE [Electronic Resource]*. 2016;11(4):e0152982.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

261. Iida T, Wagatsuma K, Hirayama D, Nakase H. Is osteopontin a friend or foe of cell apoptosis in inflammatory gastrointestinal and liver diseases? *International Journal of Molecular Sciences*. 2018;19 (1) (7).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

262. Iinuma H, Okinaga K, Tamura J, Kumagai H, Kitamura Y. Effect of splen preservation in postoperative immunochemotherapy of patients with gastric cancer. *Biotherapy (Dordrecht, Netherlands)*. 1995;9(3):312?3.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

263. Iinuma H, Okinaga K, Tamura J, Kumagai H, Yago T, Baba Y. Immunoresponse to OK-432 of gastric cancer patients. [Japanese]. *Biotherapy*. 1998;12(1):231-3.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

264. Iinuma H, Okinaga K, Tamura J, Kumagai H, Yokohata T, Fukushima R. Response to OK-432 in immunochemotherapy for patients with gastric cancer. [Japanese]. *Biotherapy*. 1996;10(3):488-90.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

265. Inagaki T, Morise K, Matsunaga H. [Effects of endoscopic intratumoral injection of lentinan in patients with gastric cancer]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1988;15(2):319-24.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

266. Inoue T, Tashiro Y, Takeuchi M, Otani T, Tsuji-Takayama K, Okochi A, et al. Potent

anti-tumor killing activity of the multifunctional Treg cell line HOZOT against human tumors with diverse origins. *International Journal of Oncology*. 2011;38(5):1299-306.

배제사유 : 동물실험 및 전임상시험연구

267. Ishibashi H, Nimura S, Ishitsuka K, Mihashi Y, Mizoguchi M, Nakamura S, et al. High Expression of Intestinal Homing Receptor CD103 in Adult T-Cell Leukemia/Lymphoma, Similar to 2 Other CD8+ T-Cell Lymphomas. *American Journal of Surgical Pathology*. 2016;40(4):462-70.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

268. Ishigami S, Natsugoe S, Hokita S, Xiangming C, Aridome K, Iwashige H, et al. Intranodal antitumor immunocyte infiltration in node-negative gastric cancers. *Clinical Cancer Research*. 2000;6(7):2611-7.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

269. Ishigami S, Natsugoe S, Miyazono F, Nakajo A, Tokuda K, Matsumoto M, et al. HLA-G expression in gastric cancer. *Anticancer Research*. 2006;26(3B):2467-72.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

270. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. *Cancer*. 2000;88(3):577-83.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

271. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. *Cancer Letters*. 2000;159(1):103-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

272. Ishigami S, Natsugoe S, Uenosono Y, Hata Y, Nakajo A, Miyazono F, et al. Infiltration of antitumor immunocytes into the sentinel node in gastric cancer. *Journal of Gastrointestinal Surgery*. 2003;7(6):735-9.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

273. Ishii H, Gouchi A, Orita K. The enhancement of cell surface ICAM-I and HLA class I antigens in human gastric cancer cell lines by IFN-gamma. *Acta Medica Okayama*. 1994;48(2):73-9.

배제사유 : 동물실험 및 전임상시험연구

274. Ishii Y. Study of preoperative lesional injection of biological response modifiers to augment immunologic defence effect of the regional lymphnode lymphocyte in the patients with primary gastric cancer. [Japanese]. *Fukushima Medical Journal*. 1991;41(1):51-64.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

275. Ishikawa H, Kobayashi J, Takagi A, Takeyoshi I, Ohwada S, Morishita Y. The efficacy of cimetidine for postoperative immunity in patients with gastric cancer. [Japanese]. *Kitakanto Medical Journal*. 2003;53(2):103-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

276. Ishikawa K, Shimoda K, Shiraishi N, Adachi Y, Kitano S. Induction of natural killer

suppressive factor in murine peritoneal cavity by intraperitoneal bolus administration of high-dose cisplatin. *International Journal of Clinical Oncology*. 2000;5(1):48-53.

배제사유 : 동물실험 및 전임상시험연구

277. Ishikawa K, Shimoda K, Shiraishi N, Adachi Y, Kitano S. Low-dose cisplatin-5-fluorouracil prevents postoperative suppression of natural killer cell activity in patients with gastrointestinal cancer. *Japanese Journal of Clinical Oncology*. 1998;28(6):374-7.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

278. Ishikawa T, Okayama T, Sakamoto N, Ideno M, Oka K, Enoki T, et al. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer. *International Journal of Cancer*. 2018;142(12):2599-609.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

279. Ishikawa T, Okayama T, Sakamoto N, Ideno M, Oka K, Enoki T, et al. Safety and efficacy of high purity and activity NK cells therapy in combination with IgG1 antibody in patients with gastric or colorectal cancer: A phase I clinical trial. *Cancer Research. Conference*. 2018;78(13 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

280. Isikdogan A, Ayyildiz O, Buyukcelik A, Arslan A, Tiftik N, Buyukbayram H, et al. Non-Hodgkin's lymphoma in southeast Turkey: Clinicopathologic features of 490 cases. *Annals of Hematology*. 2004;83(5):265-9.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

281. Itoh K, Shiiba K, Ebina N, Anzai R, Ouchi A, Matsuno S. [Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1993;94(8):781-90.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

282. Itoh T, Ueda Y, Okugawa K, Fujiwara H, Fuji N, Yamashita T, et al. Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. *Cancer Immunology, Immunotherapy*. 2003;52(4):207-14.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

283. Iwahashi M, Tanimura H, Yamaue H, Tani M, Noguchi K, Mizobata S, et al. Ubenimex treatment enhances the susceptibility of gastric cancer cell lines to lymphokine-activated killer cells. *Anticancer Research*. 1994;14(4A):1563-8.

배제사유 : 동물실험 및 전임상시험연구

284. Iwahashi M, Tanimura H, Yamaue H, Tsunoda T, Tani M, Tamai M, et al. [Combination of adoptive immunotherapy and chemotherapy against advanced cancer with peritoneal dissemination]. *Nippon Gan Chiryo Gakkai Shi - Journal of Japan Society for Cancer Therapy*. 1990;25(8):1558-64.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

285. Iwahashi M, Tanimura H, Yamaue H, Tsunoda T, Tani M, Tamai M, et al. Defective autologous mixed lymphocyte reaction (AMLR) and killer activity generated in the AMLR in cancer patients. *International Journal of Cancer*. 1992;51(1):67-71.  
 배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
286. Iwasaki M. Cancer incidence and novel therapies developed in Japan. *Journal of Stem Cells & Regenerative Medicine*. 2012;8(3):203-4.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
287. Izawa S, Kono K, Mimura K, Kawaguchi Y, Watanabe M, Maruyama T, et al. H2O2 production within tumor microenvironment inversely correlated with infiltration of CD56(dim) NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction. *Cancer Immunology, Immunotherapy*. 2011;60(12):1801-10.  
 배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
288. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. *Nature Reviews Clinical Oncology*. 2016;13(6):370-83.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
289. Jakel CE, Vogt A, Gonzalez-Carmona MA, Schmidt-Wolf IG. Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. *Journal of Immunological Research*. 2014;2014:897214.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
290. Jakesz R, Bohmig HJ, Depisch D, Funovics J, Hamilton G, Hofbauer F, et al. [Toxicity results of an adjuvant study with intraperitoneal chemotherapy in patients with stomach cancer. Current status and future prospects of intraperitoneal therapy]. *Wiener Klinische Wochenschrift*. 1987;99(12):415-20.  
 배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
291. Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP, Zang X. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. *Immunological Reviews*. 2017;276(1):26-39.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
292. Jarry A, Cerf-Bensussan N, Brousse N, Guy-Grand D, Muzeau F, Potet F. Same peculiar subset of HML1+ lymphocytes present within normal intestinal epithelium is associated with tumoral epithelium of gastrointestinal carcinomas. *Gut*. 1988;29(12):1632- 8.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
293. Javeed A, Zhao Y. Macrophage-migration inhibitory factor: Role in inflammatory diseases and graft rejection. *Inflammation Research*. 2008;57(2):45-50.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
294. Jesionek-Kupnicka D, Kulczycka D, Najder M, Olborski B, Kordek R. Phenotypic analysis of tumour infiltrating lymphocytes in breast cancer, colorectal cancer and gastric cancer tissue in comparison with normal control tissue and some clinico-pathological features. [Polish]. *Onkologia Polska*. 2002;5(3-4):129-34.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구

295. Ji S, Chen H, Yang K, Zhang G, Mao B, Hu Y, et al. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy. *Biomedicine and Pharmacotherapy*. 2020;129 (110457).  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
296. Jiang CM, Pang MR, Gong LY. [Clinical observation on effect of chemotherapy combined with Chinese medicine in treating advanced tumor patients and on immunologic parameters]. *Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban*. 2001;21(12):885-7.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
297. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. *Journal of Translational Medicine*. 2013;11 (1) (83).  
 배제사유 : 원자가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
298. Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. *Anticancer Research*. 2006;26(3B):2237-42.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
299. Jiang L, Zhu JS. Research advance in immuology of gastric carcinoma. [Chinese]. *World Chinese Journal of Digestology*. 2002;10(10):1190-3.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
300. Jiang Z, Liu Z, Li M, Chen C, Wang X. Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer. *Translational Oncology*. 2018;11(5):1171-87.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
301. Jprn U. The phase I clinical study about the combined therapy, high purity natural killer (NK) cell therapy and IgG1 antibody to inoperable advance and recurrence digestive cancer. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013378>. 2014.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
302. Jung IK, Kim MC, Kim KH, Kwak JY, Jung GJ, Kim HH. Cellular and peritoneal immune response after radical laparoscopy-assisted and open gastrectomy for gastric cancer. *Journal of Surgical Oncology*. 2008;98(1):54-9.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
303. Kacar F, Levi E, Dikicioglu E, Meteoglu I, Culhaci N, Yasa MH. Primary gastric T-cell lymphoma: A case report. *Turkish Journal of Cancer*. 2004;34(1):35-7.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
304. Kaieda T, Imawari M, Yamasaki Z, Ohnishi S, Koike M, Idezuki Y, et al. Identification of a tumor-associated target antigen, ATM-1, for a human T-cell clone with activated killer activity and its existence in sera of cancer patients. *Cancer Research*. 1988;48(17):4848-54.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구

305. Kaihara A, Iwagaki H, Gouchi A, Hizuta A, Isozaki H, Takakura N, et al. Soluble intercellular adhesion molecule-1 and natural killer cell activity in gastric cancer patients. *Research Communications in Molecular Pathology & Pharmacology*. 1998;100(3):283-300.  
 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
306. Kaihara A. Soluble ICAM-1 and NK activity. [Japanese]. *Biotherapy*. 1995;9(5):679-80.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
307. Kamei R, Yoshimura K, Yoshino S, Inoue M, Asao T, Fuse M, et al. Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomy. *Oncology Letters*. 2018;15(1):747-54.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
308. Kamigaki T, Ibe H, Okada S, Matsuda E, Tanaka M, Oguma E, et al. Improvement of impaired immunological status of patients with various types of advanced cancers by autologous immune cell therapy. *Anticancer Research*. 2015;35(8):4535-44.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
309. Kamocki ZK, Jurczuk A, Osada J. Lymphocyte Subpopulations in a Model of Pre-Operative Oral and Parenteral Glutamine-Based Immunonutrition in Patients with Invasive Gastric Cancer. *Clinical Nutrition*. 2019;38 (Supplement 1):S284-S5.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
310. Kan N, Imamura M. [Loco-regional immunotherapy with OK-432 and cultured autologous lymphocytes for patients with metastatic cancer]. *Human Cell*. 1993;6(2):100-5.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
311. Kan N, Okino T, Nakanishi M, Sato K, Mise K, Teramura Y, et al. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1989;16(4 Pt 2-2):1455-61.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
312. Kan N, Okino T, Nakanishi M, Satou K, Mise K, Ohgaki K, et al. [Clinical therapeutic effect of adoptive immunotherapy using IL-2-cultured autologous lymphocytes]. *Human Cell*. 1988;1(3):289-96.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
313. Kanazawa M, Mori Y, Yoshihara K, Iwadata M, Suzuki S, Endoh Y, et al. [Effect of DC therapy combined with chemotherapy in advanced cancer cases]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2003;30(11):1655-60.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
314. Kanegane H, Nomura K, Miyawaki T, Tosato G. Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. *Critical Reviews in Oncology/Hematology*. 2002;44(3):239-49.



배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

315. Kaneko Y, Chihara G, Taguchi T. Activity of lentinan against cancer and AIDS. *International Journal of Immunotherapy*. 1989;5(4):203-13.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

316. Kang HJ, Bae K, Kim JH, Cho CK, Yoo HS. Correlation Between Natural Killer Cell Activity and Systemic Inflammatory Markers for Heterogeneous Cancer Patients Treated With Wheel Balance Cancer Therapy. *Integrative Cancer Therapies*. 2018;17(2):322-31.

배제사유 : 평가대상 검사의 영향을 보고한 의료결과가 보고되지 않은 경우

317. Kannagi R, Sakuma K, Miyazaki K, Lim KT, Yusa A, Yin J, et al. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: Clues in the ongoing search for new tumor markers. *Cancer Science*. 2010;101(3):586-93.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

318. Karagoz B, Bilgi O, Kandemir EG, Sayan O, Erikci AA, Ozgun A, et al. Decreased NKG2D expression on natural killer cells in gastric cancer patients. *UHOD - Uluslararası Hematoloji-Onkoloji Dergisi*. 2009;19(1):42-7.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

319. Karimine N, Arinaga S, Inoue H, Nanbara S, Ueo H, Akiyoshi T. Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients. *Clinical & Experimental Immunology*. 1994;96(3):484-90.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

320. Karimine N, Nanbara S, Arinaga S, Asoh T, Ueo H, Akiyoshi T. Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients. *Journal of Surgical Oncology*. 1994;55(3):179-85.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

321. Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. *Cancer Immunology Research*. 2017;5(2):94-9.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

322. Karlsson-Parra A, Kovacka J, Heimann E, Jorvid M, Zeilemaker S, Longhurst S, et al. Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration. *Pharmaceutical Research*. 2018;35 (8) (156).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

323. Karpinski TM, Szkaradkiewicz A, Borejsza-Wysocki M, Drews M, Majewski P. NK cells activity and IL-10 in gastric carcinoma patients with or without Helicobacter pylori infection. *Clinical Microbiology and Infection*. 2010;2):S579-S80.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

324. Katano I, Nishime C, Ito R, Kamisako T, Mizusawa T, Ka Y, et al. Long-term

maintenance of peripheral blood derived human NK cells in a novel human IL-15-transgenic NOG mouse. *Scientific Reports*. 2017;7(1):17230.

배제사유 : 동물실험 및 전임상시험연구

325. Katano M, Yamamoto H, Kubota E, Nakamura M, Matsuo T, Nagumo F, et al. The possible use of spleen cells for the adoptive immunotherapy of cancer patients. *Surgery Today*. 1993;23(1):13-20.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

326. Kato M, Saji S, Fukada D, Miya K, Umemoto T, Kunieda K, et al. Characteristics of immunity in advanced gastrointestinal cancer patients and countermeasures against its postoperative decline. [Japanese]. *Biotherapy*. 1999;13(5):458-60.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

327. Kato M, Saji S, Miya K, Umemoto T, Bankert RB. Studies of anti-tumor effect of human IL-12 using SCID mouse engrafted human cancer cells. [Japanese]. *Biotherapy*. 1997;11(3):416-8.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

328. Kato Y, Cyon JC, Yoshimatsu K, Ogawa K. [Efficacy of activated lymphocytes transfer therapy as a novel maker for serum granulysin level with advanced gastric cancer patients]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2008;35(12):2262-4.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

329. Katoh M, Katoh M. Identification and characterization of human FMNL1, FMNL2 and FMNL3 genes in silico. *International Journal of Oncology*. 2003;22(5):1161-8.

배제사유 : 동물실험 및 전임상시험연구

330. Katsuragi S, Tanaka H, Hasegawa J, Kanayama N, Nakata M, Murakoshi T, et al. Analysis of preventability of malignancy-related maternal death from the nationwide registration system of maternal deaths in Japan. *Journal of Maternal-Fetal & Neonatal Medicine*. 2019:1-7.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

331. Kawa K. Epstein-Barr virus--associated diseases in humans. *International Journal of Hematology*. 2000;71(2):108-17.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

332. Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E, et al. Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. *Cancer*. 2001;92(8):2050-5.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

333. Kawaguchi Y, Araki H, Nakagawa A, Ishizaki M, Kamiyama Y, Nishimura N, et al. [Assessment of immunotoxicity of irinotecan determined by the novel method, by which productivity of TNF-alpha from whole blood is stimulated by lipopolysaccharide]. *Rinsho Byori - Japanese Journal of Clinical Pathology*. 2005;53(7):594-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

334. Kawalec P, Sladowska K, Malinowska-Lipien I, Brzostek T, Kozka M. European perspective on the management of rheumatoid arthritis: Clinical utility of tofacitinib. *Therapeutics and Clinical Risk Management*. 2018;14:15-29.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
335. Kelly P, Dobbs R, Charlett A, Weller C, Dobbs SM, Lawson AJ, et al. Helicobacter and idiopathic parkinsonism: Leukocyte-subset counts provide clues to a subordinate pathogenic pathway. *Helicobacter*. 2012;17 (SUPPL.1):116.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
336. Khan M, Komanduri S. Rare natural killer cell lymphoma found during surveillance endoscopy. *Journal of Gastrointestinal Cancer*. 2009;40(1-2):15-8.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
337. Khosravi N, Stoner L, Farajivafa V, Hanson ED. Exercise training, circulating cytokine levels and immune function in cancer survivors: A meta-analysis. *Brain, Behavior, and Immunity*. 2019;81:92-104.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
338. Kidane D, Chae WJ, Czocho J, Eckert KA, Glazer PM, Bothwell ALM, et al. Interplay between DNA repair and inflammation, and the link to cancer. *Critical Reviews in Biochemistry and Molecular Biology*. 2014;49(2):116-39.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
339. Kienle GS, Kiene H. Complementary cancer therapy: A systematic review of prospective clinical trials on anthroposophic mistletoe extracts. *European Journal of Medical Research*. 2007;12(3):103-19.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
340. Kijima Y, Ishigami S, Hokita S, Koriyama C, Akiba S, Eizuru Y, et al. The comparison of the prognosis between Epstein-Barr virus (EBV)-positive gastric carcinomas and EBV-negative ones. *Cancer Letters*. 2003;200(1):33-40.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
341. Kikuchi S, Noguchi K, Wakai K, Hamazaki Y, Tozawa K, Jomori T, et al. Propagermanium Induces NK Cell Maturation and Tends to Prolong Overall Survival of Patients With Refractory Cancer. *Anticancer Research*. 2019;39(9):4687-98.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
342. Kim H, Eom HS, Kong SY, Park SR, Kim SY, Ro J, et al. Prognostic significance of immune thrombocytopenic purpura in patients with malignancy. *Blood. Conference: 52nd Annual Meeting of the American Society of Hematology, ASH*. 2010;116(21).  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
343. Kim HS, Kwon HJ, Kim GE, Cho MH, Yoon SY, Davies AJ, et al. Attenuation of natural killer cell functions by capsaicin through a direct and TRPV1-independent mechanism. *Carcinogenesis*. 2014;35(7):1652-60.  
 배제사유 : 동물실험 및 전임상시험연구

344. Kim M, Pyo S, Kang CH, Lee CO, Lee HK, Choi SU, et al. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS ONE [Electronic Resource]. 2018;13(6):e0198347.  
배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
345. Kim YS, Kaidina AM, Chiang JH, Yarygin KN, Lupatov AY. Cancer stem cell molecular markers verified in vivo. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 2017;11(1):43-54.  
배제사유 : 원자가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
346. Kimura M, Yamaguchi S, Kubota S, Morita M, Yanagi Y, Higashi N, et al. Low-dose FPM therapy (skip injection method of CDDP) as a strategy for augmentation of therapeutic effect of biological response modifiers. [Japanese]. Biotherapy. 1998;12(5):670-4.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
347. Ko YH. Editorial: EBV and human cancer. Experimental and Molecular Medicine. 2015;47 (1) (e130).  
배제사유 : 원자가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
348. Koba F, Akiyoshi T, Arinaga S, Wada T, Tsuji H. Cell-mediated cytotoxic activity of regional lymph node cells from patients with gastric carcinoma. Japanese Journal of Surgery. 1987;17(2):83-90.  
배제사유 : 동물실험 및 전임상시험연구
349. Koba F, Akiyoshi T, Tsuji H. Natural killer cell activity in the perigastric lymph nodes from patients with gastric carcinoma or benign lesions. Journal of Clinical & Laboratory Immunology. 1987;23(4):191-5.  
배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
350. Kobayashi G. [Augmentation of cytotoxicity of regional lymph node lymphocytes of gastric cancer after intratumoral injection of OK-432]. Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society. 1990;91(1):68-76.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
351. Kobiashvili M, Davydova N, Bychkova N, Mihaylova I. Gastric mucosal lymphocyte subpopulations in some variants of the course and outcome of chronic inflammation of upper gastrointestinal tract. United European Gastroenterology Journal. 2013;1):A251.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
352. Kohga K, Tatsumi T, Tsunematsu H, Aono S, Shimizu S, Kodama T, et al. Interleukin-1beta enhances the production of soluble MICA in human hepatocellular carcinoma. Cancer Immunology, Immunotherapy. 2012;61(9):1425-32.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
353. Kohgo Y, Senba K, Ikeda A. Natural cytotoxicity in cancer patients. Tumor Research. 1981;Vol. 16:37-44.  
배제사유 : 원자가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

354. Kohyama M, Saijyo K, Hayasida M, Yasugi T, Kurimoto M, Ohno T. Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18. *Japanese Journal of Cancer Research*. 1998;89(10):1041-6.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
355. Konno H, Kubota T, Tsuyuki K, Nakada M, Kubouchi K, Yoshizumi Y, et al. [Immunological competence of nude mice on the growth of transplantable human tumors--with reference to natural killer cells]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1983;10(3):775-80.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
356. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. *Cancer Research*. 2002;62(20):5813-7.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
357. Koyama H, Narisawa T, Kodama M, Ishikawa K, Kusaka H, Yamazaki Y, et al. Potent effects of prostaglandin synthesis inhibitor indomethacin on cellular immune response in gastrointestinal cancer patients. [Japanese]. *Journal of Japan Society for Cancer Therapy*. 1989;24(5):1027-33.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
358. Koyama S, Ebihara T, Fukao K, Osuga T. [Two-color flow cytometry analyses of peripheral blood lymphocytes (PBL) and lymphokine-activated PBL in gastric cancer patients]. *Gan No Rinsho - Japanese Journal of Cancer Clinics*. 1988;34(4):435-41.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
359. Koyama S, Ebihara T, Fukao K, Osuga T. Differential activation of lymphokine-activated killer cells with different surface phenotypes by cultivation with recombinant interleukin 2 or T-cell growth factor in gastric cancer patients. *Japanese Journal of Cancer Research*. 1989;80(2):150-7.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
360. Koyama S, Ebihara T, Fukao K. Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma. *Journal of Cancer Research & Clinical Oncology*. 1992;118(8):609-14.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
361. Koyama S, Ebihara T. [Immunochemical therapy of stomach neoplasms]. *Nippon Naika Gakkai Zasshi - Journal of Japanese Society of Internal Medicine*. 1992;81(9):1410-2.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
362. Koyama S, Fukao K. Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumour cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma. *Journal of Cancer Research & Clinical Oncology*. 1994;120(4):240-7.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
363. Koyama S. Immunosuppressive effect of shedding intercellular adhesion molecule 1

antigen on cell-mediated cytotoxicity against tumor cells. Japanese Journal of Cancer Research. 1994;85(2):131-4.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

364. Kralickova P, Milota T, Litzman J, Malkusova I, Jilek D, Petanova J, et al. CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID. *Frontiers in Immunology*. 2018;9:3135.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

365. Kronsteiner-Dobramysl B, Bassaganya-Riera J, Washington C, Vento S, Pedragosa M, Viladomiu M, et al. Helicobacter pylori infection in pigs is dominated by a Th1 and cytotoxic immune response. *Journal of Immunology. Conference: 99th Annual Meeting of the American Association of Immunologist, IMMUNOLOGY*. 2012;188(1 MeetingAbstracts).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

366. Kuehnle MC, Attig S, Britten CM, Schulze-Bergkamen H, Lordick F, von Wichert G, et al. Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction. *Cancer Immunology, Immunotherapy*. 2014;63(12):1273-84.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

367. Kumar V, Soni P, Garg M, Kamholz S, Chandra AB. Emerging therapies in the management of advanced-stage gastric cancer. *Frontiers in Pharmacology*. 2018;9 (SEP) (404).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

368. Kume T, Oshima K, Yamashita Y, Shirakusa T, Kikuchi M. Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach. *International Journal of Cancer*. 1999;84(4):339-43.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

369. Kun L, Tang L, Wang J, Yang H, Ren J. Effect of Combined General/Epidural Anesthesia on Postoperative NK Cell Activity and Cytokine Response in Gastric Cancer Patients Undergoing Radical Resection. *Hepato-Gastroenterology*. 2014;61(132):1142-7.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

370. Kunitomi A, Konaka Y, Yagita M. Hypersensitivity to mosquito bites as a potential sign of mantle cell lymphoma. *Internal Medicine*. 2005;44(10):1097-9.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

371. Kuo SH, Chen LT, Chen CL, Doong SL, Yeh KH, Wu MS, et al. Expression of CD86 and increased infiltration of NK cells are associated with Helicobacter pylori-dependent state of early stage high-grade gastric MALT lymphoma. *World Journal of Gastroenterology*. 2005;11(28):4357-62.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

372. Kurklu B, Whitehead RH, Ong EK, Minamoto T, Fox JG, Mann JR, et al. Lineage-specific

RUNX3 hypomethylation marks the preneoplastic immune component of gastric cancer. *Oncogene*. 2015;34(22):2856-66.

배제사유 : 동물실험 및 전임상시험연구

373. Kuroda H, Saito H, Ikeguchi M. Decreased number and reduced NKG2D expression of Vdelta1 gammadelta T cells are involved in the impaired function of Vdelta1 gammadelta T cells in the tissue of gastric cancer. *Gastric Cancer*. 2012;15(4):433-9.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

374. Kuroda M, Imai S. [Epstein-Barr virus-associated diseases--from infectious mononucleosis to malignant neoplasms]. *Nippon Rinsho - Japanese Journal of Clinical Medicine*. 2003;61 Suppl 2:222-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

375. Kurokawa T, Tamakuma S, Imai J, Yamamoto T, Taguchi J. [Immunologic examination of Juzentaiho-to (TJ-48) in postoperative gastric cancer]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1989;16(4 Pt 2-2):1506-10.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

376. Kusmartsev SA, Kusmartseva IN, Afanasyev SG, Cherdyntseva NV. Immunosuppressive cells in bone marrow of patients with stomach cancer. *Advances in Experimental Medicine & Biology*. 1998;451:189-94.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

377. Kusmartsev SA, Kusmartseva IN, Tcherdyntseva NV, Afanasyev SG, Vasilyev NV. Functional characteristics of bone marrow immune suppressive cells in patients with gastric cancer. *International Journal of Immunopathology and Pharmacology*. 1998;11(3):171-8.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

378. Kuwahara Y, Kusugami K, Morise K, Shimokata K. Effect of recombinant gamma interferon on natural killer cell activity in patients with gastric cancer. *Gastroenterologia Japonica*. 1987;22(4):428-34.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

379. L?ndahl L, Holst M, Bradley M, Killasli H, Heilborn J, Hall MA, et al. Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis. *Acta dermato-venereologica*. 2018;98(3):324-8.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

380. Lazarova M, Steinle A. Impairment of NKG2D-Mediated Tumor Immunity by TGF-beta. *Frontiers in Immunology*. 2019;10 (2689).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

381. Lee BG, Lee MH, Kim NI, Haw CR. Kaposi's sarcoma associated with gastric involvement. *Annals of Dermatology*. 1989;1(2):114-8.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

382. Lee EO, Chae YR, Song R, Eom A, Lam P, Heitkemper M. Feasibility and effects of a tai chi self-help education program for Korean gastric cancer survivors. *Oncology Nursing Forum*. 2010;37(1):E1-6.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
383. Lee HE, Park DJ, Kim WH, Kim HH, Lee HS. High FOXP3 regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer. *British Journal of Cancer*. 2011;105(3):413-9.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
384. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. *Gastroenterology*. 2015;148(7):1383-91.e6.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
385. Lee K, Zhou J, Norris MK, Chow C, Dieli-Conwright CM. Prehabilitative Exercise for the Enhancement of Physical, Psychosocial, and Biological Outcomes Among Patients Diagnosed with Cancer. *Current Oncology Reports*. 2020;22 (7) (71).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
386. Lee M, Son M, Ryu E, Shin YS, Kim JG, Kang BW, et al. Quercetin-induced apoptosis prevents EBV infection. *Oncotarget*. 2015;6(14):12603-24.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
387. Leone K, Poggiana C, Zamarchi R. The interplay between circulating tumor cells and the immune system: From immune escape to cancer immunotherapy. *Diagnostics*. 2018;8 (3) (59).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
388. Li B, Jiang Y, Li G, Fisher GA, Jr., Li R. Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit. *Jci Insight*. 2020;5(9):07.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
389. Li B, Liu HY, Guo SH, Sun P, Gong FM, Jia BQ. Impact of early postoperative enteral nutrition on clinical outcomes in patients with gastric cancer. *Genetics & Molecular Research*. 2015;14(2):7136-41.  
 배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
390. Li B, Liu HY, Guo SH, Sun P, Gong FM, Jia BQ. The postoperative clinical outcomes and safety of early enteral nutrition in operated gastric cancer patients. *Journal of B.U.On*. 2015;20(2):468-72.  
 배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
391. Li L, Li M, Wang X. Cancer type-dependent correlations between TP53 mutations and antitumor immunity. *DNA Repair*. 2020;88 (102785).  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구



392. Li L, Ouyang Y, Wang W, Hou D, Zhu Y. The landscape and prognostic value of tumor-infiltrating immune cells in gastric cancer. *PeerJ*. 2019;2019 (12) (e7993).  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
393. Li M, Zhao ZW, Zhang Y, Xin Y. Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer. *Digestive Diseases and Sciences*. 2011;56(3):698-706.  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
394. Li M, Zheng H, Duan Z, Liu H, Hu D, Bode A, et al. Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines. *Cellular & Molecular Immunology*. 2012;9(1):54-61.  
배제사유 : 동물실험 및 전임상시험연구
395. Li M, Zhi L, Yin M, Guo C, Zhang H, Lu C, et al. A novel bispecific chimeric PD1-DAP10/NKG2D receptor augments NK92-cell therapy efficacy for human gastric cancer SGC-7901 cell. *Biochemical and Biophysical Research Communications*. 2020;523(3):745-52.  
배제사유 : 동물실험 및 전임상시험연구
396. Li T, Zhang Q, Jiang Y, Yu J, Hu Y, Mou T, et al. Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2. *Oncoimmunology*. 2016;5(2):e1069936.  
배제사유 : 동물실험 및 전임상시험연구
397. Li X, Wang R, Fan P, Yao X, Qin L, Peng Y, et al. A comprehensive analysis of key immune checkpoint receptors on tumor-infiltrating t cells from multiple types of cancer. *Frontiers in Oncology*. 2019;9 (OCT) (1066).  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
398. Li Y, Bai DJ, Wang K, Yang GL, Yuan HY, Shao H. Effects of perioperative cimetidine administration on natural killer cells in patients with gastrointestinal cancer. *Chinese Journal of Cancer Research*. 1999;11(1):70-3.  
배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
399. Li Y, Liu H, Chen H, Shao J, Su F, Zhang S, et al. DERL3 functions as a tumor suppressor in gastric cancer. *Computational Biology & Chemistry*. 2020;84:107172.  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
400. Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. *World Journal of Gastroenterology*. 2003;9(3):495-8.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
401. Liikanen I, Savola P, Hemminki A. Tumor-specific oncolytic adenovirus coding for trastuzumab results in local production of functional monoclonal antibody from tumor cells. *Cancer Research*. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR. 2014;74(19 SUPPL. 1).  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

402. Liikanen I, Tahtinen S, Guse K, Gutmann T, Savola P, Oksanen M, et al. Oncolytic adenovirus expressing monoclonal antibody trastuzumab for treatment of HER2-positive cancer. *Molecular Cancer Therapeutics*. 2016;15(9):2259-69.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
403. Lin CY, Bai DJ, Yuan HY, Wang K, Yang GL, Hu MB, et al. Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial. *World Journal of Gastroenterology*. 2004;10(1):136-42.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
404. Lin F, Dai C, Ge X, Tang W, Lin Y, Wang Y, et al. Prognostic significance and functional implication of immune activating receptor NKG2D in gastric cancer. *Biochemical & Biophysical Research Communications*. 2017;487(3):619-24.  
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
405. Lin SY, Liu LM, Wu LC. [Effects of Shenmai injection on immune function in stomach cancer patients after chemotherapy]. *Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban*. 1995;15(8):451-3.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
406. Lin YC. [The activity of immunologic cells from peripheral blood, splenic venous blood and spleen in patients with advanced gastric cancer. A comparative study]. *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]*. 1992;30(12):713-5, 77.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
407. Lindgren A, Sjoling A, Lundin S. H. pylori induce interferon gamma production from human NK cells via TLR2. *Helicobacter*. 2009;14 (4):355.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
408. Lindgren A, Yun CH, Sjoling A, Berggren C, Sun JB, Jonsson E, et al. Impaired IFN-gamma production after stimulation with bacterial components by natural killer cells from gastric cancer patients. *Experimental Cell Research*. 2011;317(6):849-58.  
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
409. Lissoni P, Brivio F, Ferrante R, Vigore L, Vaghi M, Fumagalli E, et al. Circulating immature and mature dendritic cells in relation to lymphocyte subsets in patients with gastrointestinal tract cancer. *International Journal of Biological Markers*. 2000;15(1):22-5.  
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
410. Liu H, Ling W, Shen ZY, Jin X, Cao H. Clinical application of immune-enhanced enteral nutrition in patients with advanced gastric cancer after total gastrectomy. *Journal of Digestive Diseases*. 2012;13(8):401-6.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

411. Liu H, Song J, Yang Z, Zhang X. Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. *Experimental and Therapeutic Medicine*. 2013;6(4):953-6.  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
412. Liu H, Wang B, Zhang J, Zhang B, Xue Y, Jia B. The effect of early postoperative enteral nutrition and parenteral nutrition in gastric cancer. [Chinese]. *Chinese Journal of Clinical Oncology*. 2014;41(18):1166-9.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
413. Liu JQ, Zhu Y, Chen FX, Zhang NZ, Lv XT, Zhou ZH, et al. [Co-stimulation of multiple activating factors on proliferation and phenotype of T lymphocytes in peripheral blood in vitro]. *Xibao Yu Fenzi Mianyixue Zazhi*. 2012;28(4):367-70.  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
414. Liu L, Lam CYK, Alderson R, Long V, Yang Y, Burns R, et al. Selection of a bispecific trivalent HER2 x CD137 TRIDENT format providing optimal tumor-anchored immune co-stimulation. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
415. Liu N, Niu Z, Niu W, Peng C, Zou X, Sun S, et al. Intraoperative sentinel lymph node mapping guides laparoscopic-assisted distal gastrectomy for distal gastric cancer. *International journal of clinical and experimental medicine*. 2015;8(4):5760-6.  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
416. Liu SQ, Saijo K, Todoroki T, Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. *Nature Medicine*. 1995;1(3):267-71.  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
417. Liu W, Wu L, Zhang M, Zhao L. Effects of general anesthesia with combined epidural anesthesia on inflammatory response in patients with early-stage gastric cancer undergoing tumor resection. *Experimental and Therapeutic Medicine*. 2019;17(1):35-40.  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
418. Liu X, Sun M, Yu S, Liu K, Li X, Shi H. Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells. *OncoTargets and Therapy*. 2015;8:3095-104.  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
419. Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. *Oncogene*. 2017;36(44):6143-53.  
배제사유 : 동물실험 및 전임상시험연구
420. Liu Y, Zhang C. The role of human gammadelta t cells in anti-tumor immunity and their potential for cancer immunotherapy. *Cells*. 2020;9 (5) (1206).  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

421. Liu Z, Zhang Q, Peng H, Zhang WZ. Animal lectins: Potential antitumor therapeutic targets in apoptosis. *Applied Biochemistry and Biotechnology*. 2012;168(3):629-37.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
422. Lombardi VRM, Lombardi C, Cacabelos R. Nutrition, immune system activation and anti-cancer strategies in animals and humans. *Current Topics in Pharmacology*. 2008;12(2):1-30.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
423. Long X, Gong X. Study of immune function and psychological intervention on patients with malignant tumor after radiotherapy. *Biomedical Research (India)*. 2017;28(5):2375-8.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
424. Lorenzo-Herrero S, Lopez-Soto A, Sordo-Bahamonde C, Gonzalez-Rodriguez AP, Vitale M, Gonzalez S. NK cell-based immunotherapy in cancer metastasis. *Cancers*. 2019;11 (1) (29).  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
425. Lotze MT, Wang E, Marincola FM, Hanna N, Bugelski PJ, Burns CA, et al. Workshop on cancer biometrics: Identifying biomarkers and surrogates of cancer in patients - A meeting held at the masur auditorium, national institutes of health. *Journal of Immunotherapy*. 2005;28(2):79-119.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
426. Lu HS, Zhang JZ, Wu XY, Huang CM, Wang C, Zhang XF. [A prospective randomized study on the method of reconstruction after total gastrectomy]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2003;25(3):255-7.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
427. Lu Q, Wang JF. Effects of postoperative TPN on immunocompetence in patients with cardia carcinoma. [Chinese]. *Chinese Journal of Clinical Oncology*. 1996;23(5):338-40.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
428. Lu WW, Zhang H, Li YM, Ji F. Gastric cancer-derived heat shock protein-gp96 peptide complex enhances dendritic cell activation. *World Journal of Gastroenterology*. 2017;23(24):4390-8.  
배제사유 : 동물실험 및 전임상시험연구
429. Lupo KB, Matosevic S. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. *Journal of Hematology and Oncology*. 2020;13 (1) (76).  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
430. Lykov AP, Bass AA, Lozhkin ID, Egorov DN, Vardosanidze KV, Abramov VV, et al. Cytotoxic activities of blood cells in patients with gastric cancer and its links with nervous system activity. *Immunologiya*. 2000(6):43-6.  
배제사유 : 동물실험 및 전임상시험연구
431. Lykov AP, Bass AA, Morozov DV, Abramov VV, Kozlov VA. [Adenocarcinoma of the stomach: clinical and immunologic features]. *Voprosy Onkologii*. 2003;49(1):41-3.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

432. Lysaght J, van der Stok EP, Allott EH, Casey R, Donohoe CL, Howard JM, et al. Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue. *Cancer Letters*. 2011;312(1):62-72.

배제사유 : 동물실험 및 전임상시험연구

433. Ma HY, Liu XZ, Liang CM. Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. *World Journal of Gastroenterology*. 2016;22(29):6619-28.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

434. Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, et al. Spectrum of Epstein-Barr virus-related diseases: A pictorial review. *Japanese Journal of Radiology*. 2009;27(1):4-19.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

435. Maeta M, Saito H, Kondo A, Yamashiro H, Tsujitani S, Ikeguchi M, et al. Effects of super-extended paraaortic lymphadenectomy (PAL) on biological responses in totally gastrectomized patients with T3 or T4 gastric cancer. *Gastric Cancer*. 1998;1(1):57-63.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

436. Maeta M, Shimizu N, Katano K, Saito H, Tsujitani S, Ikeguchi M, et al. Possible association between immunocompetence and enhanced risk of multicentric carcinogenesis in both the stomach and other organs in patients with gastric cancer. *Oncology Reports*. 1997;4(3):557-60.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

437. Maeta M, Shimizu N, Oka A, Kondo A, Yamashiro H, Tsujitani S, et al. Perioperative allogeneic blood transfusion exacerbates surgical stress-induced postoperative immunosuppression and has a negative effect on prognosis in patients with gastric cancer. *Journal of Surgical Oncology*. 1994;55(3):149-53.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

438. Mahoney D. Immunotherapy prolonged survival in stage IV cancers. *Oncology Report*. 2012(MAY):6.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

439. Maitra R, Ghalib MH, Goel S. Reovirus: A targeted therapeutic - Progress and potential. *Molecular Cancer Research*. 2012;10(12):1514-25.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

440. Maj T, Wei S, Welling T, Zou W. T cells and costimulation in cancer. *Cancer Journal (United States)*. 2013;19(6):473-82.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

441. Majima T, Ichikura T, Seki S, Takayama E, Matsumoto A, Kawabata T, et al. The influence of interleukin-10 and interleukin-18 on interferon-gamma production by

peritoneal exudate cells in patients with gastric carcinoma. *Anticancer Research*. 2002;22(2B):1193-9.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

442. Malka D, Gourgou-Bourgade S, Emile J, Laurent-Puig P, Taieb J. Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: fNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial. *Journal of clinical oncology*. 2011;29(15 SUPPL. 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

443. Malygin AM, Kurtenkov OA, Miliukhina LM. [Evaluation of the immune status of patients with cancer of the stomach]. *Voprosy Onkologii*. 1988;34(5):549-52.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

444. Mamidi S, Hone S, Kirschfink M. Improved antibody-induced cell-mediated killing (CDCC) and apoptosis of HER2 positive tumors after silencing membrane complement regulators. *Molecular Immunology*. 2013;56 (3):283-4.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

445. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. *Cytokine and Growth Factor Reviews*. 2010;21(1):27-39.

배제사유 : 원자가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

446. Marchini A, Bonifati S, Scott EM, Angelova AL, Rommelaere J. Oncolytic parvoviruses: From basic virology to clinical applications. *Virology Journal*. 2015;12 (1) (6).

배제사유 : 원자가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

447. Martinez Martinez J. An 84% survival of stage C colorectal carcinoma [2]. [Spanish]. *Oncologia*. 2003;26(8):62-3.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

448. Martucci RB, Rodrigues VD, D'Almeida CA, Souza NCS, Alves JL, Rodrigues VST, et al. Nutritional status and immune profile of gastric cancer patients. *Clinical Nutrition*. 2013;1):S162-S3.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

449. Maruo K, Shimamura K, Hioki K, Itoh M, Ueyama Y, Tamaoki N. Role of x-linked immunodeficiency (xid) and NK activity in rejection of human tumor xenotransplants in nude mice. *APMIS*. 1993;101(5):345-52.

배제사유 : 동물실험 및 전임상시험연구

450. Maruo S. Epstein-Barr virus and cancers. [Japanese]. *Biotherapy*. 2005;19(4):295-302.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

451. Maruyama T, Mimura K, Izawa S, Shiba S, Watanabe M, Kawaguchi Y, et al. Immunonutritional diet modulates natural killer cell activation and Th17 cell distribution in patients with gastric and esophageal cancer. *Nutrition*. 2011;27(2):146-52.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않

은 연구

452. Mashiba H, Matsunaga K, Tomoda H, Furusawa M, Jimi S, Tokunaga T. In vitro augmentation of natural killer activity of peripheral blood cells from cancer patients by a DNA fraction from Mycobacterium bovis BCG. Japanese Journal of Medical Science & Biology. 1988;41(5-6):197-202.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
453. Matsuda H, Sakabe H, Miyagawa A, Okumura Y, Ohishi T, Aoyama H, et al. Clinical and immunological study of chemoimmunotherapy with lentinan and tegafur for inoperable or recurrent gastric cancer. [Japanese]. Biotherapy. 1998;12(2):325-31.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
454. Matsueda S, Graham DY. Immunotherapy in gastric cancer. World Journal of Gastroenterology. 2014;20(7):1657-66.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
455. Matsumoto H, Liao S, Arakawa F, Ueno A, Abe H, Awasthi A, et al. Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody. Anticancer Research. 2002;22(4):2001-7.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
456. Matsumoto H. [Experimental and clinical studies of human natural killer cell activity in healthy subjects and patients with cancer of the digestive tract]. Nippon Gan Chiryo Gakkai Shi - Journal of Japan Society for Cancer Therapy. 1985;20(3):571-83.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
457. Matsumoto H. Intermittent intraperitoneal administration of OK-432 and CDDP for gastric cancer with peritoneal dissemination. [Japanese]. Biotherapy. 1995;9(5):726-7.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
458. McCracken VJ, Martin SM, Lorenz RG. The Helicobacter felis model of adoptive transfer gastritis. Immunologic Research. 2005;33(2):183-94.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
459. McNiff T, Dezube BJ. CCR5 antagonists in the treatment of HIV-infected persons: Is their cancer risk increased, decreased, or unchanged? AIDS Reader. 2009;19(6).  
배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
460. Mehta J. Is epstein-barr virus a lymphomaniac? Indian Journal of Hematology and Blood Transfusion. 2013;29 (4):231.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
461. Menaker RJ, Jones NL. Fascination with bacteria-triggered cell death: The significance of Fas-mediated apoptosis during bacterial infection in vivo. Microbes and Infection. 2003;5(12):1149-58.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
462. Menetrier-Caux C, Ray-Coquard I, Blay JY, Caux C. Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: An opportunity for combination with

Cytokines? Journal for ImmunoTherapy of Cancer. 2019;7 (1) (85).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

463. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. *Expert Opinion on Biological Therapy*. 2012;12(6):673-84.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

464. Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, et al. First-in-human phase i study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors. *Clinical Cancer Research*. 2016;22(4):877-85.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

465. Mi L, Lin J, Zheng H, Xu X, Zhang J, Zhang D. Bacterial translocation contributes to cachexia from locally advanced gastric cancer. *Hepato-Gastroenterology*. 2012;59(119):2348-51.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

466. Mi L, Zheng HM, Zhang J, Jiao XL, Zhang DL. Association of bacterial translocation with cachexia and its influence on the outcome of gastric cancer patients. [Chinese]. *Chinese Journal of Clinical Nutrition*. 2012;20(2):69-73.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

467. Mi L, Zhong B, Zhang DL, Zhou YB, Wang DS. [Effect of early oral enteral nutrition on clinical outcomes after gastric cancer surgery]. *Zhonghua Weichang Waike Zazhi*. 2012;15(5):464-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

468. Micu G, Staniceanu F, Zurac S, Bastian A, Gramada E, Popp C, et al. The influence of *Helicobacter pylori* presence on the immunophenotype of inflammatory infiltrate in gastric diseases. *Romanian Journal of Internal Medicine*. 2011;49(1):45-54.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

469. Mikamo S. [Adoptive immunotherapy using immobilized anti-CD3 mAb-activated autologous lymphocytes: the strong cytotoxicity was supported by CD16+ cells which proliferated in prolonged cultures]. *Human Cell*. 1992;5(3):256-66.

배제사유 : 동물실험 및 전임상시험연구

470. Milasiene V, Stratilatovas E, Norkiene V. The importance of T-lymphocyte subsets on overall survival of colorectal and gastric cancer patients. *Medicina (Kaunas, Lithuania)*. 2007;43(7):548-54.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

471. Milota T. CVID-associated tumors: Czech nationwide study focused on epidemiology, immunology and genetic background in a cohort of patients with CVID. *European Journal of Immunology*. 2019;49 (Supplement 3):1226.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)



472. Mimura K, Kamiya T, Shiraishi K, Kua LF, Shabbir A, So J, et al. Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. *International Journal of Cancer*. 2014;135(6):1390-8.  
 배제사유 : 동물실험 및 전임상시험연구
473. Minarovits J. Recent advances in the pathogenesis of EBV infection. *Clinical Microbiology and Infection*. 2011;4):S74.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
474. Minetto P, Guolo F, Pesce S, Greppi M, Obino V, Ferretti E, et al. Harnessing NK Cells for Cancer Treatment. *Frontiers in Immunology*. 2019;10 (2836).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
475. Misumi T, Tanabe K, Fujikuni N, Ohdan H. Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer. *PLoS ONE*. 2018;13 (10) (e0204880).  
 배제사유 : 동물실험 및 전임상시험연구
476. Mitachi Y, Murakawa Y, Okuno M, Kambe M, Kanamaru R, Takahasi H, et al. [Subsets of peripheral blood lymphocytes and tumor infiltrating lymphocytes in cancer patients received chemotherapy]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1990;17(3 Pt 2):482-8.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
477. Mitsuata H, Masaki Y, Enzan K, Hasegawa J, Matsumoto S, Kurosawa S. [General anesthesia and surgery inhibited natural killer cell cytotoxicity in patients with cancer or benign disease undergoing upper abdominal surgery]. *Masui - Japanese Journal of Anesthesiology*. 1991;40(11):1608-15.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
478. Miura Y, Kataoka H, Joh T, Tada T, Asai K, Nakanishi M, et al. Susceptibility to killer T cells of gastric cancer cells enhanced by Mitomycin-C involves induction of ATBF1 and activation of p21 (Waf1/Cip1) promoter. *Microbiology & Immunology*. 2004;48(2):137-45.  
 배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
479. Miya K, Saji S, Furuta T, Azuma S, Umemoto T, Takao H, et al. [Significance of antitumor effects and immunological response on endogenously induced LAK therapy for primary or metastatic liver tumor]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1992;19(10 Suppl):1453-6.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
480. Miyaji M, Ogoshi K, Nakamura K, Kondo Y, Tajima T, Mitomo T. Serum sialic acid levels and immunotherapy for gastric cancer. [Japanese]. *Biotherapy*. 1996;10(6):903-7.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
481. Mizumoto K. Analysis of antitumor activity of leukoregulin derived from PHA-activated human lymphocytes. [Japanese]. *Journal of Japan Society for Cancer Therapy*. 1994;29(11):1800-10.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구

482. Mocellin S, Rossi CR, Lise M, Marincola FM. Adjuvant immunotherapy for solid tumors: From promise to clinical application. *Cancer Immunology, Immunotherapy*. 2002;51(11-12):583-95.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
483. Moran AP, O'Donoghue Y, Mashayekhi K, Moshfegh A, Zulquernain SA, O'Keeffe J. Immune response to the gastric pathogen *H. pylori*: Microarray analysis of gastric CD2+ cells. *Helicobacter*. 2010;15 (4):317.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
484. Morikawa K, Nakano A, Oseko F, Morikawa S. Natural killer (NK) cell activity in patients with various malignancy against a variety of target cell lines: re-evaluation of clinical significance of natural killer cell activity. *Japanese Journal of Medicine*. 1989;28(4):462-70.  
 배제사유 : 동물실험 및 전임상시험연구
485. Moritani Y. [Distribution of lymphocyte subpopulation and natural killer activity in gastric cancer tissue, normal stomach and various tissues of gastric cancer patients]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1984;85(2):132-42.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
486. Morokuma A, Saeki Y, Nakamura A, Sakuma H, Ishihara Y, Abe M. Assessing antitumor and T cell immune responses by cytokine assay in cancer patients treated with immunotherapy - A pilot study. *Personalized Medicine Universe*. 2018;7:28-33.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
487. Morse MA, Lyerly HK, Clay TM, Abdel-Wahab O, Chui SY, Garst J, et al. How does the immune system attack cancer? *Current Problems in Surgery*. 2004;41(1):15-132.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
488. Mukaida N, Sasaki SI, Baba T. Two-faced roles of tumor-associated neutrophils in cancer development and progression. *International Journal of Molecular Sciences*. 2020;21 (10) (3457).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
489. Murakuni H, Kitahara S, Kudo M, Nagoshi T, Higo H, Ozawa T, et al. [Gastric carcinoma with prominent reactive lymphoid hyperplasia; report of two cases with an immunohistological study]. *Gan No Rinsho - Japanese Journal of Cancer Clinics*. 1987;33(9):1090-4.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
490. Na YM, Kim MY, Kim YK, Ha YR, Yoon DS. Exercise therapy effect on natural killer cell cytotoxic activity in stomach cancer patients after curative surgery. *Archives of Physical Medicine & Rehabilitation*. 2000;81(6):777-9.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
491. Na YM, Kim Y, Kang SW, Park JS, Ha Y. Effect of rehabilitation treatment on natural killer cell activity in stomach cancer patients after curative surgery. *Archives of physical medicine and rehabilitation*. 1998;79:1157.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

492. Nagafuchi S. Epstein-Barr virus survival: Expression and release of Fas ligand. *Internal Medicine*. 2002;41(8):603-4.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

493. Nagase-Zembutsu A, Hirotsu K, Yamato M, Yamaguchi J, Takata T, Yoshida M, et al. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity. *Cancer Science*. 2016;107(5):674-81.

배제사유 : 동물실험 및 전임상시험연구

494. Nagashima S, Kashii Y, Reichert TE, Suminami Y, Suzuki T, Whiteside TL. Human gastric carcinoma transduced with the IL-2 gene: increased sensitivity to immune effector cells in vitro and in vivo. *International Journal of Cancer*. 1997;72(1):174-83.

배제사유 : 동물실험 및 전임상시험연구

495. Nagashima S, Mailliard R, Kashii Y, Reichert TE, Herberman RB, Robbins P, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. *Blood*. 1998;91(10):3850-61.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

496. Nakachi K, Harris CC, Tahara E. Japan-US cooperative cancer research seminar on molecular epidemiological characteristics of lung and colon cancer development among atomic-bomb survivors, Bethesda, USA, february 23-24, 2006. *Cancer Science*. 2006;97(11):1279-82.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

497. Nakagomi H, Hada M, Koshizuka K, Mutoh S, Watanabe K, Takano K, et al. [Immunomodulatory effect of daily low-dose cisplatin treatment]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1997;24(3):323-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

498. Nakayama F, Iwagaki H, Gouchi A, Hizuta A, Isozaki H, Takakura N, et al. Effect of streptococcal lysate OK-432 on peripheral blood mononuclear cells in gastric cancer patients. *Journal of Medicine*. 1998;29(3-4):199-215.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

499. Nan KJ, Wei YC, Zhou FL, Li CL, Sui CG, Hui LY, et al. Effects of depression on parameters of cell-mediated immunity in patients with digestive tract cancers. *World Journal of Gastroenterology*. 2004;10(2):268-72.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

500. Nct. Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer. <https://clinicaltrials.gov/show/NCT01116791>. 2010.

배제사유 : 동물실험 및 전임상시험연구

501. Nct. Obesity - Inflammation - Metabolic Disease: effect of Lactobacillus Casei Shirota. <https://clinicaltrials.gov/show/NCT01182844>. 2010.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
502. Nct. Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer. <https://clinicaltrials.gov/show/NCT04385641>. 2020.  
배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
503. Neeman E, Zmora O, Ben-Eliyahu S. A new approach to reducing postsurgical cancer recurrence: Perioperative targeting of catecholamines and prostaglandins. *Clinical Cancer Research*. 2012;18(18):4895-902.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
504. Niccolai E, Taddei A, Prisco D, Amedei A. Gastric cancer and the epoch of immunotherapy approaches. *World Journal of Gastroenterology*. 2015;21(19):5778-93.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
505. Nikniaz Z, Somi MH, Nagashi S, Nikniaz L. Impact of Early Enteral Nutrition on Nutritional and Immunological Outcomes of Gastric Cancer Patients Undergoing Gastrectomy: A Systematic Review and Meta-Analysis. *Nutrition & Cancer*. 2017;69(5):693-701.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
506. Nio Y, Ohgaki K, Tsuchitani T, Imai S, Shiraishi T, Tobe T. Orally administered streptococcal preparation, OK-432 augments the antitumor immunity of patients with gastric or colorectal cancer. *Biotherapy*. 1990;2(3):213-22.  
배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
507. Nio Y, Shiraishi T, Imai S, Tsubono M, Morimoto H, Tseng CC, et al. The clinical status and histopathological factors affecting natural killer cells of peripheral blood lymphocytes in patients with gastric cancer. *Journal of Clinical & Laboratory Immunology*. 1991;35(3):97-108.  
배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
508. Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Imai S, et al. In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer. *Cancer Immunology Immunotherapy*. 1991;32(6):335-41.  
배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
509. Nishijima TF, Kardos J, Chai S, Smith CC, Bortone DS, Mose LE, et al. Molecular and clinical characterization of a claudin (CLDN)-low subtype of gastric cancer (GC). *Journal of Clinical Oncology*. Conference. 2017;35(4 Supplement 1).  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
510. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. *International Journal*

of Cancer. 2010;127(4):759-67.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

511. Noguchi A, Kaneko T, Naitoh K, Saito M, Iwai K, Maekawa R, et al. Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy. *International Immunopharmacology*. 2014;18(1):90-7.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

512. Nomura E, Isoda KI, Yamanaka K, Yamaguchi M, Hakamada A, Mizutani H. Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy. *Journal of Dermatology*. 2005;32(3):204-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

513. Numa K, Tani T, Kodama M. Trial of anticancer immunotherapy with immobilized pokeweed mitogen: immunotherapy by extracorporeal circulation. *Cancer Immunology, Immunotherapy*. 1990;32(2):125-30.

배제사유 : 동물실험 및 전임상시험연구

514. Oberg HH, Kellner C, Gonnermann D, Sebens S, Bauerschlag D, Gramatzki M, et al. Tribody [(HER2) 2xCD16] is more effective than trastuzumab in enhancing gammadelta T cell and natural killer cell cytotoxicity against HER2-expressing cancer cells. *Frontiers in Immunology*. 2018;9 (APR) (814).

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

515. Ochiai T, Isono K, Suzuki T, Koide Y, Gunji Y, Nagata M, et al. Effect of immunotherapy with lentinan on patients' survival and immunological parameters in patients with advanced gastric cancer: Results of a multi-centre randomized controlled study. *International Journal of Immunotherapy*. 1992;8(3):161-9.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

516. Ochiai T, Sato H, Isono K, Uematsu T, Nakajima K, Mukai M, et al. [A multi-center trial of MY-1, a new biological response modifier, on the immunological parameters of postoperative gastric cancer patients]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1986;13(4 Pt 1):959-69.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

517. Ochiai T, Suzuki T, Nakajima K. Studies on lymphocyte subsets of regional lymph nodes after endoscopic injection of biological response modifiers in gastric cancer patients. *International Journal of Immunotherapy*. 1986;2(4):259-65.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

518. Ogasawara M. Dendritic cell vaccine-based immunotherapy in combination with salvage chemotherapy for patients with advanced or relapsed gastric cancer. *Annals of Oncology*. 2018;29 (Supplement 5):v21.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

519. Oh S, Lee JH, Kwack K, Choi SW. Natural killer cell therapy: A new treatment paradigm for solid tumors. *Cancers*. 2019;11 (10) (1534).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

520. Ohwada S, Takeshita M, Miyamoto Y, Izumi M. [A clinical study of immunological status in gastric cancer patients--with special reference to T-cell subsets in the lymphocytes of regional lymph nodes]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society.* 1990;91(10):1560-6.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

521. Oka M, Mitsunaga H, Hazama S, Yoshino S, Suzuki T. Natural killer activity and serum immunosuppressive acidic protein levels in esophageal and gastric cancers. *Surgery Today.* 1993;23(8):669-74.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

522. Okada K, Nannmark U, Vujanovic NL, Watkins S, Basse P, Herberman RB, et al. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer. *Cancer Research.* 1996;56(7):1599-608.

배제사유 : 동물실험 및 전임상시험연구

523. Okano M, Gross TG. Acute or chronic life-threatening diseases associated with Epstein-Barr virus infection. *American Journal of the Medical Sciences.* 2012;343(6):483-9.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

524. Okano M. Haematological associations of Epstein-Barr virus infection. *Bailliere's Best Practice and Research in Clinical Haematology.* 2000;13(2):199-214.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

525. Okayama T, Ishikawa T, Sakamoto N, Ideno M, Oka K, Enoki T, et al. NK cell therapy in combination with IgG1 antibody in patients with gastric/colorectal cancer: A phase I clinical trial. *Cancer Science.* 2018;109 (Supplement 2):1328.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

526. Okinaga K, Iinuma H, Kitamura Y, Yokohata T, Inaba T, Fukushima R. Effect of immunotherapy and spleen preservation on immunological function in patients with gastric cancer. *Journal of Experimental & Clinical Cancer Research.* 2006;25(3):339-49.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

527. Okino T, Kan N, Mise K, Nakanishi M, Satoh K, Yamasaki S, et al. [Adoptive immunotherapy against peritoneal metastases from stomach cancer--application of regional lymph node lymphocytes]. *Nippon Gan Chiryo Gakkai Shi - Journal of Japan Society for Cancer Therapy.* 1990;25(3):613-20.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

528. Okita R, Yamaguchi Y, Emi A, Matsuura K, Toge T. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies. *Oncology Reports.* 2007;17(6):1429-35.

배제사유 : 동물실험 및 전임상시험연구

529. Okuno K, Ohnishi H, Shilayama Y, Hirohata T, Ozaki M, Yasutomi M. Augmentation of human lymphokine-activated killer cell activity in splenic lymphocytes by the combination of low-dose interleukin 2 plus interleukin 3. *Molecular Biotherapy*. 1992;4(2):83-6.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
530. Okuno K, Takagi H, Nakamura T, Nakamura Y, Iwasa Z, Yasutomi M. Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells. *Cancer*. 1986;58(5):1001-6.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
531. Okuno K, Tanaka A, Shigeoka H, Hirai N, Kawai I, Kitano Y, et al. Suppression of T-cell function in gastric cancer patients after total gastrectomy with splenectomy: implications of splenic autotransplantation. *Gastric Cancer*. 1999;2(1):20-5.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
532. Omar HA, El-Serafi AT, Hersi F, Arafa ESA, Zaher DM, Madkour M, et al. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment. *FEBS Journal*. 2019;286(18):3540-57.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
533. Osada J, Kamocki Z, Pietruczuk M, Dabrowska M, Kedra B. [An assessment of peripheral blood lymphocytes populations and subpopulation in patients with stomach cancer]. *Polski Merkuriusz Lekarski*. 2006;20(115):26-31.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
534. Osada J, Kamocki Z, Pietruczuk M, Dabrowska M, Kedra B. An assessment of peripheral blood lymphocytes populations and subpopulation in patients with stomach cancer. [Polish]. *Polski Merkuriusz Lekarski*. 2006;20(115):26-31.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
535. Osaki T, Saito H, Yoshikawa T, Matsumoto S, Tatebe S, Tsujitani S, et al. Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. *Clinical Cancer Research*. 2007;13(2 Pt 1):382-7.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
536. Osato T. Epstein-Barr virus infection and oncogenesis. *Gann Monographs on Cancer Research*. 1998;45:3-16.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
537. Oshimi K, Wakasugi H, Seki H, Kano S. Streptococcal preparation OK-432 augments cytotoxic activity against an erythroleukemic cell line in humans. *Cancer Immunology, Immunotherapy*. 1980;9(3):187-92.  
 배제사유 : 동물실험 및 전임상시험연구
538. Oshita H, Saji S, Sugiyama Y, Tanemura H, Sakata K, Tanaka S, et al. [Observation on natural killer cell activity in gastric cancer patients and effect of nonspecific immunopotentiator administration on its postoperative reduction]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1985;86(10):1417-25.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

539. Oshita H. Observations on natural killer activity and other nonspecific immunologic parameters in tumor-bearers. With special reference to influence of operative stress and effect of nonspecific immunopotentiator. [Japanese]. Acta Scholae Medicinalis Universitatis in Gifu. 1984;32(6):735-81.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

540. Ostrovskii AB. [Natural killer cells and T-suppressors in patients with chronic gastritis]. Voprosy Onkologii. 1988;34(12):1464-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

541. Othman N, Jamal R, Abu N. Cancer-Derived Exosomes as Effectors of Key Inflammation-Related Players. Frontiers in Immunology. 2019;10 (2103).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

542. Oucherif O, Naimi D. Function of HLA-G in cancer immunoediting and its clinical benefits. Journal Africain du Cancer. 2015;7(3):132-9.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

543. Papamichos SI. NKG2E comprises an immunogenic peptide, derived from an alu-retrotransposon: An attractive novel target for immunotherapeutic approaches. Annals of Oncology. 2019;30 (Supplement 11):xi53.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

544. Papila C, Papila I, Bilir M, Cagatay T, Yanardag H, Koksall S. Effect of vitamin E supplementation on natural killer cell activity in patients with solid tumors. Journal of B.U.ON. 1999;4(4):435-7.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

545. Park BG, Park CJ, Kim S, Yoon CH, Kim DH, Jang S, et al. Comparison of the Cytodiff flow cytometric leucocyte differential count system with the Sysmex XE-2100 and Beckman Coulter UniCel DxH 800. International Journal of Laboratory Hematology. 2012;34(6):584-93.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

546. Park BG, Park CJ, Yoon CH, Jang S, Chi HS, Ryu MH, et al. The extended leukocyte differential count using the Cytodiff flow cytometric system reveals that higher CD16+ cytotoxic NK+T lymphocyte levels predict superior survival outcomes in patients with metastatic carcinoma. Cytometry Part B, Clinical Cytometry. 2013;84(3):202-4.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

547. Park JE, Keam B, Park HR, Kim S, Ock CY, Kim M, et al. Combination of NK Cells and anti-PD-L1 Ab with ADCC enhances the anti-tumor effects in PD-L1 high cancer cells. Journal for ImmunoTherapy of Cancer. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)



548. Park MJ, Bae JH, Chung JS, Kim SH, Kang CD. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy. *Immunological Investigations*. 2011;40(4):367-82.  
배제사유 : 동물실험 및 전임상시험연구
549. Patton JT, Lustberg ME, Garman SL, Kinghorn AD, Pan L, Lucas DM, et al. Silvestrol modulates direct anti-tumor activity against Epstein-Barr Virus (EBV)-associated lymphomas while sparing innate and antigen specific adaptive immunity. *Blood*. Conference: 53rd Annual Meeting of the American Society of Hematology, ASH. 2011;118(21).  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
550. Peng LS, Mao FY, Zhao YL, Wang TT, Chen N, Zhang JY, et al. Altered phenotypic and functional characteristics of CD3+CD56+ NKT-like cells in human gastric cancer. *Oncotarget*. 2016;7(34):55222-30.  
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
551. Peng LS, Zhang JY, Teng YS, Zhao YL, Wang TT, Mao FY, et al. Tumor-associated monocytes/macrophages impair NK-cell function via TGFbeta1 in human gastric cancer. *Cancer Immunology Research*. 2017;5(3):248-56.  
배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
552. Peng YP, Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC, et al. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. *Journal of Translational Medicine*. 2013;11:262.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
553. Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, et al. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. *Gastric Cancer*. 2020;23(1):73-81.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
554. Peters KM, Pfeiffer R, Bornhofen B, Ko HL, Beuth J, Grundmann R, et al. Comparative study on lymphocyte subpopulations in cancer patients after immunostimulation with propionibacteria and in renal transplant patients after combined immunosuppression. *Arzneimittel-Forschung/Drug Research*. 1990;40(10):1162-6.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
555. Pfister K, Radons J, Busch R, Tidball JG, Pfeifer M, Freitag L, et al. Patient survival by Hsp70 membrane phenotype: association with different routes of metastasis. *Cancer*. 2007;110(4):926-35.  
배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

556. Phan TG, Long GV, Scolyer RA. Multiple checkpoints on the long road towards cancer immunotherapy. *Immunology and Cell Biology*. 2015;93(4):323-5.  
 배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
557. Pires BRB, Silva RCMC, Ferreira GM, Abdelhay E. NF-kappaB: Two sides of the same coin. *Genes*. 2018;9 (1) (24).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
558. Piso P, Aselmann H, von Wasielewski R, Dahlke MH, Klempnauer J, Schlitt HJ. Prevention of peritoneal carcinomatosis from human gastric cancer cells by adjuvant-type intraperitoneal immunotherapy in a SCID mouse model. *European Surgical Research*. 2003;35(6):470-6.  
 배제사유 : 동물실험 및 전임상시험연구
559. Plitt T, Zamarin D. Cancer therapy with Newcastle disease virus: Rationale for new immunotherapeutic combinations. *Clinical Investigation*. 2015;5(1):75-87.  
 배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구
560. Podil'chak MD, Kun ND, Raspertov VA. [Study of immunologic reactivity of patients with cancer of the stomach based on the data of the adhesive capacity of lymphocytes]. *Klinicheskaja Khirurgija*. 1992(5):30-1.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
561. Podil'chak MD, Teretskaia LM, Krasivskii EZ. [The quantitative determination of peripheral blood natural killers in stomach cancer patients]. *Voprosy Onkologii*. 1990;36(7):870-2.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
562. Podilchak MD, Terletskaya LM, Krasivsky EZ. Measurement of peripheral blood-natural killer level in gastric cancer patients. [Russian]. *Voprosy Onkologii*. 1990;36(7):870-2.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
563. Podil'chak MD. [Value of the natural killer cell count in the peripheral blood of patients with surgical diseases of the stomach and duodenum]. *Klinicheskaja Khirurgija*. 1990(8):19-21.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
564. Pottier C, Wheatherspoon A, Roncarati P, Longuespee R, Herfs M, Duray A, et al. The importance of the tumor microenvironment in the therapeutic management of cancer. *Expert Review of Anticancer Therapy*. 2015;15(8):943-54.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
565. Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. *Oncogene*. 2014;33(27):3485-95.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
566. Prinz C, KaBisch R, Anderl F, Gerhard M. Involvement of Toll-like receptors in Dendritic cell activation. *Helicobacter*. 2010;15 (4):318-9.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

567. Qi YF, Sun JN, Ren LF, Cao XL, Dong JH, Tao K, et al. Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China. *Digestive Diseases & Sciences*. 2019;64(5):1193-203.  
 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
568. Qu J, Hou Z, Han Q, Jiang W, Zhang C, Tian Z, et al. Intracellular poly(I:C) initiated gastric adenocarcinoma cell apoptosis and subsequently ameliorated NK cell functions. *Journal of Interferon & Cytokine Research*. 2014;34(1):52-9.  
 배제사유 : 동물실험 및 전임상시험연구
569. Queiroz DM, Rocha GA, Rocha AMC, Soares TF, Melo FF, Castro LP. Helicobacter pylori infection displays a mixed inflammatory/regulatory cytokine profile in children characterized by increased gastric TH1, TH2, TH17 and treg cytokines. *Gastroenterology*. 2010;1):S245.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
570. Raghavan S, Quiding-Jadierbrink M. Regulatory T cells in gastrointestinal tumors. *Expert Review of Gastroenterology and Hepatology*. 2011;5(4):489-501.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
571. Rao XQ, Yu RC, Zhang JH. [Sheng xue tang on immunological functions of cancer patients with spleen-deficiency syndrome]. *Chung Hsi i Chieh Ho Tsa Chih Chinese Journal of Modern Developments in Traditional Medicine*. 1991;11(4):218-9.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
572. Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: Preclinical rationale and ongoing clinical investigations. *Journal of Gastrointestinal Oncology*. 2015;6(5):561-9.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
573. Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, et al. Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity. *Expert Review of Anticancer Therapy*. 2015;15(6):689-702.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
574. Ravindranath MH, Filippone EJ, Devarajan A, Asgharzadeh S. Enhancing Natural Killer and CD8+ T Cell-Mediated Anticancer Cytotoxicity and Proliferation of CD8+ T Cells with HLA-E Monospecific Monoclonal Antibodies. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 2019;38(2):38-59.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
575. Recchia F, Candeloro G, Necozone S, Bisegna R, Bratta M, Rea S. Immunotherapy in patients with less than complete response to chemotherapy. *Anticancer Research*. 2009;29(2):567-72.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
576. Recchia F, De Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L, et al. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic

acid as maintenance therapy in advanced cancer. *Clinical Cancer Research*. 2001;7(5):1251-7.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

577. Recchia F, Saggio G, Candeloro G, Cesta A, Amiconi G, Blasio AD, et al. Chemoimmunotherapy in the treatment of metastatic gastric cancer. *Anti-Cancer Drugs*. 2007;18(5):597-604.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

578. Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: A phase 1 study. *Journal of Immunotherapy*. 1997;20(1):79-87.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

579. Redzovic A, Laskarin G, Dominovic M, Haller H, Rukavina D. Mucins help to avoid alloreactivity at the maternal fetal interface. *Clinical and Developmental Immunology*. 2013;2013 (542152).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

580. Ribeiro CH, Kramm K, Galvez-Jiron F, Pola V, Bustamante M, Contreras HR, et al. Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients. *Oncology Reports*. 2016;35(3):1309-17.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

581. Rickinson A. Epstein-barr virus - Pathogenesis and immunobiology. *European Journal of Cancer*. 2012;50:S7.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

582. Rickinson AB. Co-infections, inflammation and oncogenesis: future directions for EBV research. *Seminars in Cancer Biology*. 2014;26:99-115.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

583. Rittenhouse-Olson K. Immunological Investigations: Letter from the editor. *Immunological Investigations*. 2010;39(4-5):293-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

584. Roper J, Shen X. Novel Three-Dimensional Cultures of Patient-Derived Cancer and Tumor Immune Cells. *Gastroenterology*. 2019;157(1):260-1.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

585. Rosso D, Rigueiro MP, Kassab P, Ilias EJ, Castro OA, Novo NF, et al. [Correlation of natural killer cells with the prognosis of gastric adenocarcinoma]. *ABCD, Arquivos Brasileiros de Cirurgia Digestiva*. 2012;25(2):114-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

586. Rudnicka K, Miszczyk E, Matusiak A, Walencka M, Chmiela M. NK and NKT cell responses to h. pylori lipopolysaccharide in relation to lymphocyte cytotoxic activity and H. Pylori status. *Postepy Mikrobiologii*. 2013;1:90-1.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

587. Rudnicka K, Włodarczyk M, Moran AP, Rehcinski T, Miszczyk E, Matusiak A, et al. Helicobacter pylori antigens as potential modulators of lymphocytes' cytotoxic activity. *Microbiology & Immunology*. 2012;56(1):62-75.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

588. Rupeshkumar M, Chettri U, Jaikumar S, Rathi Bai M, Paarakh PM. Ganoderma lucidum: A review with special emphasis on the treatment of various cancer. *Journal of Applied Pharmacy*. 2016;8(4):1-5.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

589. Ryan-Harshman M, Aldoori W. The relevance of selenium to immunity, cancer, and infectious/inflammatory diseases. *Canadian Journal of Dietetic Practice and Research*. 2005;66(2):98-102.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

590. Sagakyants AB, Kit OI, Samoylenko NS, Novikova IA, Zlatnik EY, Frantsiyants EM, et al. Parameters of local cellular immunity in metastatic gastric cancer. *Annals of Oncology*. 2019;30 (Supplement 5):v309-v10.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

591. Saigusa S, Ichikura T, Tsujimoto H, Sugasawa H, Majima T, Kawarabayashi N, et al. Serum granulysin level as a novel prognostic marker in patients with gastric carcinoma. *Journal of Gastroenterology & Hepatology*. 2007;22(8):1322-7.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

592. Sairenji M, Yanoma S, Motohashi H, Kobayashi O, Okada K, Okamoto T, et al. Induction of cytolytic activity of lymphocytes from carcinomatous pleural effusion by IL-2 and autologous tumor cells. *Biotherapy*. 1993;6(4):283-90.

배제사유 : 동물실험 및 전임상시험연구

593. Saito H, Osaki T, Ikeguchi M. Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer. *Gastric Cancer*. 2012;15(1):27-33.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

594. Saito H, Takaya S, Osaki T, Ikeguchi M. Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients. *Gastric Cancer*. 2013;16(4):473-9.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

595. Saji S, Sugiyama Y, Kunieda K. Pre- and/or post-operative immunochemotherapy for advanced digestive cancer. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1997;24 Suppl 1:239-49.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

596. Sakai Y, Koizumi K. Cell-mediated cytotoxicity of mononuclear cells isolated from

- cancer and normal mucosa of the stomach. *Gastroenterology*. 1982;82(6):1374-80.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
597. Sakai Y, Maeda M, Koyama W, Totsuka S, Sakamoto S, Kanayama M. [A case of advanced gastric cancer responsive to intratumoral OK-432 injection]. *Gan to Kagaku Ryoho* [Japanese Journal of Cancer & Chemotherapy]. 1988;15(6):1978-80.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
598. Sakamoto N, Ishikawa T, Kokura S, Okayama T, Oka K, Ideno M, et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. *Journal of Translational Medicine*. 2015;13 (1) (277).  
 배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
599. Salar A, Domingo-Domenech E, Panizo C, Nicolas C, Bargay J, Muntanola A, et al. Long-term results of the multicenter phase II trial with bendamustine and rituximab as first line treatment for patients with MALT lymphoma (MALT-2008-01). *Hematological oncology*. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. 2017;35:147?8.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
600. Sano T, Saijo N, Sasaki Y, Shinkai T, Eguchi K, Tamura T, et al. [Phase I-II study of recombinant interleukin-2]. *Gan to Kagaku Ryoho* [Japanese Journal of Cancer & Chemotherapy]. 1987;14(3 Pt 2):903-13.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
601. Saraswathi J, Venkatesh K, Baburao N, Hilal MH, Rani AR. Phytopharmacological importance of pelargonium species. *Journal of Medicinal Plants Research*. 2011;5(13):2587-98.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
602. Sasada A, Takagi M, Tabata S, Abe M, Abe H. A patient with stage IV gastric cancer who acquired complete remission after undergoing multi-peptide dendritic cell immunotherapy in combination with standard therapies. *Personalized Medicine Universe*. 2015;4:70-2.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
603. Sasanami T, Fujishima A, Moriya Y, Imai K, Yachi A. [NK activities in cancer patients--their modification by an immunopotentiator]. *Gan to Kagaku Ryoho* [Japanese Journal of Cancer & Chemotherapy]. 1982;9(12):2186-92.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
604. Satge D, Seidel MG. The pattern of malignancies in down syndrome and its potential context with the immune system. *Frontiers in Immunology*. 2018;9 (3058).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
605. Sathe A, Grimes SM, Lau BT, Chen J, Suarez C, Huang RJ, et al. Single-Cell Genomic Characterization Reveals the Cellular Reprogramming of the Gastric Tumor Microenvironment. *Clinical Cancer Research*. 2020;26(11):2640-53.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

606. Sato Y, Koshita Y, Hirayama M, Matuyama T, Wakimoto H, Hamada H, et al. Augmented antitumor effects of killer cells induced by tumor necrosis factor gene-transduced autologous tumor cells from gastrointestinal cancer patients. *Human Gene Therapy*. 1996;7(15):1895-905.  
 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
607. Satoh T, Shitara K, Iwasa S, Yamaguchi K, Muro K, Komatsu Y, et al. Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors. *Journal of Clinical Oncology*. Conference. 2019;37(Supplement 4).  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
608. Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M. Redirection of T-cell effector functions for cancer therapy: Bispecific antibodies and chimeric antigen receptors. *Future Oncology*. 2013;9(4):527-39.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
609. Schirmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory. *Cancer Immunology, Immunotherapy*. 2005;54(6):587-98.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
610. Schmidt-Rimpler C, Burges A, Ruf P, Schulze E, Heiss MM, Parsons SL. Overview of the development of catumaxomab in malignant ascites. *Journal of Cancer Research and Clinical Oncology*. 2012;118(1):115.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
611. Schwab C, Gabrysch A, Olbrich P, Patino V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. *Journal of Allergy & Clinical Immunology*. 2018;142(6):1932-46.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
612. Schwartzkopff S, Grundemann C, Schweier O, Rosshart S, Karjalainen KE, Becker KF, et al. Tumor-associated E-cadherin mutations affect binding to the killer cell lectin-like receptor G1 in humans. *Journal of Immunology*. 2007;179(2):1022-9.  
 배제사유 : 동물실험 및 전임상시험연구
613. Sebastian M, Kuemmel A, Schmidt M, Schmittel A. Catumaxomab: A bispecific trifunctional antibody. *Drugs of Today*. 2009;45(8):589-97.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
614. Sedman PC, Ramsden CW, Brennan TG, Giles GR, Guillou PJ. Augmentation of lymphokine-activated killer cell activity in patients with gastrointestinal cancer. *British Journal of Surgery*. 1988;75(6):591-4.  
 배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
615. See D, Mason S, Roshan R. Increased Tumor Necrosis Factor alpha (TNF-alpha) and Natural Killer Cell (NK) function using an integrative approach in late stage cancers. *Immunological Investigations*. 2002;31(2):137-53.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

616. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. *Cancer Treatment Reviews*. 2010;36(6):458-67.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

617. Sekizuka H, Noro K, Haruyama S, Kiribuchi Y, Hayashi F. [Antibody-dependent cell-mediated cytotoxicity (ADCC) in gastric and colorectal cancer]. *Gan No Rinsho - Japanese Journal of Cancer Clinics*. 1986;32(8):879-82.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

618. Senba T, Kuroki M, Arakawa F, Yamamoto T, Kuwahara M, Haruno M, et al. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. *Anticancer Research*. 1998;18(1A):17-24.

배제사유 : 동물실험 및 전임상시험연구

619. Sephton S, Spiegel D. Circadian disruption in cancer: A neuroendocrine-immune pathway from stress to disease? *Brain, Behavior, and Immunity*. 2003;17(5):321-8.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

620. Settanni CR, Ianiro G, Franceschi F, Gasbarrini G, Gasbarrini A. From Regular Catharsis with Castor Oil to Recognizing the Importance of the Intestinal Microbiota. *Digestive Diseases*. 2020;38(2):128-36.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

621. Sfikakis PP, Gourgoulis GM, Mouloupoulos LA, Kouvatseas G, Theofilopoulos AN, Dimopoulos MA. Age-related thymic activity in adults following chemotherapy-induced lymphopenia. *European Journal of Clinical Investigation*. 2005;35(6):380-7.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

622. Shadman M, Ajami A, Rafiei A, Hussein-Nattaj H, Hosseini V, Taghvaei T, et al. Phenotypic evaluation of natural killer (NK) and natural killer T (NKT)-like cells in patients with peptic ulcer and gastric cancer caused by helicobacter pylori infection. [Persian]. *Journal of Mazandaran University of Medical Sciences*. 2014;23(110).

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

623. Shahid A, Bharadwaj M. The connection between the Th17 cell related cytokines and cancer stem cells in cancer: Novel therapeutic targets. *Immunology Letters*. 2019;213:9-20.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

624. Shannon-Lowe C, Rickinson A. The Global Landscape of EBV-Associated Tumors. *Frontiers in Oncology*. 2019;9:713.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

625. Shao YJ, Liao ZP, Wu YH. Impact of postoperative analgesia with dezocine plus



ropivacaine versus fentanyl plus ropivacaine on stress response and immune function in patients with gastric cancer. [Chinese]. World Chinese Journal of Digestology. 2018;26(10):616-22.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

626. Shchepotin IB, Valetsky VL, Chorny VA, Shabahang M, Nauta RJ, Buras RR, et al. Carcinoma of the stomach following the Chernobyl nuclear accident. European Journal of Cancer. 1997;33(9):1413-8.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

627. Shen JC, Sun HL, Zhang MQ, Liu XY, Wang Z, Yang JJ. Flurbiprofen improves dysfunction of T-lymphocyte subsets and natural killer cells in cancer patients receiving post-operative morphine analgesia. International Journal of Clinical Pharmacology & Therapeutics. 2014;52(8):669-75.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

628. Shen X. Hmgb1 induced anti-cancer effect of dendritic cells (DCs) in vitro. Respiriology. 2011;2:157-9.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

629. Shi J, Jiang D, Yang S, Zhang X, Wang J, Liu Y, et al. LPAR1, Correlated With Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer. Frontiers in Oncology. 2020;10 (846).

배제사유 : 위암 환자를 대상으로 하지 않은 연구

630. Shi L, Yang L, Wu Z, Xu W, Song J, Guan W. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy? International Immunopharmacology. 2018;63:58-65.

배제사유 : 원자가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

631. Shi Y, Yu PW, Zeng DZ, Zhang C. Effects of compound Kushen injection on the immunologic function of patients after gastric cancer resection. [Chinese]. Pharmaceutical Care and Research. 2006;6(3):183-5.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

632. Shiiba K, Ebina N, Saito Y, Mizoi T, Anzai R, Okoshi T, et al. Intraperitoneal administration of recombinant interleukin-2 (rIL-2) against peritoneal dissemination of gastric cancer: Clinical and immunological evaluation on anti-tumor effects and analysis of its mechanism. [Japanese]. Journal of Japan Society for Cancer Therapy. 1994;29(6):895-907.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

633. Shimada-Hiratsuka M, Fukayama M, Hayashi Y, Ushijima T, Suzuki M, Hishima T, et al. Primary gastric T-cell lymphoma with and without human T-lymphotropic virus type 1. Cancer. 1997;80(2):292-303.

배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구

634. Shimizu Y, Weidmann E, Iwatsuki S, Herberman RB, Whiteside TL. Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma. Cancer Research. 1991;51(22):6153-62.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

635. Shimura T, Suehiro T, Suzuki H, Mochida Y, Okada K, Mochiki E, et al. Peptides derived from a soluble molecule of the human leukocyte antigen (HLA) class I cause apoptosis in gastric cancer cell lines. *Digestive Diseases & Sciences*. 2009;54(1):63-9.  
 배제사유 : 동물실험 및 전임상시험연구
636. Shin WJ, Zabel BA, Pachynski RK. Mechanisms and functions of chemerin in cancer: Potential roles in therapeutic intervention. *Frontiers in Immunology*. 2018;9 (NOV) (02772).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
637. Shiraishi K, Mimura K, Kua LF, Koh V, Siang LK, Nakajima S, et al. Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility. *Journal of Gastroenterology*. 2016;51(12):1101-11.  
 배제사유 : 동물실험 및 전임상시험연구
638. Shiraishi T, Nio Y, Imai S, Tsubono M, Morimoto H, Tseng CC, et al. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)]. *Nippon Gan Chiryō Gakkai Shi - Journal of Japan Society for Cancer Therapy*. 1990;25(4):799-811.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
639. Shiraiwa H, Sekine T, Tobisu K, Kakizoe T, Koiso K. A new form of specific targeting cancer immunotherapy using anti-tumor monoclonal antibody-conjugated lymphokine-activated killer cells. *Japanese Journal of Cancer Research*. 1991;82(6):621-3.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
640. Shirakabe M, Kusunoki T, Utsunomiya J. The clinicopathological characteristics of gastric cancer patients showing decreased peripheral blood natural killer cell activity. [Japanese]. *Journal of Japan Society for Cancer Therapy*. 1995;30(10):1746-57.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
641. Shirakawa T, Tokunaga A, Onda M. Release of immunosuppressive substances after gastric resection is more prolonged than after mastectomy in humans. *International Surgery*. 1998;83(3):210-4.  
 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
642. Shirato M. [Cytotoxic activity of tumor-infiltrating lymphocytes and macrophages in gastric cancer]. *Nippon Shokakibyō Gakkai Zasshi - Japanese Journal of Gastroenterology*. 1985;82(7):1665-74.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
643. Shitara K, Satoh T, Iwasa S, Yamaguchi K, Muro K, Komatsu Y, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors. *Journal for Immunotherapy of Cancer*. 2019;7(1):219.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

644. Shparik Ia V, Bilynskii BT, Kim Sun G. [State of natural killer cells after surgical treatment of oncologic patients]. *Klinicheskaia Khirurgiia*. 1990(5):16-7.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
645. Sidagis J, Ueno K, Tokunaga M, Ohyama M, Eizuru Y. Molecular epidemiology of Epstein-Barr virus (EBV) in EBV-related malignancies. *International Journal of Cancer*. 1997;72(1):72-6.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
646. Sikora J, Dworacki G, Trybus M, Batura-Gabryel H, Zeromski J. Correlation between DNA content, expression of Ki-67 antigen of tumor cells and immunophenotype of lymphocytes from malignant pleural effusions. *Tumour Biology*. 1998;19(3):196-204.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
647. Sima P, Richter J, Vetvicka V. Glucans as new anticancer agents. *Anticancer Research*. 2019;39(7):3373-8.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
648. Singh S, Banerjee S. Downregulation of HLA-ABC expression through promoter hypermethylation and downmodulation of MIC-A/B surface expression in LMP2A-positive epithelial carcinoma cell lines. *Scientific Reports*. 2020;10(1):5415.  
 배제사유 : 동물실험 및 전임상시험연구
649. Skinnider LF, Alexander S, Horsman D. Concurrent thymoma and lymphoma: a report of two cases. *Human Pathology*. 1982;13(2):163-6.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
650. Slaton J, Verneris M, Lu H, Wenner C. East meets west: The mushroom extract PSK enhances docetaxel therapy for castrate resistant prostate cancer. *Journal of Urology*. 2011;1:e295.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
651. Smirnova OV, Sinyakov AA, Tereshchenko SY. Features of cellular immunity in chronic atrophic gastritis. *Allergy: European Journal of Allergy and Clinical Immunology*. 2019;74 (Supplement 106):244.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
652. Smyth MJ. Imatinib mesylate - Uncovering a fast track to adaptive immunity. *New England Journal of Medicine*. 2006;354(21):2282-4+12.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
653. Solcia E, Necchi V, Sommi P, Ricci V. Proteasome-rich PaCS as an oncofetal UPS structure handling cytosolic polyubiquitinated proteins. In vivo occurrence, in vitro induction, and biological role. *International Journal of Molecular Sciences*. 2018;19 (9) (2767).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
654. Solinas C, Migliori E, De Silva P, Willard-Gallo K. LAG3: The biological processes that motivate targeting this immune checkpoint molecule in human cancer. *Cancers*. 2019;11

(8) (1213).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

655. Solinas C, Pusole G, Demurtas L, Puzzoni M, Mascia R, Morgan G, et al. Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. *Critical Reviews in Oncology/Hematology*. 2017;110:106-16.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

656. Song GM, Tian X, Liang H, Yi LJ, Zhou JG, Zeng Z, et al. Role of Enteral Immunonutrition in Patients Undergoing Surgery for Gastric Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Medicine*. 2015;94(31):e1311.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

657. Song H, Kim J, Cosman D, Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. *Cellular Immunology*. 2006;239(1):22-30.

배제사유 : 동물실험 및 전임상시험연구

658. Song Y. [Natural killer (NK) activity of the peripheral blood lymphocytes in cancer patients]. *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]*. 1989;27(6):357-8, 81-2.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

659. Sordo-Bahamonde C, Lorenzo-Herrero S, Payer AR, Gonzalez S, Lopez-Soto A. Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer. *International Journal of Molecular Sciences*. 2020;21 (10) (3726).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

660. Soulas C, Remark R, Brezar V, Lopez J, Bonnet E, Caraguel F, et al. Combination of monalizumab and durvalumab as a potent immunotherapy treatment for solid human cancers. *Cancer Research. Conference*. 2018;78(13 Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

661. Souza BDO, Diaz BF, Guidugli GS, Ferraz LS, Amarante MK, Rocha SPD, et al. Natural killer cells: Prospects in cancer immunotherapy. *Current Immunology Reviews*. 2018;14(2):100-4.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

662. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: Possible mechanisms. *Integrative Cancer Therapies*. 2008;7(3):189-203.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

663. Streltsova MA, Barsov EV, Erokhina SA, Sapozhnikov AM, Kovalenko EI. Current approaches to engineering of NK cells for cancer immunotherapy. *Current Pharmaceutical Design*. 2018;24(24):2810-24.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

664. Strohle MA, Grutzner KU, Schildberg FW, Heiss MM. Induction of cytotoxicity against autologous tumour cells by interleukin-12: Evidence for intrinsic anti-tumor immune capacity in curatively resected gastrointestinal tumour patients. *Cancer Immunology*,

Immunotherapy. 2002;51(9):505-12.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

665. Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, et al. Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. *PLoS Pathogens*. 2013;9(5):e1003341.

배제사유 : 동물실험 및 전임상시험연구

666. Strykowska-Gora A, Karczmarek-Borowska B, Gora T, Krawczak K. Statins and cancers. *Wspolczesna Onkologia*. 2015;19(3):167-75.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

667. Subhash VV, Yeo MS, Tan WL, Yong WP. Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. *Journal of Immunology Research*. 2015;2015 (308574).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

668. Sugawara K, Iwai M, Yajima S, Tanaka M, Yanagihara K, Seto Y, et al. Efficacy of a Third-Generation Oncolytic Herpes Virus G47DELTA in Advanced Stage Models of Human Gastric Cancer. *Molecular Therapy Oncolytics*. 2020;17:205-15.

배제사유 : 동물실험 및 전임상시험연구

669. Sugiyama Y, Kato M, Takao H, Kida H, Kunieda K, Umemoto T, et al. Immunological effects of locoregional immunochemotherapy for liver metastases of gastric cancer. *Japanese Journal of Cancer and Chemotherapy*. 1993;20(11):1461-4.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

670. Sugiyama Y, Takao H, Umemoto T, Niwa H, Kida H, Saji S, et al. [Cytotoxicity of interleukin 2-induced lymphocytes and effects of serum immunosuppressive factors]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1986;87(1):3-9.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

671. Sun HX, Chen LQ, Zhang J, Chen FY. Anti-tumor and immunomodulatory activity of peptide fraction from the larvae of *Musca domestica*. *Journal of Ethnopharmacology*. 2014;153(3):831-9.

배제사유 : 동물실험 및 전임상시험연구

672. Sun J, Tao H, Li X, Wang L, Yang J, Wu P, et al. Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer. *Oncology Letters*. 2017;14(2):2405-9.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

673. Sun S, Li XM, Li XD, Yang WS. Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. *Cancer Biotherapy & Radiopharmaceuticals*. 2005;20(2):173-80.

배제사유 : 동물실험 및 전임상시험연구

674. Suresh K, Jayavardhanan K, Shyamsundar K, Kuttapan C, Vasudevan D. Natural-killer-cell and antibody-dependent cellular cytotoxicity in gastric-carcinoma patients - modulatory effects of IL-2 and 5-Fluorouracil. *Oncology Reports*.

1994;1(2):439-43.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

675. Suresh K, Jayavardhanan KK, Nirmala K, Vasudevan DM. Direct correlation between IL-2-R gene transcription and natural cell mediated cytotoxicity in patients with gastric carcinoma. *Oncology Reports*. 1995;2(3):481-5.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

676. Suzawa K, Shien K, Huang P, Sakaguchi M, Watanabe M, Hashida S, et al. Distant bystander effect of REIC/DKK-3 gene therapy through immune system stimulation in a murine model of thoracic malignancies. *Journal of Thoracic Oncology*. 2015;2):S599.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

677. Svensson MC, Berntsson J, Hedner C, Borg D, Nodin B, Leandersson K, et al. The difference in prognostic value of tumour-infiltrating T cells according to adjuvant chemotherapy in radiochemona?ve gastroesophageal cancer. *Journal of clinical oncology*. 2017;35(7):41?.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

678. Svensson MC, Warfvinge CF, Fristedt R, Hedner C, Borg D, Eberhard J, et al. The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. *Oncotarget*. 2017;8(42):72108-26.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

679. Szkaradkiewicz A, Karpinski TM, Drews M, Borejsza-Wysocki M, Majewski P, Andrzejewska E. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. *Journal of Biomedicine & Biotechnology*. 2010;2010:901564.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

680. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. *Clinical Cancer Research*. 2013;19(5):1021-34.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

681. Tachibana S. Fundamental and clinical studies on adoptive immunotherapy. With special reference to postoperative changes in lymphokine-activated killer cell activity induced from peripheral blood lymphocytes of gastric and colorectal cancer patients, character analysis of various activated lymphocytes, and their clinical application. [Japanese]. *Acta Scholae Medicinalis Universitatis in Gifu*. 1987;35(6):1086-130.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

682. Taguchi T, Kimoto Y. [Interleukin 2]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1987;14(5 Pt 1):1203-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

683. Taguchi T. [Lentinan]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1986;13(11):3294-304.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

684. Takacs M, Segesdi J, Banati F, Koroknai A, Wolf H, Niller HH, et al. The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas. *Mediterranean Journal of Hematology & Infectious Diseases*. 2009;1(2):e2009012.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
685. Takagi H, Okuno K, Nakamura T, Kokudo S, Iwasa Z, Yasutomi M. [Induction of tumoricidal effectors from the tumor-bearer's splenocytes and the prospects of their utilization for adoptive immunotherapy]. *Nippon Gan Chiryō Gakkai Shi - Journal of Japan Society for Cancer Therapy*. 1986;21(4):721-7.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
686. Takahashi M, Fujimoto S, Takai M, Ohno K, Endoh F, Masuda Y, et al. Two-color flow cytometric analysis of splenic lymphocyte subpopulations in patients with gastric cancer. *Surgery Today*. 1992;22(1):35-9.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
687. Takao H, Saji S, Sugiyama Y, Tachibana S, Goshima H, Kunii Y, et al. [Effects of serum immunosuppressive factors on the cytotoxicity of lymphokine-activated killer (LAK) cells induced by recombinant interleukin 2(R-IL2)]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1988;89(7):992-8.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
688. Takao S. [Studies on malignant behavior of human gastric cancer using athymic nude mice. I. Factors affecting the malignant behavior. II. Establishment of transplantable and metastasizing tumor lines]. *Igaku Kenkyū - Acta Medica*. 1984;54(1):78-105.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
689. Takata K, Noujima-Harada M, Miyata-Takata T, Ichimura K, Sato Y, Miyata T, et al. Clinicopathologic analysis of 6 lymphomatoid gastropathy cases: expanding the disease spectrum to CD4+CD8+ cases. *American Journal of Surgical Pathology*. 2015;39(9):1259-66.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
690. Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. *American Journal of Gastroenterology*. 2001;96(2):574-8.  
 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
691. Takeuchi K, Yokoyama M, Ishizawa S, Terui Y, Nomura K, Marutsuka K, et al. Lymphomatoid gastropathy: A distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. *Blood*. 2010;116(25):5631-7.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
692. Tamura T, Kunitomo K, Korematsu H, Ikuno F, Nakata Y, Tsuge S, et al. Clinical significance of the K cell measurement in gastric cancer patients. *Tokushima Journal of Experimental Medicine*. 1981;28(3-4):97-101.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

693. Tan GW, Visser L, Tan LP, Van Den Berg A, Diepstra A. The microenvironment in epstein-barr virus-associated malignancies. *Pathogens*. 2018;7 (2) (40).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
694. Tan JBL, Becker A, DiRenzo D, Zhang K, Chen A, Thomas-Tran R, et al. Reversal of adenosine-mediated immune suppression by AB421, a potent and selective small-molecule CD73 inhibitor. *Journal for ImmunoTherapy of Cancer*. Conference: 32nd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2017;5(Supplement 2).  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
695. Tanabe H, Imai N, Takeuchi K. Studies on usefulness of preoperative administration of lentinan for patients with gastric cancer. [Japanese]. *Journal of Japan Society for Cancer Therapy*. 1992;27(5):939-46.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
696. Tanabe H. Studies on early enteral nutrition for patients with gastric cancer from the view of immunity. *Nippon Geka Hokan - Archiv fur Japanische Chirurgie*. 1993;62(3):135-44.  
 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
697. Tanabe H. Study of effect of surgical stress on immunity in patients with gastrointestinal cancer. *Nippon Geka Hokan - Archiv fur Japanische Chirurgie*. 1993;62(3):145-52.  
 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
698. Tanaka H, Shinto O, Yashiro M, Yamazoe S, Iwauchi T, Muguruma K, et al. Transforming growth factor beta signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. *Oncology Reports*. 2010;24(6):1637-43.  
 배제사유 : 동물실험 및 전임상시험연구
699. Tanaka H, Tamura T, Okita Y, Yoshii M, Tokumoto M, Go Y, et al. [Significance of Immune-Cell Infiltration in Gastric]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2018;45(2):217-21.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
700. Tanaka H, Yashiro M, Sunami T, Sakate Y, Kosaka K, Hirakawa K. ICAM-2 gene therapy for peritoneal dissemination of scirrhus gastric carcinoma. *Clinical Cancer Research*. 2004;10(14):4885-92.  
 배제사유 : 동물실험 및 전임상시험연구
701. Tanaka N, Gotoh K, Kobayashi G, Gouchi A, Orita K. Augmentation in cytotoxicity of lymphnode lymphocytes by OK-432. *International Journal of Immunopharmacology*. 1994;16(2):131-5.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
702. Tanaka N, Hashimoto T, Matsui T, Ohida J, Ono M, Orita K. Natural cytotoxic reactivity of peripheral blood lymphocytes from digestive tract cancer patients against a colon



cancer cell line and virus-infected HeLa cells. Gann. Japanese Journal of Cancer Research. 1983;74(3):419-25.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

703. Tanaka N, Ohida J, Ono M, Yoshiwara H, Beika T, Terasawa A, et al. [Augmentation of NK activity in peripheral blood lymphocytes of cancer patients by intermittent GE-132 administration]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 1984;11(6):1303-6.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

704. Tanaka T, Megahed N, Takata K, Asano N, Niwa Y, Hirooka Y, et al. A case of lymphomatoid gastropathy: An indolent CD56-positive atypical gastric lymphoid proliferation, mimicking aggressive NK/T cell lymphomas. Pathology, Research & Practice. 2011;207(12):786-9.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

705. Tanaka Y, Aoike A, Hosokawa T, Yamaguchi N, Akasaka Y. [The relationship of natural killer activity with progression of gastric cancer (author's transl)]. Nippon Shokakibyo Gakkai Zasshi - Japanese Journal of Gastroenterology. 1979;76(12):2456.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

706. Tani M, Tanimura H, Yamaue H, Iwahashi M, Tsunoda T, Tamai M, et al. In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. European Journal of Clinical Pharmacology. 1992;42(6):623-7.

배제사유 : 동물실험 및 전임상시험연구

707. Tao K, He M, Tao F, Xu G, Ye M, Zheng Y, et al. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment. Cancer Chemotherapy and Pharmacology. 2018;82(5):815-27.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

708. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: Couples therapy. Nature Reviews Cancer. 2013;13(9):663-73.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

709. Terada T. Histopathological study using computer database of 10 000 consecutive gastric specimens: (2) malignant lesions. Gastroenterology Report. 2016;4(1):54-8.

배제사유 : 동물실험 및 전임상시험연구

710. Terme M, Pernot S, Marcheteau E, Castan F, Bouche O, Bennouna J, et al. Peripheral natural killer cells are a prognostic factor in advanced oesogastric adenocarcinoma and are associated with intestinal types in the randomized trial PRODIGE17- ACCORD20 (UNICANCER GI). Journal of clinical oncology. 2016;34.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

711. Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N. Potential role of NK cells in the induction of immune responses: Implications for NK cell-based immunotherapy for cancers and viral infections. International Reviews of Immunology. 2008;27(3):93-110.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

712. Than SS, Kataoka K, Sakaguchi M, Murata H, Abarzua F, Taketa C, et al. Intraperitoneal administration of an adenovirus vector carrying REIC/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma. *Oncology Reports*. 2011;25(4):989-95.  
배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
713. Thiel A, Ehlers M, Anlauf M, Raffel A, Stoecklein NH, Schott M. The immune system in neuroendocrine tumors. *Hormone and Metabolic Research*. 2011;43(12):890-6.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
714. Thomas-Tikhonenko A, Hunter CA. Infection and cancer: The common vein. *Cytokine and Growth Factor Reviews*. 2003;14(1):67-77.  
배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
715. Toganel E, Toganel D, Reza A, Brilinschi C. Effect of cantastim on the circulating lymphocyte subsets after surgery for gastric or colorectal carcinomas (cytochemical study). *Romanian Journal of Gastroenterology*. 1996;5(2):91-5.  
배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
716. Toge T, Seto Y, Kuroi K, Yamada H, Aratani K, Fujita T, et al. Relationship of the distribution of Leu-2+ cells with suppressor cell activities in the spleen and lymph-nodes from gastric cancer. *Japanese Journal of Surgery*. 1987;17(2):72-7.  
배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
717. Toge T, Yamada H, Aratani K, Kameda A, Kuroi K, Hisamatsu K, et al. Effects of intraperitoneal administration of OK-432 for patients with advanced cancer. *Japanese Journal of Surgery*. 1985;15(4):260-5.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
718. Toge T, Yamaguchi Y, Sawamura A. The role of lymphocyte surface binding sites for wheat germ agglutinin in the negative regulation of cancer patients. *Surgery Today*. 1993;23(9):765-70.  
배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
719. Toh U, Yamana H, Kido K, Mine T, Fujii T, Horiuchi H, et al. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2003;30(11):1566-70.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
720. Toledo K, Ribeiro C, Garate V, Morales M, Kramm K, Gonzalez P, et al. Immunological and clinical significance of major histocompatibility complex class I-related chains A (MICA) alleles in gastric cancer patients. *European Journal of Immunology*. 2019;49 (Supplement 3):288.  
배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
721. Tsimberidou AM, Fountzilias E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. *Cancer Treatment Reviews*. 2020;86 (102019).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

722. Tsoi IG, Saparov AS, Bulegenova MG, Dzhumagulova AB, Seksenbaev BD. Functional activity of cytotoxic lymphocyte subpopulations of local and systemic immunity in gastric ulcer and cancer. [Russian]. *Immunologiya*. 1994(4):43-5.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

723. Tsuburaya A, Noguchi Y, Yoshikawa T, Nomura K, Fukuzawa K, Makino T, et al. Long-term effect of radical gastrectomy on nutrition and immunity. *Surgery Today*. 1993;23(4):320-4.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

724. Tsuchiya S. Diagnosis of Epstein-Barr virus-associated diseases. *Critical Reviews in Oncology/Hematology*. 2002;44(3):227-38.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

725. Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J, Hase K. Roles of inflammatory cytokines in the progression of gastric cancer: Friends or foes? *Gastric Cancer*. 2010;13(4):212-21.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

726. Tsunoda T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tamai M, et al. Augmentation of cytotoxic activity by combination with interleukin 2 and interferon gamma. *Nippon Geka Hokan - Archiv fur Japanische Chirurgie*. 1991;60(6):396-405.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

727. Tu H, Zhang L, Ding L, Jin Y, Zhou F. Effect of compound kushen injection on immune function for patients with newly diagnosed multiple myeloma undergoing chemotherapy. *HemaSphere*. 2018;2 (Supplement 2):970-1.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

728. Turriziani M, Fantini M, Benvenuto M, Izzi V, Masuelli L, Sacchetti P, et al. Carcinoembryonic antigen (CEA)-based cancer vaccines: Recent patents and antitumor effects from experimental models to clinical trials. *Recent Patents on Anti-Cancer Drug Discovery*. 2012;7(3):265-96.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

729. Ueno A, Arakawa F, Abe H, Matsumoto H, Kudo T, Asano R, et al. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. *Anticancer Research*. 2002;22(2A):769-76.

배제사유 : 동물실험 및 전임상시험연구

730. Uphoff C, Weste J, Denkmann S, Drexler H. Lytic phase replication of epstein-barr virus in replication competent leukemia/lymphoma cell lines. *Haematologica*. 2012;1):125-6.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

731. Uracz W, Mytar B, Zembala M, Ruggiero I, Popiela T, Czupryna A. "Activated" monocytes in gastric cancer patients. II. Suppressor and cytostatic activity in vitro. *Journal of Cancer Research & Clinical Oncology*. 1982;104(3):307-13.

배제사유 : 동물실험 및 전임상시험연구

732. Vacca P, Martini S, Garelli V, Passalacqua G, Moretta L, Mingari MC. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. *European Journal of Immunology*. 2013;43(2):550-61.  
 배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
733. Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, et al. Trial watch: Immunostimulatory cytokines in cancer therapy. *OncoImmunology*. 2014;3 (6) (e29030).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
734. Vallentin B, Barlogis V, Piperoglou C, Cypowyj S, Zucchini N, Chene M, et al. Innate lymphoid cells in cancer. *Cancer Immunology Research*. 2015;3(10):1109-14.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
735. Vannucci L, Stepankova R, Grobarova V, Kozakova H, Rossmann P, Klimesova K, et al. Colorectal carcinoma: Importance of colonic environment for anti-cancer response and systemic immunity. *Journal of Immunotoxicology*. 2009;6(4):217-26.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
736. Vargas JA, Alvarez-Mon M, Manzano L, Albillos A, Fernandez-Corugedo A, Gea-Banacloche JC, et al. Natural killer cell activity in patients with pernicious anemia. *Digestive Diseases & Sciences*. 1995;40(7):1538-41.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
737. Vazquez B, Rebollo J, Martinez E, Sureda M, Gonzalez Manzano R. Long-term low-dose interleukin-2 (IL-2), alfa-interferon (alpha-IFN) and 13-cis-retinoic acid (RA) as maintenance therapy in cancer patients. A preliminary study. *European Journal of Immunology*. 2009;1):S525-S6.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
738. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. *Current Pharmaceutical Design*. 2012;18(26):3831-52.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
739. Vesterinen E, Pukkala E, Timonen T, Aromaa A. Cancer incidence among 78,000 asthmatic patients. *International Journal of Epidemiology*. 1993;22(6):976-82.  
 배제사유 : 위암 환자를 대상으로 하지 않은 연구
740. Vetvicka V, Vetvickova J. beta 1, 3-glucan in cancer treatment. *American Journal of Immunology*. 2012;8(2):38-43.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
741. Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcarcel M, Gallot N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. *Cancer and Metastasis Reviews*. 2006;25(3):417-34.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
742. Voskens CJ, Watanabe R, Rollins S, Campana D, Hasumi K, Mann DL. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and

autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. *Journal of Experimental & Clinical Cancer Research*. 2010;29:134.

배제사유 : 동물실험 및 전임상시험연구

743. Vujanovic NL, Yasumura S, Hirabayashi H, Lin WC, Watkins S, Herberman RB, et al. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. *Journal of Immunology*. 1995;154(1):281-9.

배제사유 : 동물실험 및 전임상시험연구

744. Wakasugi H, Oshimi K, Miyata M, Morioka Y. Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors. *Journal of Clinical Immunology*. 1981;1(3):154-62.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

745. Wakasugi T, Takeda T, Monden T, Katsumoto Y, Sakita I, Nagaoka H, et al. Augmentation of splenic antitumor immunity by local immunotherapy in gastric cancer patients. *Biotherapy*. 1997;10(2):99-106.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

746. Wakiguchi H. Overview of Epstein-Barr virus-associated diseases in Japan. *Critical Reviews in Oncology-Hematology*. 2002;44(3):193-202.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

747. Wald N, Cuende J, Mercier M, Nyawouame F, Brouwer M, Houthuys E, et al. Phenotyping of TIGIT pathway members may be used for cancer selection in the clinical application of anti-TIGIT antibody EOS884448. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

748. Wald N, Mercier M, Cuende J, Nyawouame F, Prasad S, Brouwer M, et al. TIGIT pathway phenotyping sheds light on promising strategies to restore anti-tumor immunity. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

749. Wan R, Wang ZW, Li H, Peng XD, Liu GY, Ou JM, et al. Human Leukocyte Antigen-G Inhibits the Anti-Tumor Effect of Natural Killer Cells via Immunoglobulin-Like Transcript 2 in Gastric Cancer. *Cellular Physiology & Biochemistry*. 2017;44(5):1828-41.

배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

750. Wang C, Li YY, Wan J, Yang LY, Li GH. Effect of VIP on NKG2D signal pathway and its contribution in immune escape of MKN45 cells. *Journal of Gastroenterology and Hepatology*. 2013;3):152.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

751. Wang C, Zhou XJ, Li YY, Wan J, Yang LY, Li GH. Effect of vasoactive intestinal peptide (VIP) on NKG2D signal pathway and its contribution to immune escape of MKN45 cells. *TheScientificWorldJournal*. 2013;2013:429545.

배제사유 : 동물실험 및 전임상시험연구

752. Wang GT. [Treatment of operated late gastric carcinoma with prescription of strengthening the patient's resistance and dispelling the invading evil in combination with chemotherapy: follow-up study of 158 patients and experimental study in animals]. Chung Hsi i Chieh Ho Tsa Chih Chinese Journal of Modern Developments in Traditional Medicine. 1990;10(12):712-6, 07.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

753. Wang H. [Influence of extirpative surgery on the natural killer cell activity in peripheral blood in cancer patients]. Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]. 1990;28(10):622-4, 38.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

754. Wang J, Xie Z, Li H. Short-term efficacy of DC-CIK biotherapy combined with chemotherapy for patients with advanced gastric cancer. [Chinese]. Journal of Practical Oncology. 2016;31(1):38-42.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

755. Wang J, Zheng X, Qin Z, Wei L, Lu Y, Peng Q, et al. Epstein-Barr virus miR-BART3-3p promotes tumorigenesis by regulating the senescence pathway in gastric cancer. Journal of Biological Chemistry. 2019;294(13):4854-66.

배제사유 : 동물실험 및 전임상시험연구

756. Wang JB, Tan Y, Song GP. [A study of lymphokine-activated killer cells (LAK) activity of the peripheral blood from patients with gastric cancer]. Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine. 1990;29(9):550-2, 76.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

757. Wang JT, Li H, Zhang H, Chen YF, Cao YF, Li RC, et al. Intratumoral il17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. Annals of Oncology. 2019;30(2):266-73.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

758. Wang K, Siu H, Deng S, Bienkowska JR, Leung SY. Characterizing the immunogenicity of gastric cancer by transcriptomic expression based immune phenotyping. Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR. 2016;76(14 Supplement).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

759. Wang L, Yin J, Wang X, Shao M, Duan F, Wu W, et al. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits. Gastroenterology. 2016;150(5):1183-95e16.

배제사유 : 동물실험 및 전임상시험연구

760. Wang M, Busuttill RA, Pattison S, Neeson PJ, Boussioutas A. Immunological battlefield in gastric cancer and role of immunotherapies. World Journal of Gastroenterology. 2016;22(28):6373-84.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

761. Wang M, Huang YK, Sun Y, Halse H, Di Costanzo N, Busuttill R, et al. Density and Distribution of Tumour-Infiltrating CD4+FOXP3+ T Cells Show Strong Prognostic Significance in Gastric Cancer. *Gastroenterology*. 2018;154 (6 Supplement 1):S-173-S-4.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
762. Wang N, Yang J, Lu J, Qiao Q, Wu T, Du X, et al. A polysaccharide from *Salvia miltiorrhiza* Bunge improves immune function in gastric cancer rats. *Carbohydrate Polymers*. 2014;111:47-55.  
 배제사유 : 동물실험 및 전임상시험연구
763. Wang Q, Gao X, Yuan Z, Wang Z, Meng Y, Cao Y, et al. Methionine enkephalin (MENK) improves lymphocyte subpopulations in human peripheral blood of 50 cancer patients by inhibiting regulatory T cells (Tregs). *Human Vaccines and Immunotherapeutics*. 2014;10(7):1836-40.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
764. Wang SC, Zhu M, Nassour I, Shen J, Mansour JC, Agarwal D, et al. Using NSG recipient mice improves engraftment of gastric cancer patient derived xenografts. *Journal of Clinical Oncology. Conference*. 2017;35(4 Supplement 1).  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
765. Wang W, Jin J, Dai F, Long Z, Liu X, Cai H, et al. Interleukin-15 suppresses gastric cancer liver metastases by enhancing natural killer cell activity in a murine model. *Oncology Letters*. 2018;16(4):4839-46.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
766. Wang XD, Gao NN, Diao YW, Liu Y, Gao D, Li W, et al. Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects. *World Journal of Gastroenterology*. 2015;21(26):8052-60.  
 배제사유 : 동물실험 및 전임상시험연구
767. Wang Y, Wang C, Xiao H, Niu C, Wu H, Jin H, et al. Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer. *Cancer Medicine*. 2017;6(1):45-53.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
768. Wang Z, Si X, Xu A, Meng X, Gao S, Qi Y, et al. Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications. *PLoS ONE [Electronic Resource]*. 2013;8(10):e75788.  
 배제사유 : NK 세포 활성화도(activity)를 다루지 않은 연구
769. Wang Z, Zhu J, Gu H, Yuan Y, Zhang B, Zhu D, et al. The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer. *Immunological Investigations*. 2015;44(6):578-89.  
 배제사유 : 동물실험 및 전임상시험연구
770. Wang ZY, Wang CQ, Yang JJ, Sun J, Huang YH, Tang QF, et al. Which has the least immunity depression during postoperative analgesia--morphine, tramadol, or tramadol with lornoxicam? *Clinica Chimica Acta*. 2006;369(1):40-5.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

771. Wasser SP. Medicinal mushrooms in human clinical studies. Part I. anticancer, oncoimmunological, and immunomodulatory activities: A review. *International Journal of Medicinal Mushrooms*. 2017;19(4):279-317.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

772. Watanabe M, Kubota T, Kitajima M, Hakomori S. Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice. *Cancer Immunology, Immunotherapy*. 1993;37(4):245-50.

배제사유 : 동물실험 및 전임상시험연구

773. Watanabe T, Ogawa K. Study on preoperative intratumor administration of Lentinan for gastric cancer cases. II. Antitumor immune response of regional lymph nodes. *Journal of Japan Society for Cancer Therapy*. 1995;30(7):948-55.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

774. Wei L, Chang J, Han Z, Wang R, Song L. Recombinant human growth hormone (rhGH) treatment of MKN-45 xenograft mice improves nutrition status and strengthens immune function without promoting tumor growth. *PLoS ONE* [Electronic Resource]. 2019;14(1):e0210613.

배제사유 : 동물실험 및 전임상시험연구

775. Wei MF, Gu ZS, Zheng LL, Zhao MX, Wang XJ. Long non-coding RNA GAS5 promotes natural killer cell cytotoxicity against gastric cancer by regulating miR-18a. *Neoplasma*. 2020;16.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

776. Weidmann E, Bergmann L, Hechler P, Mitrou PS. Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2. *Cancer Immunology, Immunotherapy*. 1991;33(6):398-402.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

777. Willer A. Reduction of the individual cancer risk by physical exercise. *Onkologie*. 2003;26(3):283-9.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

778. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstien B. Increase of regulatory T cells in the peripheral blood of cancer patients. *Clinical Cancer Research*. 2003;9(2):606-12.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

779. Wong E, Ritchie DS, Davis JE. CIK immunotherapy in refractory hematologic malignancies. *Leukemia Research*. 2016;49:60-1.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

780. Wouters MM, Balemans D, Van Wanrooy S, Dooley J, Cibert-Goton V, Alpizar YA, et al.



Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. *Gastroenterology*. 2016;150(4):875-87.e9.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

781. Wu CW, Chi CW, Ho CK, Chien SL, Liu WY, P'Eng F K, et al. Effect of arginase on splenic killer cell activity in patients with gastric cancer. *Digestive Diseases & Sciences*. 1994;39(5):1107-12.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

782. Wu HY, Chen YM, Lin L, Lin YG, Qiu QA, Liu N. Lentinan enhances the efficacy of the DCF regimen in patients with advanced gastric cancer: An analysis of 40 cases. [Chinese]. *World Chinese Journal of Digestology*. 2011;19(20):2176-80.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

783. Wu J, Zhou HF, Wang CH, Sui GJ. Comparison of the effects of ubenimex on quality of life and immune function in patients with digestive tract cancer through chemotherapy. *Chinese journal of clinical rehabilitation*. 2004;8(29):6299-301.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

784. Wu M, Wang Y, Liu H, Song J, Ding J. Genomic analysis and clinical implications of immune cell infiltration in gastric cancer. *Bioscience Reports*. 2020;40 (5) (BSR20193308).

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

785. Wu X, Huang S. HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer. *Bulletin du Cancer*. 2019;106(11):946-58.

배제사유 : 동물실험 및 전임상시험연구

786. Wu XT, Liu JQ, Lu XT, Chen FX, Zhou ZH, Wang T, et al. The enhanced effect of lupeol on the destruction of gastric cancer cells by NK cells. *International Immunopharmacology*. 2013;16(2):332-40.

배제사유 : 동물실험 및 전임상시험연구

787. Wu Y, Li J, Jabbarzadeh Kaboli P, Shen J, Wu X, Zhao Y, et al. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy. *Pharmacological Research*. 2020;155 (104691).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

788. Wurfel FM, Winterhalter C, Trenkwalder P, Wirtz RM, Wurfel W. European patent in immunoncology: From immunological principles of implantation to cancer treatment. *International Journal of Molecular Sciences*. 2019;20 (8) (1830).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

789. Xia P, Xu XY. DKK3 attenuates the cytotoxic effect of natural killer cells on CD133+ gastric cancer cells. *Molecular Carcinogenesis*. 2017;56(7):1712-21.

배제사유 : 동물실험 및 전임상시험연구

790. Xia X, Zhang Z, Xu J, Zhao G, Yu F. Comparison of postoperative lymphocytes and interleukins between laparoscopy-assisted and open radical gastrectomy for early gastric cancer. *Journal of International Medical Research*. 2019;47(1):303-10.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
791. Xiao W, Wu K, Yin M, Han S, Ding Y, Qiao A, et al. Wogonin Inhibits Tumor-derived Regulatory Molecules by Suppressing STAT3 Signaling to Promote Tumor Immunity. *Journal of Immunotherapy*. 2015;38(5):167-84.  
 배제사유 : 동물실험 및 전임상시험연구
792. Xin F, Mzee SAS, Botwe G, He H, Zhiyu S, Gong C, et al. Short-term evaluation of immune levels and nutritional values of EN versus PN in gastric cancer: a systematic review and a meta-analysis. *World Journal of Surgical Oncology*. 2019;17(1):114.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
793. Xin M, Wang J, Zhou C. [Clinical study on Shenqi Fuzheng injection combined with chemotherapy in treating malignant tumor of digestive tract]. *Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban*. 1998;18(11):658-61.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
794. Xing R, Li L, Chen L, Gao Z, Wang H, Li W, et al. Copy number variations of HLA-I and activation of NKp30 pathway determine the sensitivity of gastric cancer cells to the cytotoxicity of natural killer cells. *Oncogene*. 2016;35(20):2584-91.  
 배제사유 : 동물실험 및 전임상시험연구
795. Xu JW, Li CG, Huang XE, Li Y, Huo JG. Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. *Asian Pacific Journal of Cancer Prevention: Apjcp*. 2011;12(4):985-7.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
796. Xu LC, Chen P, Bu P, Liu XD, Gao P, Wang YX. Curative effect in gastric cancer patients with autologous tumor cell vaccine curcuma modified. [Chinese]. *Chinese Journal of Cancer Prevention and Treatment*. 2009;16(20):1587-9.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
797. Xu X, Li J, Zou J, Feng X, Zhang C, Zheng R, et al. Association of Germline Variants in Natural Killer Cells with Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk. *JAMA Network Open*. 2019;2 (9) (e199292).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
798. Xu X, Xu L, Ding S, Wu M, Tang Z, Fu W, et al. Treatment of 23 patients with advanced gastric cancer by intravenously transfer of autologous tumor-infiltrating lymphocytes combined with rIL-2. *Chinese Medical Sciences Journal*. 1995;10(3):185-7.  
 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

799. Xu Y, Chen L, Xu B, Xiong Y, Yang M, Rui X, et al. Higher Numbers of T-Bet+ Tumor-Infiltrating Lymphocytes Associate with Better Survival in Human Epithelial Ovarian Cancer. *Cellular Physiology & Biochemistry*. 2017;41(2):475-83.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
800. Xu YC, Xu Q, Li JJ, Gu XF, Lin XL, Sun L, et al. Chemotherapy with or without autologous cytokine-induced killer cell transfusion as the first-line treatment for stage IV gastrointestinal cancer: a phase II clinical trial. *Journal of Cancer Research and Clinical Oncology*. 2016;142(6):1315-23.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
801. Xu ZY. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 1990;12(5):345-7.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
802. Xue XC, Fang GE, Wang XH, Liu F, Bi JW, Cao GS, et al. Therapeutic effect of replication-competent adenovirus-mediated transfer of interleukin-12 gene on the mouse transplanted gastric cancer in vivo. [Chinese]. *World Chinese Journal of Digestology*. 2004;12(7):1522-6.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
803. Yagita A, Orima I, Okada N, Ootsuka S, Oda T, Takeuchi N, et al. [A case report of patient with advanced stomach carcinoma of linitis plastica type responding to multi-immunotherapy and chemotherapy]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1987;14(1):196-9.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
804. Yamada J, Tanaka N, Kamitani S, Goto K, Gangi J, Orita K. [Effect of human recombinant-gamma interferon on the immune function of peripheral blood lymphocytes in cancer patients]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1986;13(5):1946-52.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
805. Yamagishi H, Naito K, Maeda Y, Kobayashi M, Kurioka H, Fujimori C, et al. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1983;10(7):1670-8.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
806. Yamaguchi T, Bamba K, Kitayama A, Kuroiwa Y, Yoshimatsu K, Shimakawa T, et al. Long-term intravenous administration of activated autologous lymphocytes for cancer patients does not induce antinuclear antibody and rheumatoid factor. *Anticancer Research*. 2004;24(4):2423-9.  
배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
807. Yamaguchi Y, Miyahara E, Hihara J. Efficacy and safety of orally administered lentinula edodes mycelia extract for patients undergoing cancer chemotherapy: A pilot study.

American Journal of Chinese Medicine. 2011;39(3):451-9.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

808. Yamaguchi Y, Takashima I, Funakoshi M, Kawami H, Toge T. Defective natural killer activity in gastric cancer patients: possible involvement of suppressor factor receptor. In Vivo. 1994;8(3):279-83.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

809. Yamamoto J, Fujishima F, Ichinohasama R, Imatani A, Asano N, Harigae H. A case of benign natural killer cell proliferative disorder of the stomach (gastric manifestation of natural killer cell lymphomatoid gastroenteropathy) mimicking extranodal natural killer/T-cell lymphoma. Leukemia and Lymphoma. 2011;52(9):1803-5.

배제사유 : 동물실험 및 전임상시험연구

810. Yamamoto T, Arakawa F, Nakamura K, Senba T, Tomita Y, Ikeda S, et al. Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model. Cancer Immunology, Immunotherapy. 1999;48(4):165-71.

배제사유 : 동물실험 및 전임상시험연구

811. Yamauchi C, Fujii S, Kimura T, Kuwata T, Wada N, Mukai H, et al. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells. International Journal of Cancer. 2011;128(9):2125-37.

배제사유 : 동물실험 및 전임상시험연구

812. Yamaue H, Tanimura H, Tsunoda T, Iwahashi M, Tani M, Inoue M, et al. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes]. Nippon Gan Chiryō Gakkai Shi - Journal of Japan Society for Cancer Therapy. 1990;25(5):978-89.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

813. Yamaue H, Tanimura H, Tsunoda T, Iwahashi M, Tani M, Tamai M, et al. Enhancement of tumor cell susceptibility to lymphokine-activated killer cells by treatment with the streptococcal preparation OK432. Biotherapy. 1992;5(1):83-93.

배제사유 : 동물실험 및 전임상시험연구

814. Yamaue H, Tanimura H, Tsunoda T, Iwahashi M, Tani M, Tamai M, et al. Functional and phenotypic analysis of interleukin 2-activated tumor-infiltrating lymphocytes. Biotherapy. 1990;2(3):247-59.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

815. Yan M. [Effects of perioperative parenteral nutrition on immunocompetence in patients with gastric cancer]. Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]. 1990;28(12):739-41, 82.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

816. Yan WH. HLA-G expression in cancers: Potential role in diagnosis, prognosis and therapy. *Endocrine, Metabolic and Immune Disorders - Drug Targets*. 2011;11(1):76-89.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
817. Yan Y, Liu S, Li M, Zhao Y, Shao X, Hang M, et al. Recombinant Newcastle disease virus expressing human IFN-lambda1 (rL-hIFN-lambda1)-induced apoptosis of A549 cells is connected to endoplasmic reticulum stress pathways. *Thoracic Cancer*. 2018;9(11):1437-52.  
 배제사유 : 동물실험 및 전임상시험연구
818. Yanagawa E, Toge T, Nakanishi K. Natural killer activity and antibody-dependent cellular cytotoxicity of peripheral blood lymphocytes against allogeneic carcinoma cells in patients with gastric cancer. [Japanese]. *Japanese Journal of Cancer and Chemotherapy*. 1981;8(Suppl.):10-8.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
819. Yanagawa E, Toge T, Sawamura A, Kegoya Y, Baba N, Hattori T. The regulation of natural killer cell activity by splenic nonspecific suppressor cells and its modification in cancer patients. *Japanese Journal of Surgery*. 1988;18(6):660-7.  
 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
820. Yang C, Jiang H, Huang S, Hong H, Huang X, Liao W, et al. The prognostic role of pretreatment thrombocytosis in gastric cancer A systematic review and meta-analysis. *Medicine (United States)*. 2018;97 (31) (e11763).  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
821. Yang CA, Scheibenbogen C, Bauer S, Kleinle C, Wex T, Bornschein J, et al. A frequent Toll-like receptor 1 gene polymorphism affects NK- and T-cell IFN-gamma production and is associated with Helicobacter pylori-induced gastric disease. *Helicobacter*. 2013;18(1):13-21.  
 배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
822. Yang F, Jin H, Wang J, Sun Q, Yan C, Wei F, et al. Adoptive cellular therapy (ACT) for cancer treatment. *Advances in Experimental Medicine and Biology*. 2016;909:169-239.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
823. Yang H, Wu M, Yin W, Sun W, Zhang G. Diagnosis and treatment of a patient with primary gastric extranodal natural killer/T-cell lymphoma, nasal type. *Leukemia and Lymphoma*. 2010;51(11):2137-40.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
824. Yang J, Li W, Luo F, Zhao N, Zhang W, Zhang D, et al. Low percentage of CD24hiCD27+CD19+ B cells decelerates gastric cancer progression in XELOX-treated patients. *International Immunopharmacology*. 2015;26(2):322-7.  
 배제사유 : 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
825. Yang L, Chen C, Li M, Qiu L, Shen J, Bu X. Effects of anesthesia methods on insulin, blood glucose, immune and postoperative infection of gastric cancer patients

complicated with diabetes mellitus. *Minerva Endocrinologica*. 2018;43(3):388-90.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

826. Yang S, Zhang G, Li J. Effects of postoperative analgesia with buprenorphine on cell immunity in patients with gastric cancer. [Chinese]. *Chinese Journal of Clinical Oncology*. 2011;38(11):647-9.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

827. Yang X, Liu L, Fang F, Redati D, Wang H. Correlation between cellular immune function and prognosis of gastric cancer. *International Journal of Clinical and Experimental Medicine*. 2017;10(1):1275-82.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

828. Yang Y, Lee JH, Kim KY, Song HK, Kim JK, Yoon SR, et al. The interferon-inducible 9-27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells. *Cancer Letters*. 2005;221(2):191-200.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

829. Yang Y, Ting W, Xiao L, Shufei F, Wangxiao T, Xiaoying W, et al. Immunoregulation of Shenqi Fuzheng Injection Combined with Chemotherapy in Cancer Patients: A Systematic Review and Meta-Analysis. *Evidence-based Complementary and Alternative Medicine*. 2017;2017 (5121538).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

830. Yang YM, Feng AL, Zhou CJ, Liang XH, Mao HT, Deng BP, et al. Aberrant expression of chemokine receptor CCR4 in human gastric cancer contributes to tumor-induced immunosuppression. *Cancer Science*. 2011;102(7):1264-71.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

831. Yao X, Ajani JA, Song S. Molecular biology and immunology of gastric cancer peritoneal metastasis. *Translational Gastroenterology and Hepatology*. 2020;5 (57).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

832. Yao XX, Yin L, Sun ZC. The expression of hTERT mRNA and cellular immunity in gastric cancer and precancerosis. *World Journal of Gastroenterology*. 2002;8(4):586-90.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

833. Yao XX, Yin L, Zhang JY, Bai WY, Li YM, Sun ZC. hTERT expression and cellular immunity in gastric cancer and precancerosis. [Chinese]. *World Chinese Journal of Digestology*. 2001;9(5):508-12.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

834. Yasuda T, Ishikawa T, Ohta T, Yoshida J, Oka K, Doi T, et al. Exosomes derived from heat stress tumor cells could downregulate NK cell activity. *Cancer Science*. Conference: 76th Annual Meeting of the Japanese Cancer Association, JCA. 2017;109(Supplement 1).

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)

835. Yasumura S, Amoscato A, Hirabayashi H, Lin WC, Whiteside TL. Proliferation of

hematopoietic cell lines induced by a soluble factor derived from human squamous cell carcinomas of the head and neck. *Cancer Immunology, Immunotherapy*. 1994;39(6):407-15.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

836. Yasumura S, Lin WC, Hirabayashi H, Vujanovic NL, Herberman RB, Whiteside TL. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells. *Cancer Research*. 1994;54(14):3808-16.

배제사유 : 동물실험 및 전임상시험연구

837. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. *Journal of the National Cancer Institute*. 2003;95(7):516-25.

배제사유 : 동물실험 및 전임상시험연구

838. Yin XY, Yuan DD. [Preliminary study of the role of natural killer cells in human tumor immunity]. *Chung-Hua Ping Li Hsueh Tsa Chih - Chinese Journal of Pathology*. 1986;15(3):179-82.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

839. Yokota M, Tagawa Y, Okada D, Yasutake T, Mine Y, Ishikawa H, et al. Peri-operative immunotherapy with OK-432. *Biotherapy*. 1990;2(3):207-12.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

840. Yokoyama H, Nakanishi H, Kodera Y, Ikehara Y, Ohashi N, Ito Y, et al. Biological significance of isolated tumor cells and micrometastasis in lymph nodes evaluated using a green fluorescent protein-tagged human gastric cancer cell line. *Clinical Cancer Research*. 2006;12(2):361-8.

배제사유 : 동물실험 및 전임상시험연구

841. Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE. Boosting cancer immunotherapy with anti-CD137 antibody therapy. *Clinical Cancer Research*. 2015;21(14):3113-20.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

842. Yoon SJ, Heo DS, Kang SH, Lee KH, Kim WS, Kim GP, et al. Natural killer cell activity depression in peripheral blood and ascites from gastric cancer patients with high TGF-beta 1 expression. *Anticancer Research*. 1998;18(3A):1591-6.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

843. Yoshida H, Takizawa C, Misaka R, Kawaguchi M. Effect of a combination of UFT chemotherapy with lentinan immunotherapy on regional lymphocyte infiltration into a stomach cancer. [Japanese]. *Journal of Tokyo Medical College*. 1997;54(3):324-33.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

844. Yoshikawa K, Shimada M, Kurita N, Sato H, Iwata T, Nishioka M, et al. The effect of polysaccharide k with S-1 based chemotherapy in advanced gastric cancer. *Hepato-Gastroenterology*. 2013;60(126):1387-90.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

845. Yoshimoto K. [Elevation of soluble transferrin receptor substance in serum of cancer patients with suppressed natural killer activity]. *Nippon Gan Chiryō Gakkai Shi - Journal of Japan Society for Cancer Therapy*. 1989;24(10):2418-25.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
846. Yoshimura K, Fuse M. Correlation between NKG2D ligand/NKG2D interaction and antitumor effect against gastric cancer. *Cancer Science. Conference: 76th Annual Meeting of the Japanese Cancer Association, JCA*. 2017;109(Supplement 1).  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
847. Yoshimura K, Inoue M, Asao T, Fuse M, Wada S, Kuramasu A. Expression levels of UL16 binding protein 1 and natural killer group 2 member D in patients with gastric cancer. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
848. Yoshimura K, Wada S, Tsunoda T. What is the checkpoint of the immunotherapy against GI cancer? *Cancer Science*. 2018;109 (Supplement 2):371.  
 배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)
849. Yoshino S, Oka M, Hazama S, Suzuki T. [Effect of intrapleural and/or intraperitoneal lentinan therapy in carcinomatous pleuritis and peritonitis]. *Gan to Kagaku Ryōho [Japanese Journal of Cancer & Chemotherapy]*. 1990;17(8 Pt 2):1588-91.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
850. Yoshino S, Oka M, Hazama S, Suzuki T. [Effect of intrapleural and/or intraperitoneal lentinan therapy on carcinomatous pleuritis and peritonitis with special reference to immunological evaluation]. *Nippon Geka Hokan - Archiv für Japanische Chirurgie*. 1989;58(3):310-9.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
851. You W, Tang Q, Zhang C, Wu J, Gu C, Wu Z, et al. IL-26 promotes the proliferation and survival of human gastric cancer cells by regulating the balance of STAT1 and STAT3 activation. *PLoS ONE [Electronic Resource]*. 2013;8(5):e63588.  
 배제사유 : 동물실험 및 전임상시험연구
852. Youn JK, Kim BS, Min JS, Choi HJ, Lee YB, Lee DW, et al. Adjuvant treatment with chemotherapeutic agents and polyadenylic-polyuridylic acid in operable stomach cancers. I. Enhancement of natural killer cell activity. *Yonsei Medical Journal*. 1985;26(1):1-7.  
 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
853. Youn JK, Kim BS, Min JS, Lee KS, Choi HJ, Lee YB, et al. Adjuvant treatment of operable stomach cancer with polyadenylic-polyuridylic acid in addition to chemotherapeutic agents. Differential effect on natural killer cell and antibody-dependent cellular cytotoxicity. *International Journal of Immunopharmacology*. 1987;9(3):313-24.  
 배제사유 : 동물실험 및 전임상시험연구



854. Young L. The editor's page. Epstein-Barr Virus Report. 2002;9(1):35-6.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
855. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nature Reviews. Cancer. 2004;4(10):757-68.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
856. Young LS, Yap LF, Murray PG. Epstein-Barr virus: More than 50 years old and still providing surprises. Nature Reviews Cancer. 2016;16(12):789-802.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
857. Young LS. The editor's page. Epstein-Barr Virus Report. 2002;9(4):136-7.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
858. Yu QM, Yu CD, Ling ZQ. Elevated circulating CD19+ lymphocytes predict survival advantage in patients with gastric cancer. Asian Pacific Journal of Cancer Prevention: Apjcp. 2012;13(5):2219-24.  
 배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구
859. Yu RC, Guan CF, Zhang JH. [Immune function of cancer patients with spleen-deficiency syndrome]. Chung Hsi i Chieh Ho Tsa Chih Chinese Journal of Modern Developments in Traditional Medicine. 1990;10(9):535-7, 16.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
860. Yu X, Li Z. TOX gene: A novel target for human cancer gene therapy. American Journal of Cancer Research. 2015;5(12):3516-24.  
 배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
861. Yuan JM, Yu QM, Ling ZQ. [Impact of lymphocytes subgroups in peripheral blood on survival rate of patients with gastric cancer]. Zhonghua Weichang Waike Zazhi. 2011;14(10):796-8.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
862. Yutaka I, Tanabe H. Investigation of preoperative administration of BRM for patients with gastric cancer. [Japanese]. Biotherapy. 1996;10(3):471-3.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
863. Zakiryanova GK, Kustova E, Urazalieva NT, Baimuchametov ET, Nakisbekov NN, Shurin MR. Abnormal Expression of c-Myc Oncogene in NK Cells in Patients with Cancer. International Journal of Molecular Sciences. 2019;20(3):11.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
864. Zeniya M, Deura M, Arashiyama Y, Aizawa Y, Kameda H, Miyazaki H, et al. Immunological effects of oral administration of the streptococcal preparation OK-432 on gastrointestinal malignancies. Jikeikai Medical Journal. 1989;36(1):55-62.  
 배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구
865. Zhang GQ, Zhao H, Wu JY, Li JY, Yan X, Wang G, et al. Prolonged overall survival in gastric cancer patients after adoptive immunotherapy. World Journal of

Gastroenterology. 2015;21(9):2777-85.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

866. Zhang J, Yang Y, Fu H. CIK cell therapy for solid tumor. Nano Biomedicine and Engineering. 2014;6(2):60-6.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

867. Zhang K, Duan JY, Song YG, Liu CL, Guan XH. Significance of detection of DNA ploidy and T lymphocytes in patients with gastric cancer or precancerous lesions. [Chinese]. World Chinese Journal of Digestology. 2016;24(9):1433-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

868. Zhang X, Yang Y, Fan D, Xiong D. The development of bispecific antibodies and their applications in tumor immune escape. Experimental Hematology and Oncology. 2017;6(1) (12).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

869. Zhang Y, Lu N, Xue Y, Zhang M, Li Y, Si Y, et al. Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance. Molecular Medicine Reports. 2012;5(4):910-6.

배제사유 : 동물실험 및 전임상시험연구

870. Zhang YX, Ma W, Wu ZH. Clinical efficacy of intraperitoneal hyperthermic perfusion chemotherapy for patients with gastric cancer peritoneal metastasis: Impact on immune function and prognosis. World Chinese Journal of Digestology. 2018;26(32):1893-900.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

871. Zhang ZM, Li YJ, Guan X, Yang XY, Gao XM, Yang XJ, et al. Down-regulation of human leukocyte antigens class I on peripheral T lymphocytes and NK cells from subjects in region of high-incidence gastrointestinal tumor. Chinese Medical Journal. 2011;124(12):1813-7.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

872. Zhao H, Zhao H, Wang Y, Jing H, Ding Q, Xue J. Randomized clinical trial of arginine-supplemented enteral nutrition versus standard enteral nutrition in patients undergoing gastric cancer surgery. Journal of Cancer Research & Clinical Oncology. 2013;139(9):1465-70.

배제사유 : 기타 (논문발간철회)

873. Zhao J, Mo H. The Impact of Different Anesthesia Methods on Stress Reaction and Immune Function of the Patients with Gastric Cancer during Peri-Operative Period. Journal of the Medical Association of Thailand. 2015;98(6):568-73.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

874. Zhao P, Chen D, Cheng H. Prognostic significance of soluble major histocompatibility complex class I-related chain A (sMICA) in gastric cancer. British Journal of Biomedical

Science. 2018;75(4):203-5.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

875. Zhao Q, Li Y, Wang LL. [Effect of shenqi fuzheng injection on immune function in gastric carcinoma patients in post-operational and chemotherapeutic period]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2001;21(6):424-6.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

876. Zhao Q, Li Y, Yang JQ, Chen SX, Jiao ZK, Zhang ZD, et al. Effects of Chinese medicine strengthening the spleen and replenishing qi on spleen deficiency syndrome and biological behavior of patients with gastric carcinoma. Chinese Journal of Clinical Rehabilitation. 2004;8(35):8148-51.

배제사유 : NK 세포 활성화도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

877. Zhao S, Wang H, Nie Y, Mi Q, Chen X, Hou Y. Midkine upregulates MICA/B expression in human gastric cancer cells and decreases natural killer cell cytotoxicity. Cancer Immunology, Immunotherapy. 2012;61(10):1745-53.

배제사유 : 동물실험 및 전임상시험연구

878. Zhao S, Zhao H, Lv C, Gong J, Zhang J, Fang W, et al. Anticancer drug R&D landscape in China. Journal of Hematology and Oncology. 2020;13 (1) (51).

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

879. Zheng W, Li H, Liu B, Wu C. Association between the SNPs in trace element-related metabolic genes and the risk of gastric cancer: a case-control study in Xianyou of China. Journal of Genetics. 2019;98.

배제사유 : NK 세포 활성화(activity)를 다루지 않은 연구

880. Zheng X, Song X, Shao Y, Xu B, Chen L, Zhou Q, et al. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A meta-analysis. Oncotarget. 2017;8(34):57386-98.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

881. Zhong C, Lang Q, Yu J, Wu S, Xu F, Tian Y. Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis. Clinical & Experimental Immunology. 2020;200(1):12-21.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

882. Zhong HJ, Ying JE, Ma SL. [Effect of Supportan on nutritional status and immune function of late-staged gastric cancer patients undergoing chemotherapy]. Zhonghua Weichang Waiké Zazhi. 2006;9(5):405-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

883. Zhou K, Wang J, Liu B. [Clinical study on effect of shenqi fuzheng injection combined with chemotherapy in treating gastric cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu

Ban. 1999;19(1):11-3.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

884. Zhou LW, Ding HL, Li MQ, Jin S, Wang XS, Ji LJ. Effect of tramadol on perioperative immune function in patients undergoing gastric cancer surgeries. *Albang Maqalat Wa Abhat Fi Altahdir Waalinas*. 2013;7(1):54-7.

배제사유 : NK 세포 활성도는 다루었으나 인터페론 감마(Interferon gamma, IFN- $\gamma$ )를 측정하지 않은 연구

885. Zhou Y, Shi D. [Effect of GrB- positive expression in benign and malignant gastric epithelial tissue on local immune response]. *Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]*. 2002;82(14):966-9.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

886. Zhou YJ, Xiong YX, Li CP, Shi D. Suppression of local immune response by GrB expression in gastric cancer cells. *Chinese Medical Journal*. 2004;117(10):1573-5.

배제사유 : NK 세포 활성도(activity)를 다루지 않은 연구

887. Zhou YM, Huang ZQ, Hu MH, Zhou SH, Huang T, Xu Y, et al. Clinical study on the effect of Shengxueling on idiopathic thrombocytopenic purpura. *Chinese journal of integrative medicine*. 2005;11(1):60-4.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

888. Zhou Z, Liu W, Chen W. [Transduction of the IL-2 gene into human gastric cancer cell: an experimental study]. *Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine*. 1997;36(4):225-7.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

889. Zhu YP, Yan W, Sun TW. Effect of polysaccharide-peptide plus chemotherapy on the immune function and quality of life in patients with ovarian or endometrial cancer. *Chinese Journal of Clinical Rehabilitation*. 2006;10(47):212-4.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

890. Zhu Z. [Immune status of the spleen and surgical treatment in patients with advanced gastric cancer]. *Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]*. 1992;72(6):330-3, 81.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

891. Zhu ZG. Experimental and clinical study of splenic immunopotency in gastric cancer patients. [Chinese]. *Chinese Journal of Clinical Oncology*. 1994;21(8):574-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

892. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. *Nature Reviews Immunology*. 2015;15(7):405-14.

배제사유 : 원저가 아닌 연구 (체계적 문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

## 2. 국내 DB

1. An GD, Kim KH, Lim HH, Kim MC, Lee SY. Comparison of Interferon-gamma Secretion by Stimulated NK Cells and T cells from Healthy Subjects. *Laboratory Medicine Online*. 2018;8(1):15.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
2. Byun JS, Jeong WI. Involvement of hepatic innate immunity in alcoholic liver disease. *Immune Netw*. 2010;10(6):181-7.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
3. Chung IB HH, Kim NO, Ha JS, Park HS, Park JY. The role of Interferon-gamma on the Expression of Class I Human Leukocyte Antigens in a Human First Trimester Trophoblast Cell Line. *Korean J Obstet Gynecol* 2003;Feb;46(2):378-386.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
4. GC J. Natural killer T cell and pathophysiology of asthma. *Korean J Pediatr*. 2010;2010 Feb;53(2):136-145.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
5. Guang Hua X, 김재화, Gao L, 유익동. 짓버섯아재비 자실체로부터 분리한 Azulene계 화합물이 Interferon- 생성에 미치는 영향. *대한화장품학회지*. 2010;36(2):151-6.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
6. Hisamatsu T, Mikami Y, Matsuoka K, Kanai T, Hibi T. Immunological Abnormalities in the Pathogenesis of Inflammatory Bowel Disease. *Intestinal Research*. 2012;10(4):317.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
7. Jo DS HJ, Kim SY, Kim MS, Yi HK, Lee DY, Hwang PH. Changes in the expression of cytokines and apoptosis-related genes in children with infectious mononucleosis. *Korean J Pediatr*. 2009;Dec;52(12):1348-1357.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
8. Kim DH KM, Cho JH, Lim NK, Park JI, Jeong SH, Lee HW, et al. Aging Effects on Dendritic Cells after Total Body Irradiation in Mice. *Korean J Hematol*. 2007;Sep;42(3):224-232.  
배제사유 : 동물실험 및 전임상시험연구
9. Kim JY, Huh K, Lee KY, Yang JM, Kim TJ. Nickel induces secretion of IFN-gamma by splenic natural killer cells. *Exp Mol Med*. 2009;41(4):288-95.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
10. Kim KJ PS, Lee YS. Immunologic Effect of Gamma Interferon on Human Melanoma Cell Line A - 375 - With Special Emphasis on Cytolytic Activity , Antiproliferative Activity and HLA Antigen Expression. *Korean J Dermatol* 1990;Apr;28(2):147-158.  
배제사유 : 동물실험 및 전임상시험연구
11. Lee CB SW, Park JK, Haw CR. Effects of RETinoids on Keratinocytes HLA - DR and ICAM - 1 Expression Induced by Interferon - gamma. *Korean J Dermatol* 1995;Feb;33(1):33-43.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

12. Lee JS YC, Lyu CJ, Park SM, Cho HS, Kim KY. T Cell Function before, during and after Chemotherapy in Children with Acute Lymphoblastic Leukemia. Korean J Pediatr Hematol Oncol. 1997;Oct;4(2):350-362.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

13. Lee JT PS, Lee JH, Kim BK, Kim NK. Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon. J Korean Med Sci 1996;Feb;11(1):26-32.

배제사유 : 동물실험 및 전임상시험연구

14. Lim YA, Kim SS, Cho SW, Cheong JY. Evaluation of the Effectiveness of NK Vue Gold Kit in Patients with Chronic Hepatitis B. Journal of Laboratory Medicine and Quality Assurance. 2016;38(3):151-8.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

15. Maeng SH LJ, Park CW, Cho YJ. The effect of Der p 2 antigen on the production of interferon gamma by CD3+T, CD56+NK and CD3+CD56+TNK cells from patients with mild persistent allergic asthma. J Asthma Allergy Clin Immunol 2003;Jun;23(2):341-348.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

16. Park AJ LM. Peripheral Th1 and Th2 Lymphocytes Values by Intracellular Cytokine Staining for Interferon-and Interleukin-4 in the Patients with Repeated Spontaneous Abortion. Korean J Lab Med. 2005;Apr;25(2):111-115.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

17. Park S, Mun YC, Seong C-M, Huh HJ, Huh J. Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. Laboratory Medicine Online. 2018;8(2):41.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

18. Uyangaa E, Choi JY, Ryu HW, Oh SR, Eo SK. Anti-herpes Activity of Vinegar-processed Daphne genkwa Flos Via Enhancement of Natural Killer Cell Activity. Immune Netw. 2015;15(2):91-9.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

19. 고창권, Matsuda M, 예상규, 민본홍, 이광호, Jong Gu Park. 배양 Monocytes에서 세포농도에 따른 Fc $\gamma$  Receptors의 선택적 표현. 대한면역학회지. 1998;20(3):277-83.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

20. 김광수, 박경순. XRP44X Enhances the Cytotoxic Activity of Natural Killer Cells by Activating the c-JUN N-Terminal Kinase Signaling Pathway. 발생과생식. 2020;24(1):53-61.

배제사유 : 동물실험 및 전임상시험연구

21. 김광중, 박성희, 이유신. 인체 흑색종 세포주 A - 137 에 대한 감마 인터페론의 세포 살해능, 증식 억제능, HLA항원 표현에 관한 연구. 大韓皮膚科學會誌. 1990;28(2):147-58.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

22. 김대원, 이의섭, 최윤표, 강승우, 정재준, 서보승. 게르마늄 수경재배 미나리 추출물 처리에 의한 In Vitro/In Vivo에서의 사이토카인 감소 및 면역 활성화에 대한 효과. 한국식품영양과학회지.

2020;49(1):101-10.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

23. 김영건, 노홍규, 박은신, 김호, 유순희, 박수정, et al. 갑상선 세포에서 전사보조활성인자인 CBP와 CIITA는 인터페론-감마 활성 부위에 대하여 서로 다른 조절 작용을 나타낸다. *Endocrinology and Metabolism*(구 대한내분비학회지). 1999;14(3):493-504.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
24. 김용석, 김홍식. 진행 내장암환자에서 5-Fluorouracil 및 재조합 감마 인터페론(인터맥스(r)) 병용요법의 제2상 임상시험. *계명의대논문집*. 1994;13(2):131-45.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
25. 김창욱, 신주엽, 윤승규, 허원희, 남순우, 장우임, et al. 구연 : 라미부딘을 사용하고 있는 만성 B형 간염에서 숙주의 HBV 특이 T세포 면역반응을 반영하는 ELISPOT Assay의 유용성. *Clinical and Molecular Hepatology*(대한간학회지). 2003;9(3s):50.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
26. 맹선희, 이지수, 박창환, 조영주. 알레르기성 기관지천식환자의 말초 혈액 T세포, NK세포 TNK세포의 Der p 2 항원의 자극에 의한 interferon gamma의 생산. *천식및알레르기*. 2003;23(2):341-8.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
27. 박설희, 문영철, 성주명, 허희진, 허정원. Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. *Laboratory Medicine Online*. 2018;8(2):41-51.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
28. 변진석, 정원일. Involvement of Hepatic Innate Immunity in Alcoholic Liver Disease. *Immune Network*. 2010;10(6):181-7.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
29. 성혜란, 김지연, 박민경, 김일희, 이동욱, 한상배, et al. 결장암에 대한 활성 자연살해세포의 항암효능. *약학회지*. 2010;54(3):192-9.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
30. 안규대, 김경희, 임현호, 김민찬, 이상엽. 건강인에서 NK세포 자극 후와 T세포 자극 후 분비된 Interferon-gamma 농도의 비교. *Laboratory Medicine Online*. 2018;8(1):15-8.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
31. 유수연, 박원봉. 섬오가피 추출물의 항암관련 사이토카인 분비활성. *약학회지*. 2010;54(4):232-9.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
32. 윤도희, 이은경, 김정원. The effect of histamine on the production of interferongamma and interleukin-12 in peripheral blood mononuclear cells from patients with atopic dermatitis. *천식및알레르기*. 1999;19(3):459-67.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
33. 이춘봉, 심우영, 박재경, 허충림. 원저 : Retinoids가각질형성세포에서 감마인터페론에 의한 HLA - DR , ICAM - 1 발현에 미치는 영향. *대한피부과학회지*. 1995;33(1):33-43.  
배제사유 : 위암 환자를 대상으로 하지 않은 연구
34. 이해리, 전준호, 이기은. The Poly- $\gamma$ -D-Glutamic Acid Capsule of Bacillus licheniformis, a Surrogate of Bacillus anthracis Capsule Induces Interferon-Gamma Production in NK Cells

through Interactions with Macrophages. Journal of Microbiology and Biotechnology. 2017;27(5):1032-7.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

35. 임영애, 김순선, 조성원, 정재연. 만성B형간염 환자에서의 NK Vue Gold Kit 시약의 유효성 평가. 임상검사와정도관리. 2016;38(3):151-8.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

36. 전준호, 이해리, 이기은. 탄저균 poly- $\gamma$ -d-glutamic acid 캡슐에 의한 자연살해세포의 인터페론 감마 생산 기전. 주간 건강과 질병. 2018;11(5):128-32.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

37. 정다운, 변정수, 구나연, 정문희, 김은희, 김형석, et al. 개 유선종양세포에 대한 자연살해세포 독성. 대한수의학회지. 2020;60(1):25-32.

배제사유 : 동물실험 및 전임상시험연구

38. 정원일. 실험적 항섬유화 치료법의 임상적용. Clinical and Molecular Hepatology(대한간학회지). 2011;17(1(S)):48-54.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

39. 정인배, 한혜경, 김나옥, 하정식, 박현숙, 박주영. 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. 대한산부인과학회지. 2003;46(2):378-86.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

40. 천은미, 김미선, 장윤희, 박성숙, 조영주. 중증 기관지천식 환자의 말초단핵구에서 자연살해세포의 비율과 자연살해세포에서 interferon gamma의 생산. 천식및알레르기. 2000;20(3):535-44.

배제사유 : 위암 환자를 대상으로 하지 않은 연구

41. 최영희, 이진희, 윤종현. S-689 콜라겐 유도 관절염 마우스 모델에서 편백나무추출오일의 치료 효과. 대한내과학회 추계학술대회. 2016;2016(1):394.

배제사유 : 회색문헌(초록만 발표된 연구, 학위논문 등)